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Abstract 
Diabetes mellitus (DM) is a major chronic disease, affecting over 300 million people worldwide. 
Pancreatic islet β-cell dysfunction is known as the major cause of glucose metabolism disorder, 
which leads to hyperglycemia and eventually DM. Inside the cell, mitochondria perform a crucial 
role in coupling glucose metabolism to insulin secretion by the β-cell and on other cell functions 
requiring normal energy balance. Abnormal activity of mitochondria, such as increased apoptosis, 
contributes to β-cell dysfunction and diabetes related pathological changes in other cell types, for 
example, depressed growth hormone (GH) secretion was observed in the diabetic state. Cardiac 
complications of diabetes, also named diabetic cardiomyopathy, account for over 70% of the 
mortality among diabetic patients, which is characterized as cardiac systolic and diastolic 
dysfunctions. There are currently no effective targeted treatments. GH secretagogues (GHS) 
stimulate insulin secretion and GH release in the diabetic rodent model, and protect cardiomyocytes 
from ischemia/reperfusion injury. To further clarify the mechanism of GHS on diabetes and its 
cardiovascular complications, the present study employed mouse a β-cell line (MIN6) and 
streptozotocin (STZ)-induced diabetic rat model treated with the synthetic GHS, hexarelin (Hex), to 
investigate β-cell function, pulsatile GH secretion and cardiomyocyte contractility.  
 
Diabetes was induced by a single dosage of STZ (65mg/kg) IP injection in male Wistar rats with 
vehicle control group. After 4 weeks of disease development, animals received Hex (100μg/kg) 
treatment for 2 weeks. In vitro cell study mimicked the in vivo treatment regime; MIN6 cells were 
exposed to STZ (1mM) for 4 hours followed by a 2 hour Hex (1μM) incubation. Cell viability and 
mitochondrial function were measured by MTS and Rhodamine assay. Immunohistochemistry of rat 
pancreas sections was performed to determine islet morphology and apoptosis signaling pathways. 
ELISA was conducted to examine pulsatile GH and circulating levels of insulin, insulin-like growth 
factor-1 (IGF-1) and free fatty acids (FFA). Rat cardiomyocyte contractility and intracellular 
Ca
2+
concentration were investigated by cell shortening and Ca
2+
 transient measurement after 
cardiomyocyte isolation. Whole-cell patch clamp was performed to study membrane potential and 
transient outward potassium current (Ito). The expression of the GHS receptor, GHS-R, was 
determined by Western blot. Apoptotic markers were also assessed by protein expression 
determination in both MIN6 cells and rat cardiomyocytes. 
II 
 
STZ-treated MIN6 cells showed a decrease in cell proliferation and impaired mitochondrial 
function with increased expression of apoptotic markers, such as caspase-3, caspase-9 and the ratio 
of Bax/Bcl-2, while incubation of Hex recovered these parameters towards control levels. 
STZ-induced diabetic rats showed evidence of symptoms of clinical diabetes such as hyperglycemia, 
polyphagia, polydipsia and polyuria. Body weight gain was decreased in STZ-treated rats with 
declines in the weight of heart and adipose tissue. Hex treatment ameliorated hyperglycemia and 
polyuria in the STZ group. Increased body weight gain was observed in both control and diabetic 
rats with elevated heart and adipose tissue weight. In addition, Hex elevated insulin release in both 
the control and diabetic groups, under fasting and normal conditions, which associated with a 
normalized structure of the rat pancreatic islets and reduced staining of apoptotic proteins, Bax and 
caspase-9. Correlated with normalized insulin release, increased circulating levels of FFAs in STZ 
rats were also reduced by Hex, but IGF-1 remained unchanged. Diminished pulsatile GH release 
was displayed in the STZ-treated group, whereas Hex attenuated this depressed release of GH and 
increase pulsatile GH levels in control animals. A diabetic cardiomyopathy study revealed a 
depression of measured parameters in cell shortening and intracellular Ca
2+
 transient with prolonged 
APD and suppressed Ito activity. Hex treatment normalized abnormal cell shortening, intracellular 
Ca
2+
 transients, APD and Ito activity with up-regulated GHS receptor (GHS-R) and protection 
against mitochondrial-mediated apoptosis.  
 
In conclusion, Hex was able to ameliorated hyperglycemia via stimulation of insulin secretion and 
protection against β-cell apoptosis both in vivo and in vitro. The cardio-protective effect of Hex in 
diabetic cardiomyopathy was confirmed by improvement of contractility and regulation of 
intracellular Ca
2+
 homeostasis, associated with increased expression of GHS-R and decreased 
expression of apoptotic signal molecules. These results provided a potential therapeutic application 
of Hex in diabetic patients. 
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CHAPTER ONE – LITERATURE REVIEW, HYPOTHESIS AND AIMS 
1.1 Introduction 
Diabetes mellitus (DM) is a major chronic disease affecting many people across the world. It has 
been estimated that there are over 300 million people worldwide with diabetes [1]. DM is often 
diagnosed with symptoms such as excessive hunger, thirst and urination with high blood glucose. 
Generally, DM is divided into two types: Type 1 diabetes (T1D) and Type 2 diabetes (T2D). T1D is 
characterized by autoimmune disorder in which the β-cells in islet of Langerhans are selectively 
destroyed by immune system, leading to elimination of insulin production and eventually resulting 
in insulin deficiency [2]. T2D is a metabolic syndrome in which muscle and adipose cells do not 
respond to normal insulin release, consequently inducing insulin resistance [3]. Because T1D is 
usually diagnosed in younger people less than age of 30, it is also named as juvenile-onset diabetes, 
though it can be occurred at any age. T2D, however, is often associated with older age and obesity. 
In common, both T1D and T2D have hyperglycemia (high blood glucose) which can induce severe 
complications, including heart diseases, kidney failure, stroke and blindness.  
1.2 Literature review 
1.2.1 The islet of Langerhans      
The islets of Langerhans are located in the endocrine glandular tissue of the pancreas and constitute 
approximately 1-2% of the total gland mass (as shown in Figure 1.1). In humans, the pancreas 
contains around one million islets, which are separated from the exocrine tissue by a bunch of tissue 
fibers and glial-like cells [4]. There are four different types of cells in islets: β-cell, which is 
responsible for insulin production and composed 60-80% of islet mass, α-cell, which secrets 
glucagon (10-20%), δ-cell, which produces somatostatin (~5%) and PP-cell, which performs the 
action for polypeptide release in pancreas (<1%) [5, 6]. In most mammalian islets, the β-cell is 
centrally located and surrounded by a layer comprised of α-, δ- and PP-cells. β-cells are the first 
sensor of metabolic changes via blood because afferent arterioles split into a branching system of 
capillaries that across β-cell mass before reaching the layer of α- and δ-cells [2]. Glucagon secretion 
is inhibited by insulin, but glucagon itself stimulates insulin release. Somatostatin inhibits both 
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insulin and glucagon and its inhibiting effect of insulin secretion leads to suppression of β-cell 
mediated glucose metabolism [7]. Therefore, the anatomical relationship of the islet cells is critical 
to the function of the organ [2].       
 
Figure 1.1 The islet of Langerhans 
The pancreas is connected with the duodenum. The islet is enlarged and close to the exocrine acinar 
cells. The islets contain four different types of cells: The majority of insulin-secreted β-cell, 
glucagon-secreted α-cell, somatostatin-secreted δ-cell and pancreatic polypeptide-secreted PP-cell 
(adapted from [2]). 
1.2.1.1 Pancreatic β-cell as glucose sensor 
Glucose homeostasis particularly relies on pancreatic β-cell regulated insulin secretion and insulin 
action on its target tissue. It is important to maintain the balance between glucose metabolism and 
response of insulin release [8]. As glucose is the most common nutrient, the function of the glucose 
sensor – the β-cell – is crucial to regulate insulin secretion and adjust blood glucose levels. 
Mitochondria are the processor of glucose uptake and insulin secretion, which plays a central role in 
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coupling of glucose metabolism and insulin release. The abnormal function of mitochondria in 
β-cell is able to induce alterations in nutrient supply and usage, hyperglycemia, and eventually 
diabetes [9].  
 
Glucose transporter 2 (GLUT2) and glucokinase (GK) are two major components of the glucose 
sensor. In β-cells, plasma glucose move across the membrane through GLUT2 and is subsequently 
phosphorylated by GK to glucose-6-phosphate (G6P) during glycosis [10]. In hyperglycemia and 
the diabetic state, the expression of GLUT2 is changed because of altered glucose responses in the 
β-cell, though GLUT2 expression varies in different species [11]. The activity of GK is a 
rate-limiting step for glucose metabolism in β-cells [12]. Low glucose level (< 2.5mmol/L) results 
in a low level of glycolytic influx and index of ATP/ADP due to down-regulation of hexokinases in 
the β-cell. However, GK-mediated glucose phosphorylation triggers a high ratio of ATP/ADP when 
glucose level is over 2.5mmol/L, leading to further increase of glycolytic influx and mitochondrial 
oxidation [13]. As a gate-keeping role of metabolic signaling in the β-cell, low expression of GK 
conducted with lower levels of glucose-induced insulin secretion compared to those with higher 
expression. In the young diabetic population, disrupted expression of GK was associated with 
insufficient insulin-secretary response to glucose. Moreover, disrupted glucose-induced insulin 
release was accompanied with down-regulated GK in mice [14-17].  
 
In the cytosol, inhibition of glycolysis is prevented by maintained glycolytic flux, which reoxidizes 
NADH to NAD
+
. NADH is from glycolysis extracted reducing equivalent [18]. In most of cells, 
lactate dehydrogenase converts pyruvate into lactate in the cytosol while in the β-cell, due to the 
absence of lactate dehydrogenase, a mitochondrial NADH shuttle is mainly responsible for this 
process, which transfers electrons and pyruvate generated from glycolysis to mitochondria [19, 20]. 
The activation of mitochondrial metabolism is induced by entry of pyruvate, which is converted to 
acetyl-COA by pyruvate dehydrogenase or oxaloacetate by pyruvate carboxylase (anaplerosis) [21]. 
After oxidation and decarboxylation of acetyl-COA and oxaloacetate, citrate and α-ketoglutarate are 
generated which promotes the redox state of mitochondria, and eventually produce glutamate from 
the Krebs cycle in β-cells [22]. ATP production is a result of mitochondrial activation induced by 
glucose-derived pyruvate. Although FA and amino acids are also involved in oxidization of the 
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Krebs cycle, carbohydrates are the primary fuel in β-cells under normal physiological condition 
[23]. The ATP-sensitive K
+
 channel on the cell membrane is closed by exportation of ATP to the 
cytosol, which depolarizes the cell membrane and triggers Ca
2+
 influx through voltage-gated Ca
2+
 
channels, leading to an elevation of intracellular Ca
2+
 concentration and initiation of exocytosis of 
insulin [23-25].  
 
Figure 1.2 The model of coupling of glucose metabolism to insulin secretion in β-cell 
Plasma glucose entre the cytosol across membrane through glucose transporter 2 (GLUT2) and is 
metabolized via glycolysis and Krebs (tricarboxylic acid, TCA) cycle. The elevated level of 
Adenosine triphosphate (ATP)/Adenosine diphosphate (ADP) result in the closure of the 
ATP-sensitive K
+
 channel in cytosolic membrane, depolarization of cytosolic membrane and Ca
2+
 
influx through opening gate of Ca
2+
 channels. Increased intracellular Ca
2+
 concentraton stimulates 
exocytosis and subsequent insulin release. GK, glucokinase; G6P, glucose-6-phosphate; PFK, 
phosphofructokinase; PK, pyruvate kinase; NADH, nicotinamide adenine dinucleotide; H
+
, hydron; 
PDH, pyruvate dehydrogenase; Acetyl-COA, acetyl coenzyme A; FFA, free fatty acid; 
FADH2,  flavin adenine dinucleotide; CO2, carbon dioxide; O2, oxygen; Pi, phosphate ions; K
+
, 
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potassium ion; Ca
2+
, calcium ion (adapted from [2]). 
1.2.1.2 Reactive oxygen species (ROS), mitochondria and β-cell function 
ROS consist of superoxide (O2
-•
), hydrogen peroxide (H2O2) and hydroxyl radical (OH
•
). 
Superoxide dismutase can convert superoxide to H2O2 and can be further catalyzed to oxygen and 
water by antioxidant proteins, including peroxidase, catalase, peroxiredoxin and glutathione [26]. 
Generation of ROS is located on the electron-transport chain of mitochondria in the cell and 
electron carriers of the respiratory chain are accumulated by electrons produced from catabolized 
glucose, fatty acid (FA) and amino acid. Associated with electron transport, ROS is formed as a 
byproduct of normal mitochondrial respiration via oxygen molecule reduction from a single 
electron, which occurs at the inter-membrane space of mitochondria adherent with complex I and 
complex III [27, 28]. Depressed transportation of electrons is happened with impaired 
respiration-chain complex under stress conditions or exceeded cellular energy demand for ATP 
production, which is considered as a result of increased generation of mitochondrial free radicals 
[29, 30]. ROS is not only produced from mitochondria. NADPH oxidases increase ROS production 
in the T2D diabetic obese rat and its phagocyte-like isoform reduced cAMP activity to generate 
ROS through negative regulation of the secretary response in β-cell [31, 32].    
 
Oxidative stress from oxidant exposure and gluco-lipotoxicity has been reported to cause β-cell 
dysfunction [33, 34]. Inactivation of mitochondria is a result of elevated ROS in β-cell, which 
uncouples the glucose metabolism from insulin release via impaired signal transduction [33]. 
Transient oxidative stress can lead to loss of electron transport with rapid down-regulation of 
respiration-chain protein and elevation of ROS production in mitochondria, resulting in persistent 
damage to β-cell function [35]. Glucose infusion induced hyperglycemia in rats are also interrupted 
the glucose-sensed insulin secretion accompanied with increased mitochondrial superoxide [36]. A 
study on T2D Zucker diabetic fatty rats demonstrated that increased ROS formation was associated 
with mitochondrial dysfunction and diabetes [37].     
 
Besides oxidative stress, mitochondrial uncoupling is another phenomenon of β-cell dysfunction, 
which is the dissociation of electron-dependent oxygen consumption from ATP production in 
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respiratory chain [38]. In islet β-cell, uncoupling protein 2 (UCP-2) is expressed and its 
overexpression reduced ATP production and glucose-stimulated insulin secretion [39]. Studies on 
UCP-2 deficient mice and T2D model demonstrated that absent, or inadequate, UCP-2 promoted 
ATP synthesis, maintained blood glucose and increased insulin secretary ability [40, 41]. 
Up-regulated UCP-2 gene expression was also observed in FAs-exposed INS-1 β-cell with 
decreased glucose response and mitochondrial uncoupling [42]. Therefore, UCP-2 performs a 
significant role in mitochondrial dysfunction and pathogenesis of T2D, inhibitor of UCP-2 may be a 
potential target to treat diabetes [38, 43]. 
1.2.1.3 Mitochondrial-dependent apoptosis in β-cells 
As state above, mitochondria play a key role in β-cell function. They are also core organelles 
regulating apoptosis [44]. The mechanism of mitochondria-dependent apoptosis is maintained by a 
large number of proteins and several of them are from the Bcl-2 family. Depending on the different 
Bcl-2 homology domain containing in the sequence, the Bcl-2 family consists of anti-apoptotic 
proteins (Bcl-2, Bcl-XL, Bcl-w and Mcl-1) and pro-apoptotic proteins (Bax, Bad, Bik and Bid) [45]. 
In mitochondria, Bcl-2 and Bcl-XL prevent release of apoptosis-associated factors, cytochrome c 
and apoptosis-inducing factor (AIF) from the inner-membrane of mitochondria to the cytosolic 
space. Activation of caspases is directly initiated once cytochrome c and AIF reach the cytoplasma 
[46-49]. It has been demonstrated that mitochondrial dysfunction, such as loss of membrane 
potential and transition of membrane permeability, contribute to the release of AIF [50]. Bax and 
Bak, however, trigger cytochrome c release and mitochondrial dysfunction [51-53].  
 
In β-cells, ROS promotes translocation of cytochrome c and AIF from the mitochondrial outer 
membrane to the cytosol and membrane permeabilization, which induces caspase-dependent 
signaling pathways [54]. High glucose triggers apoptosis by tanslocational regulation of Bad and 
Bid associated with increased level of Bax/Bcl-2 ratio, cytochrome c release and caspase-3 
activation. Anti-oxidant agents are able to prevent the apoptotic mechanism regulated by Bcl-2 
family in pancreatic islet cells [55, 56], suggesting oxidative stress is involved in 
mitochondrial-mediated apoptosis in β-cell.  
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As stated above, T1D is induced by an autoimmune disorder, where β-cells in islet of Langerhans 
are selectively destructed by the immune system [2]. During the development of T1D, perforin and 
granzyme are released by immune cell CD8+ T cells. Perforin can break the β-cell membrane to 
enable granzyme to be transported into the cytosolic space of β-cell and initiate apoptosis through 
activation of the pro-apoptotic protein Bid by granzyme cleavage [57, 58]. Perforin and granzyme 
induced apoptosis was suppressed in Bid-knockut mice [59]. While in T2D, gluco-lipotoxicity, via 
FFAs and high glucose, is the major stimuli for β-cell apoptosis [60]. Investigation of 
palmitate-induced ER stress revealed that, anti-apoptotic proteins expression from Bcl-2 family 
(Mcl-1, Bcl-2 and Bcl-XL) were translationally shut down due to activation of protein kinase R-like 
ER kinase (PERK) and phosphorylation of eukaryotic initiation factor 2 α-subunit (eIF2α) [61]. 
Human islets exposed to high glucose showed up-regulated Bad, Bid and Bik with down-regulated 
Bcl-XL, suggesting FFAs and high glucose (gluco-lipotoxicity) contribute to apoptosis in T2D [55].   
1.2.2 Growth hormone (GH) in diabetes 
In addition to insulin, GH is the most potent anabolic hormone regulating metabolic balance in the 
body. GH is synthesized, stored and secreted by somatotrophs in the anterior pituitary gland. The 
secretion of GH is predominantly regulated by hypothalamic growth hormone releasing hormone 
(GHRH) and somatotropin releasing inhibiting factor (SRIF) neurons, which exert stimulating and 
inhibiting effect on pituitary GH release [62, 63]. GH modulates the release of IGF-1 in various of 
tissues, especially hepatic tissue as over 50% of circulating IGF-1 is originally produced from liver 
[64]. The GH/IGF-1 axis plays a key role in cell and tissue function because both factors improve 
growth and affect metabolism where GH acts directly or indirectly through IGF-1 [65]. GH is 
conversely linked with glucose because the response of GH is increased in the hypoglycemic state. 
Increased GH concentrations in peripheral tissues inhibit glucose oxidation by increasing lypolysis, 
FFAs and gluconeogenesis [66, 67]. 
 
Experimental and clinical DM studies differ in the awkward change in GH activity, and so the 
mechanism of GH alteration in diabetes remains unclear. Although GH may be increased or 
decreased, depressed IGF-1 activity is consistently demonstrated, indicating disassociation of 
GH/IGF-1 axis in diabetes [68-74]. In T1D patients, the hypersecretion of GH was observed with 
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decreased IGF-1, where increased GH was unable to stimulate IGF-1 release [75-77]. It has been 
suggested that suppression of IGF-1 was possibly caused by metabolism alterations in diabetes, 
where substrates were used for fuel homeostasis rather than cell growth and proliferation [77]. 
Moreover, the response of IGF-1 becomes less active to exogenous GH in poorly controlled T1D 
[78]. In Insulin-treated T1D, elevated GH was inhibited after insulin injection with increased levels 
of circulating IGF-1 [75, 79]. Decreased IGF-1 may also contribute to the elevation of GH in 
patients with T1D. IGF-1 is able to stimulate somatostatin secretion or suppress GHRH release via 
action on hypothalamus, or even directly inhibit GH release acting on pituitary [80-83]. Therefore, 
increased GH secretion might be a result of reduced IGF-1. Another possible explanation of GH 
hypersecretion in T1D patients is insulin deficiency. Insulin is effective in suppressing GH secretion 
from pituitary somatotrophs. Due to drastically decreased insulin levels, it was not surprising to 
observe increases in GH level [84]. Besides the GH/IGF-1 axis, GH pulsatility was also modified in 
diabetic patients. Clinical investigations on T1D patients reported that GH pulses were increased 50% 
in both diabetic males and females with markedly elevated amplitude of GH pulses and total GH 
concentrations compared to age-matched controls [85]. Further study on T2D revealed that GH 
burst frequency was increased with unchanged GH secretion as GH burst mass was reduced and 
correlated with the degree of obesity [86].  
 
It is important to note that GH studies in experimental models produced a converse result from 
observations in diabetic patients, where depressed GH levels were associated with decreased IGF-1 
[72-74]. Suppression of GH release in a diabetic animal model was characterized by reduction of 
basal GH and loss of GH pulsatility, which might be a result from lack of GH synthesis and storage 
[87-89]. Suppressed GH pulsatility was observed in STZ-induced diabetic rats and this inhibitory 
effect was abolished by SRIF antiserum [74]. Decreased levels of GH in the diabetic model were 
correlated with increased content of somatotropin and reduced GH response to GHRH [72, 90-92]. 
Depressed hypothalamic GHRH secretion was also observed in diabetic rats [63, 89, 90]. 
Suppressed expression of GH receptor appears to be another factor contributing to reduced GH 
secretion in the diabetic model [93]. Insulin was proposed to regulate the GH receptor together with 
other hormone receptors, such as hepatic glucagon receptors [94]. Insulin deficiency in 
experimental diabetes led to down-regulation of GH receptors and insulin treatment recovered 
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expression of GH receptors with normalized level of IGF-1 [93].  
1.2.3 Diabetic cardiomyopathy 
Cardiovascular complications, especially coronary artery disease (CAD), account for 70% of deaths 
among diabetic patients. In addition to a clear CAD influence, in 1972, Rubler reported several 
diabetic patients with heart failure under normal coronary artery condition and subsequently 
proposed a new clinical entity – diabetic cardiomyopathy [95]. With experimental and clinical 
evidence for thirty years, diabetic patients and animals have been recognized with increased risk of 
developing cardiovascular disease, including heart failure even without CAD or hypertension. 
Diabetic cardiomyopahty is considered as depressed ventricular function, which further results in 
pathologically myocardial structural and functional changes. 
1.2.3.1 Cardiac dysfunction 
The concept of diabetic cardiomyopathy is defined as ventricular dysfunction without evidence of 
CAD or hypertension. Diabetic patients are at increased risk of developing CAD and hypertension. 
However, the existence of diabetic cardiomyopathy is considered to occur even without presence of 
CAD or hypertension. Diabetic cardiomyopathy is a specific cardiomyopathy, which may affect the 
myocardium secondary to diabetes. This cardiomyopathy may in fact occur in combination with 
CAD or hypertension and therefore be a significant contributing factor to diabetic fatality. In either 
clinical or animal experiments, however, in order to isolate diabetic cardimyopathy, CAD and 
hypertension have to be excluded. Therefore, diabetic cardiomyopathy is a disease affecting 
myocardial remodeling and eventually leads to cardiac diastolic and systolic dysfunction. 
1.2.3.1.1 Diastolic dysfunction 
Diastolic dysfunction is a major characteristic of diabetic cardiomyopathy. Initially, scientists 
recorded dynamic cardiac parameters using cardiac catheterization and demonstrated a decrease in 
left ventricular end-diastolic volume and an increase end-diastolic pressure in diabetic patients 
without CAD [96]. However, the abnormal diastolic function in patients was mainly studied using 
Doppler techniques. It has been reported that there is a significant impairment in diastolic function 
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in individual with Type 1 and Type 2 diabetes, even without CAD and heart failure (HF) [97]. A 
study of Type 2 diabetic patients with normal blood pressure and glucose levels indicated over 50% 
of the diastolic abnormality compared to healthy controls [98, 99]. Furthermore, in animal models 
of Type 2 diabetes, Zucker Diabetic Fatty rat and db/db mice, diastolic dysfunction were observed 
in the left ventricle. Independent of atherosclerosis, these animal models were characterized by 
insulin resistance, obesity and different level of hyperglycemia, which might lead to cardiac 
complications [100, 101]. Scientists using the db/db mouse model assumed a possible mechanism 
underlying Type 2 diabetes related to diastolic dysfunction. They proposed an increased fatty acid 
uptake by and altered calcium homeostasis in, cardiomyocytes, which caused an elevated cardiac 
triglyceride concentration and contractile dysfunction. Decreased contractility is associated with 
impaired sarcoplasmic reticulum (SR) Ca
2+
 release, which probably exerts an impact on diastolic 
abnormality [102-104]. Detailed calcium homeostasis in diabetic cardiomyocytes may be directly 
related to diastolic dysfunction and needs further investigation.  
1.2.3.1.2 Systolic dysfunction 
Systolic dysfunction is the reduced ability of the myocardium to eject blood, which is a later 
development after diastolic dysfunction in diabetic cardiomyopathy. Although several studies have 
confirmed that systolic dysfunction is associated with diabetes, there is a lack of specific and 
conclusive reports [105]. Clinically, standard 2D (two-dimensional) echocardiograph may miss the 
detection of subtle systolic dysfunction. Recently, more sensitive methods, such as tissue Doppler 
strain analysis, have detected systolic abnormalities in diabetic patients with diastolic dysfunction 
[106-108]. Experimental investigations in rodent models have indicated systolic dysfunction by 
magnetic resonance imaging and pressure-volume loop measurement in both type 1 and Type 2 
diabetes [109-111]. Clinical evidence from diabetic patients reveals, with decreased systolic 
function, a shortened ejection time and prolonged pre-ejection along with attenuated relaxation of 
left ventricular ejection fraction [112]. More careful investigation of cardiac systolic function in 
diabetic animal model may clarify this issue further. 
1.2.3.2 Pathological mechanisms of diabetic cardiomyopahty 
The rodent is considered as an ideal animal model to study potential mechanisms underlying 
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diabetic cardiomyopathy owing to its relatively resistant to develop atherosclerosis, which provides 
researchers the diabetic cardiomyopathy without a contribution from CAD [113]. Currently, several 
diabetic rodent models have been developed, such as streptozotocin (STZ) induced diabetic model, 
to reflect the Type 1 diabetes; and diet-induced obesity and diabetes model, to represent the Type 2 
diabetes. Genetically modified models, such as ob/ob and db/db, are also used to study the 
pathology of Type 2 diabetes. Although rodents have different cardiac cycle, ion channel expression 
and contractile protein isoforms from human, they have similar genomes to humans, and have 
typical diabetic phenotypes, such as hyperglycemia, insulin deficiency and insulin resistance [114]. 
These characteristics further result in diabetic cardiomyopathy through cellular pathological 
changes, which may be composed of impaired calcium handling, increased oxidative stress, altered 
metabolism, mitochondrial dysfunction, cardiac autonomic neuropathy, activation of 
renin-angiotensin system and abnormal ion channel activity [115, 116]. In the following sections, I 
will discuss these underlying mechanisms in details. 
1.2.3.2.1 Impaired calcium handling 
Intracellular calcium (Ca
2+
) performs a significant role in regulating cardiac contractile function. In 
cardiomyocytes, the mechanism of calcium-induced calcium release initiates the myocardial 
contraction by increasing intracellular calcium concentration via activation of Ca
2+
 channel, 
activation of ryanodine receptor, and reduced sodium/calcium exchanger process [117]. For 
relaxation to occur, intracellular calcium concentration ([Ca
2+
]i) decreases to diastolic level through 
activated sarcoplasmic reticulum (SR) Ca
2+
 pump (SERCA2a), increased sodium/calcium 
exchanger process and activation of sarcolemmal Ca
2+
 ATPase to speed up Ca
2+
 uptake [118]. In 
diabetic cardiomyocytes, calcium homeostasis is altered by reduced activity of the sodium/calcium 
exchanger and ATPase and decreased sarcoplasmic reticulum Ca
2+
 uptake [119, 120]. Isolated type 
1 diabetic rat cardiomyocytes exhibit decreased activity of the ryanodine receptor and SR Ca
2+ 
ATPase associated with attenuated SR Ca
2+
 store and reduced Ca
2+
 efflux via sodium/calcium 
exchanger [121]. Studies on type 2 diabetes animal model also display the depressed Ca
2+
 efflux 
and SR Ca
2+
 load and reduced expression of ryanodine receptor [122]. Furthermore, in both type 1 
and type 2 diabetes, decreased expression of SERCA2a and sodium/calcium exchanger is observed 
[123, 124]. Noda et al. demonstrated, in isolated diabetic cardiomyocytes, a declined contraction 
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amplitude and lower relaxation velocity compared to controls [125]. Mitochondrial investigation on 
diabetic models have suggested that reduce calcium uptake is closely related to the development of 
hyperglycemia. STZ-induced diabetic rats showed a lower calcium uptake in cardiomyocytes versus 
that in controls [126]. It has also been revealed that accumulated calcium is not preserved by 
diabetic cardiomyocytes owing to an increased opening of the mitochondrial permeability transition 
pore (MPTP) [127]. Therefore, these investigations indicated impaired calcium homeostasis in 
diabetic hearts, which results in decreased cardiac contractility and dilation.   
1.2.3.2.2 Increased oxidative stress 
Increased production of reactive oxygen species (ROS) is another major progression of diabetic 
cardiomyopathy. It has been reported that approximately 90% of ROS is produced by mitochondria 
in myocardial tissue [128]. Mitochondria produced ROS can cause protein damage by oxidation or 
lipids oxidation to form lipid peroxidation products, causing protein or phospholipid damage. ROS 
also increase DNA damage which is caused by reduced activity of DNA repairing pathways, 
especially the pathway involved in mitochondrial DNA repair [129]. Moreover, interaction between 
ROS and nitric oxide (NO) generates nitrotyrosine species that may lead to impaired mitochondrial 
respiration. Experimental studies on human myocardial samples reveal that cardiomyocyte 
apoptosis is associated with an increase in 3-nitrotyrosine [130].  Similar evidence is also obtained 
in STZ-induced Type 1 diabetes model [131]. Additionally, tyrosine nitration is involved in cardiac 
mitochondrial protein in Type 1 diabetic mice. It is reported that increased 3-nitrotyrosine is 
associated with increased apoptosis in myocardial tissue [132]. Overexpression of antioxidant 
protein, metallothionein, reduces nitration damage [131]. Similar investigations on Type 1 diabetic 
OVE26 mice indicated that overexpressed metallothionein is able to normalize oxidized glutathione 
and recover contractile dysfunction [133]. Thus, this evidence demonstrates oxynitrate damage 
pathways in diabetic cardiomyopathy.  
 
A ROS defense mechanism is involved in oxidative damage as well. Manganese superoxide 
dismutase (MnSOD) is a major antioxidant, which preserves cardiomyocytes from 
superoxide-induced damage by converting superoxide to H2O2 [134]. Data from db/db mice of Type 
2 diabetes have revealed that up-regulation of MnSOD activity is associated with an increased 
13 
 
mitochondrial H2O2 [135]. Type 1 diabetes mice also show an increased level of MnSOD, leading to 
normalized mitochondrial morphology and cardiac function [136]. In contrast, declined ROS 
scavenging proteins in the cardiomyocyte cytosol compartment contributes to oxidative damage in 
cells in diabetes [137]. 
 
Despite mitochondrial ROS production, generated ROS from the cytosol in myocardial tissues also 
play an important role in diabetes. Advanced glycation end (AGE) products and increased NADPH 
oxidase activity contribute to oxdative damage, even rising mitochondrial ROS [138, 139]. It has 
been hypothesized that AGE formation is associated with hyperglycemia, resulting in cytosolic 
ROS production induced by AGE receptor; and the whole process eventually causes MPTP opening 
and mitochondrial dysfunction [138]. It has been reported that cytosolic ROS induces MPTP 
opening in cardiac ischemia [140]. In fact, an anti-diabetic medicine, Metformin, works by causing 
inhibition of MPTP opening in diabetic rats [141]. 
1.2.3.2.3 Altered metabolism 
Elevated FA uptake contributes significantly to the development of diabetic cardiomyopathy. 
Generally, constant ATP production is strongly linked to appropriate FA and glucose oxidation by 
continuous demand of the heart. However, in diabetic myocytes, metabolism utilization shifts to 
higher level free FA and decreased glucose substrate because of insulin resistance and 
hyperlipidemia. A significantly elevated utilization of free FA by cardiomyocytes has been 
demonstrated in human and animal studies [116, 142-144]. In responding to increased levels of 
myocardial FA, the nuclear receptor transcription factor, peroxisome proliferator-activated receptor 
(PPAR), in cardiomyocytes is activated via mitochondrial beta-oxidation and over-expression of 
necessary enzymes [145]. PPAR-α was responsible for the FA utilization pathway and regulates FA 
uptake and oxidation by controlling expression of necessary enzymes [146]. In a PPAR-α-deficient 
animal model, there was decreased FA oxidation and reduced activity in the FA utilization pathway 
[147]. In contrast, PPAR-α was increased with insulin-resistance in another animal model study 
[148]. In addition, free FA is able to cause lipid accumulation by inhibiting pyruvate dyhydrogenase, 
which is detrimental to myocardial energy production [149]. Lipid accumulation leads to production 
of nonoxidative molecules – ceramide, a lipid-toxic product. It has been reported that increased 
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ceramide generation is associated with contractile dysfunction and cell apoptosis [150]. Increased 
myocardial oxygen consumption is closely related to FA utilization, which caused cardiac ischemia 
due to a significantly high level of oxygen used by FA oxidation [151, 152]. Duncan et al. 
demonstrated reduced ATP production associated with increased FA oxidation in obese-induced 
diabetic mice, which suggested a reduced efficiency of cardiac mitochondria function [148]. 
Similarly, a study on Type 2 diabetic mice indicated increased mitochondrial oxygen consumption 
and FA oxidation accompanied by a decreased cardiac efficiency and function [153]. Clinical 
evidence from women with insulin resistance also showed that the increased FA oxidation caused 
cardiac inefficiency, which might further result in decreased cardiac function [154].  
1.2.3.2.4 Mitochondrial dysfunction 
It has been widely reported that mitochondrial dysfunction is closely associated with diabetic 
cardiomyopathy [155, 156]. Thirty years ago, scientists demonstrated impaired function of the 
mitochondrial respiration in the db/db mouse model, indicating diabetes probably induces 
mitochondrial structural and functional alteration [157]. Recent studies reveal that a decreased 
mitochondrial respiration is closely linked to down-regulation of oxidative phosphorylated protein 
in diabetic mice, suggesting impaired cardiac contractility caused by reduced ATP production [158]. 
Furthermore, decreased oxidative capacity of mitochondria has been observed in a type 1 diabetic 
mouse model [159]. It has also been demonstrated that lower levels of ATP synthesis are associated 
with reduced activity of mitochondrial oxidation, which may contribute to the decrease in calcium 
uptake and cardiac dysfunction [160]. Mitochondrial functional un-coupling is a major contributor 
to mitochondrial dysfunction. ATP synthesis is tightly coupled with increased oxidative activity of 
mitochondria. Lower level of creatine phosphorylation occurs with reduced ATP synthesis protein in 
STZ-induce diabetic hearts, which is associated with attenuated mitochondrial function [161]. 
Additionally, over-expression of beta-oxidation proteins has been found in diabetic hearts with 
down-regulation of electron transport proteins; and increased beta-oxidation decreases electron 
transportation resulting in reduced ATP production in mitochondria [155, 162]. Diabetic ob/ob mice 
exhibit reduced ATP generation with higher consumption of oxygen in their mitochondria, 
indicating the existence of mitochondrial uncoupling in diabetic cardiomyopathy [158].  
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1.2.3.2.5 Cardiac autonomic neuropathy (CAN) 
Diabetic cardiovascular autonomic neuropathy is associated with sympathetic and parasympathetic 
dysfunction in the myocardium, contributing to the impaired diastolic function [163]. Studies on 
Type 1 diabetic patients without ischemic heart disease showed that severe CAN was correlated 
with abnormal cardiac diastolic filling [164]. Higher levels of ventricular fibrillation are reported in 
diabetic patients, suggesting high sympathetic activity in diabetes [165]. Moreover, ventricular 
filling abnormalities are most prominent in patients with autonomic neuropathy [166]. In addition to 
abnormal diastolic filling, an abnormal systolic blood pressure in response to standing was 
significantly associated with reduced mitral E/A ratio (ratio of early to late peak mitral filling wave 
velocities). The E/A ratio has been shown to be significantly reduced in patients with autonomic 
neuropathy, suggesting a significant correlation between E/A ratio and autonomic neuropathy [167]. 
Parasympathetic dysfunction was associated with abnormal cardiac function. It was reported that a 
lower level of heart rate variation during deep breathing was correlated with abnormal diastolic 
peak filling rates in diabetic patients [168].  
1.2.3.2.6 Diabetic vasculopathy and microangiopathy 
In diabetes, a reduction was found in coronary blood flow reserve without apparent CAD [169]. 
Vascular remodeling and vasomotor symptoms are cumulatively enhanced by increased production 
of glycated proteins and, in particular, an increase in vascular growth factors, which are caused by 
impaired NO production due to hyperglycemia [169]. Some observational studies reported that 
vascular endothelial growth factor (VEGF) might perform a significant role in response to cardiac 
injury. Studies on diabetic and insulin-resistant rats revealed that VEGF mRNA and protein level 
expression were decreased in myocardium [170]. However, clinical evidence from patients with 
myocardial infarction suggested that the expression of VEGF mRNA was dramatically increased in 
cardiomyocytes [171]. Down-regulation of VEGF probably contributed to the development of 
diabetic cardiomyopathy, since cardiac dysfunction was normalized after gene transfer of a plasmid 
encoded human VEGF into cardiomyocytes [172]. In addition, STZ-induced diabetic rats showed 
an impaired angiogenic response and reduced VEGF, which correlated with increased expression of 
endothelin 1 in the ventricles, whereas antagonism of endothelin receptor normalized VEGF 
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signaling and cardiac dysfunction [173]. 
 
Pathologically, microangiopathy may considerably impact on diabetic cardiomyopathy. Abnormal 
permeability of diabetic capillaries causes periarterial fibrosis and focal subendothelial proliferation 
and fibrosis, leading to microangiopathic alterations, such as arteriolar thickening, capillary 
microaneurysm and capillary density reduction [174]. Myocardial and ventricular hypertrophy may 
be the result of endothelial dysfunction and abnormal protein synthesis in endothelial cells, which 
facilitate the attachment of leukocytes and monocytes [175]. Studies on diabetic patients without 
overt CAD also showed that distal atherosclerosis is associated with coronary microangiopathy 
[176]. 
1.2.3.2.7 Activation of the Renin-Angiotensin System (RAS) 
In the development of diabetic cardiomyopathy, activation of the RAS has been well recognized. 
Experimental evidence has suggested activation of RAS, which is associated with increased 
oxidative damage, endothelial cell and cardiomyocyte apoptosis, further causes increased cardiac 
fibrosis and contractile dysfunction [130]. It has been reported that the angiotensin-receptor 
signaling pathway causes elevated oxidative activity via NADPH, resulting in the oxidative damage 
of cardiomyocytes to apoptosis and the increased interstitial fibrosis [177]. Moreover, the increase 
in angiotensin-II induces the production of ROS, which leads to oxidative damage of 
cardiomyocytes and endothelial cell apoptosis [178, 179]. Angiotensin-II is also induces ischemia 
by causing calcium overloading in cardiomyocytes through reduced activities of the 
sodium/calcium exchanger, sodium/hydrogen exchanger and opening of T-type calcium channels. 
Up-regulation of RAS may induce myocardial ischemia in diabetic heart through these mechanisms 
[180-182].  
 
In STZ-induced diabetic rats, inhibition of RAS and use of antioxidants decrease the production of 
ROS, which reduces the cardiac dysfunction via restoration of sarcoplasmic calcium handling and 
reverses the SR Ca
2+
 loading [183, 184]. Similarly, IGF-1 has been shown to reduce RAS activity, 
which leads to decreases in cardiac apoptosis and development of diabetic cardiomyopathy [185, 
186].   
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1.2.3.2.8 Ion channel abnormalities 
Altered metabolism causes reduced Ca
2+
 uptake as discussed above, and changes in ion channel 
activity in cardiomyocytes. Decreased [Ca
2+
]i transients triggered by electrical stimulations have 
been reported in diabetic cardiomyocytes, following reduced caffeine induced SR calcium release, 
which leads to the depressed cardiac contraction [187-189]. Combined with decreased activity of 
the SR calcium pump, it is believed that altered cardiac action potential may be involved in diabetic 
cardiomyopathy. Diabetic rat hearts have an increase in calcium currents, a decrease in 
calcium-independent transient outward currents (Ito) and prolonged action potentials [190-194]. 
Diminished Ito may prolong the duration of calcium influx through voltage-gated calcium channels, 
resulting in the delayed repolarization of cardiac action potential [195, 196]. Increased action 
potential duration in diabetic cardiomyocytes induces depressed sodium/calcium exchanger activity, 
resulting in the inhibition of calcium efflux and constant elevation of intracellular calcium 
concentrations, which may be responsible for cardiac diastolic dysfunction – a typical phenotype of 
diabetic cardiomyopathy [192]. Voltage-clamp studies revealed depressed Ito activity in isolated 
diabetic cardiomyocytes, which was normalized to control levels by insulin treatment [197]. It has 
been proposed that inhibition of Ito is attenuated by decreased glucose phosphorylation activation of 
the thioredoxin system. Reducing activity of thioredoxin inhibits the increase in Ito by insulin. Thus 
Ito activity may be regulated by the redox pathway of the thioredoxin system [198]. Diabetic 
cardiomyopathy is linked to an increase in Ca
2+
 currents and a decrease in the Ito current and 
prolonged action potential duration. Detailed biophysical analysis of ion channel kinetics and 
functional coupling of ion channel modifications to cardiac function require further careful single 
cell studies. 
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Figure 1.3 Proposed mechanism of impaired cardiac function in diabetes 
RyR, ryanodine receptor; NCX, sodium/calcium exchanger; SERCA2a, sarcoplasmic reticulum 
Ca
2+
-ATPase 2a; SR, sarcoplasmic reticulum; AP, action potential; PPARα, peroxisome 
proliferator-activated receptpr alpha; FA, fatty acid; ROS, reactive oxygen species [199]. 
1.2.4 Growth hormone secretagogues (GHS) 
Growth hormone secretagogues (GHS) are a family of ligands, including peptidyl, non-peptidyl 
molecules and small synthetic compounds, with the ability to stimulate growth hormone (GH) 
secretion from the pituitary [200]. GHSs act mainly through the GHS receptor (GHS-R), a 
seven-transmembrane-spanning G-protein coupled receptor [201]. Ghrelin, a 28 amino acid peptide 
derived from the enteroendocrine cells of the stomach, is an endogenous ligand of GHS-R. The 
ghrelin peptides circulate in two distinct forms, acylated ghrelin and des-acylated ghrelin [202]. As 
a synthetic analogue of ghrelin, hexarelin (Hex) is one of synthetic peptide GHSs that binds and 
activates the GHS-R. Ghrelin is mainly synthesized and secreted by X/A-like cells in the oxyntic 
glands of the stomach. However, lower ghrelin expression and secretion have also been 
demonstrated in other tissues, including the gastrointestinal tract, pancreas, brain, pituitary gland, 
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kidney, lung, placenta and heart [200, 202]. 
1.2.4.1 Ghrelin in islet function 
Pancreatic function studies with ghrelin have reported conflicting and controversial outcomes. 
Accumulative data have shown that insulin release is inhibited by ghrelin in mice, rats and human 
[203-206]. Meanwhile fasting insulin levels are increased with low levels of plasma ghrelin and 
insulin resistance in clinical studies [207, 208]. Furthermore, ghrelin administration induces 
elevation of blood glucose in GH-deficient mice, which is reversed by GHS-R blockers [206]. 
Taking this evidence together, ghrelin possibly performes a pathophysiological role in insulin 
release and glucose metabolism, which may be also a contributor to pathogenesis of obesity and 
diabetes. However, ghrelin showes protective effect on pancreatic islets as well. It has been stated 
that ghrelin stimulates insulin secretion in both normal and STZ-treated rats in a dose-dependent 
manner. This stimulating effect of insulin release is inhibited by calcium channel antagonists, 
suggesting ghrelin-induced insulin secretion is involved in calcium signaling pathway [209]. 
Moreover, STZ-treated neonatal rats with ghrelin administration displayed cell proliferation in islet 
β-cell [210]. It was uncertain that improved β-cell proliferation was direct or indirect from ghrelin 
treatment as ghrelin is able to stimulate food intake and GH secretion which can also contribute to 
cell growth [202, 211-214]. Further studies using ghrelin-overexpressed mice showed that, with 
unchanged level of plasma ghrelin, insulin release was enhanced in STZ-treated animals, indicating 
that ghrelin directly promotes β-cell proliferation [215]. Although the anti-apoptotic effect of 
ghrelin has been showed in vitro rat and human islet β-cell experiments [216], the study observed 
unchanged apoptotic cell number [215]. 
1.2.4.2 Stimulated GH secretion of GHSs 
GHSs have been shown to stimulate GH secretion in both animals and humans while GHRH is 
considered as the essential mediator of GHS-stimulated effect of GH release [217, 218]. 
Experimental and clinical studies have reported that GHRH antiserum or GHRH receptor (GHRH-R) 
antagonists can suppress GH responses to administration of GHS (GHRP-6) [219, 220]. GHRH-R 
deficient patients also displayed depressed GH secretion after GHS administration [221, 222]. 
Furthermore, Hex treatment increased the GHRH-R expression with elevated GH release, indicating 
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GHSs stimulate GH secretion through the GHRH [223]. GHS-R is widely expressed in the arcuate 
nucleus (ARC) GHRH neurons, the stimulating effect of GHSs increased ARC c-fos expression 
both in vivo and in vitro [224-226]. Administration of GHRP-6 in pigs demonstrated that increased 
GH secretion was associated with activation of c-fos in the pituitary, but not hypothalamus, 
indicating that the GHS-mediated GH release effect primarily occurs in the pituitary [227]. 
However, ghrelin-signaled GH-releasing pathway is different, but complementary to, the 
GHRH-mediated GH secretion. Ghrelin activates phospholipase C (PLC) via the GHS-R, inducing 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). DAG further activates protein kinase C (PKC), triggering Ca
2+
 influx 
through voltage-gated Ca
2+
 channels and subsequently elevated intracellular Ca
2+
 concentration, 
which cause GH release. GHRH increases cAMP cycling through GHRH-R binding, resulting in 
elevated synthesis and secretion of GH [228]. Although the GH-releasing effect of ghrelin is 
primarily through PLC, GHS also stimulates GH secretion through the cAMP pathway with/without 
GHRH. This may explain why GH synthesis and secretion was increased with response to GHSs in 
GHRH deficient status [229-231].        
1.2.4.3 The cardio-protective effect of GHSs 
Both ghrelin and Hex induce beneficial effects on the cardiovascular system. Recent evidence 
indicates that GHSs modulate a variety of cardiovascular activities, including an increase in 
myocardial contractility [232, 233], improvement of left ventricular dysfunction and left ventricular 
pathological remodeling [234, 235], protection of cardiomyocytes from angiotensin II-induced 
apoptosis [236] and proliferation of cardiac fibroblasts [237]. A series of studies in animals and 
humans have confirmed the protective effects and suggested the underlying mechanisms of GHSs 
(shown in Figure 1.5). Administration of ghrelin in humans causes a significant reduction in mean 
arterial pressure. In experimental and clinical studies of chronic heart failure, ghrelin treatment 
improves LV dysfunction [235] and attenuates of cardiac cachexia [238] possibly through inhibition 
of inflammatory response such as interleukin (IL)-1β and tumor necrosis factor-α (TNF-α) [239]. In 
addition, ghrelin and Hex produce a positive inotropic effect on isolated cardiomyocytes through 
GHS-R1a and PKC [240]. GHSs also has protective effects against myocardial injury either in vitro 
or in vivo mainly via inhibition of TNF-α induced nuclear factor-κB (NF-κB) activation, 
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mitochondrial apoptosis (bcl-2), oxidative pathway (superoxide dismutase) and endothelin-1 (ET-1) 
[241, 242]. Moreover, ghrelin and Hex enhance cardiac performance, such as induced 
vasoconstriction in rat vasculature through activation of PKC and Ca
2+
 handling [243], inhibited 
apoptosis of primary rat cardiomyocytes and the H9c2 cell line by activation of extracellular 
signal-regulated kinase-1/2 (ERK-1/2) and Akt serine kinases [244], activate eNOS phosphorylation 
and generate NO in mouse aorta possibly through activation of AMP-activated protein kinase 
(AMPK) and Akt [241]. 
 
Figure 1.4 Putative signaling pathways that mediate the actions of GHSs  
AMPK, AMP-activated protein kinase; DAG, diacylglycerol; eNOS, endothelial NO synthase; ER, 
endoplasmic reticulum; ERK-1/2, extracellular signal-regulated kinase-1/2; ET-1, endothelin-1; 
IL-1β, interleukin-1β; IP3, inositol 1,4,5-trisphosphate; NF-κB, nuclear factor-κB; PKC, protein 
kinase C; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C; TNF-α, tumor necrosis factor-α 
(Adapted from [245]). 
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1.3 Aims and hypothesis 
As stated above, diabetes is characterized by β-cell dysfunction, depressed GH secretion and 
cardiovascular complications (diabetic cardiomyopathy). With an increased role for GHSs in 
stimulating pancreatic islet β-cell proliferation, insulin secretion, GH release and cardiac 
performance, I hypothesize that GHSs (Hex) will be able to recover β-cell dysfunction, depressed 
GH secretion and abnormal cardiac activity in diabetes. I will test this hypothesis under five specific 
aims: 
(1) To determine the effect of Hex on metabolism of STZ-induced diabetic rats (addressed in 
Chapter 3); 
(2) To assess the effect of Hex on pancreatic islet β-cell function of STZ-induced diabetes both in 
vitro and in vivo through insulin secretion, mitochondrial function and cell apoptosis (addressed 
in Chapter 4.1 and 4.2); 
(3) To assess the effect of Hex on pulsatile GH secretion in STZ-induced diabetic rats (addressed in 
Chapter 4.3); 
(4) To investigate the cardio-protective effect of Hex on STZ-induced diabetic cardiomyocyte 
function through measuring contractility, intracellular calcium concentrations, membrane 
potential, ion channel activity and apoptosis pathways (addressed in Chapter 5). 
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CHAPTER TWO – METHODS AND MATERIALS 
2.1 Cell culture and treatment 
The mouse β-cell line (MIN6) at passage number 25-28 was maintained at 37°C incubator with 5% 
CO2, and cultured in Dulbecco’s Modified Eagle Medium (DMEM) medium containing 4.5g/L 
D-glucose, supplemented with 50μM β-mercaptoethanol, 10% fetal bovine serum and 1% 
Penicillin-Streptomycin. To test the effect of Hex on STZ-induced β-cell damage, MIN6 cells were 
seeded in 96-well or 24-well plates. After the cells became ~85% confluent, they were serum 
starved for 6 hours. Cells were then divided into 4 groups: 1) Control group: cells were incubated 
with serum free medium (SFM) for 4 hours then incubated for another 2 hours with refreshed SFM; 
2) STZ treatment group: cells were incubated with 1mM STZ for 4 hours and then replaced with 
SFM for 2 hours; 3) Hex treatment group: cells were incubated with SFM for 4 hours and then 
replaced with 1μM Hex for 2 hours and 4) STZ+Hex treatment group: cells were incubated with 
1mM STZ for 4 hours and then replaced with 1uM Hex for 2 hours. To identify a suitable dosage of 
STZ for the experiments, MIN6 cells were seeded on several 2×2 cm2 coverslips, serum free 
medium were changed for 6 hours after cells became ~90% confluent. Cells were then treated with 
different concentrations of STZ (0, 0.5, 1.0, 2.0mM) in different time courses (0, 2, 6 hours). HE 
staining was performed using a previously established procedure with a minor modification [246]. 
2.1.1 Cell viability assay (MTS) 
MTS is a colorimetric method for sensitive quantification of viable cells in proliferation and 
cytotoxicity. Based on the reduction of MTS tetrazolium compound by viable cells, a purple colored 
product, formazan, is generated in the culture media. NADPH-dependent dehydrogenase enzymes 
are considered to carry out this process in metabolically active cells. The formazan dye produced by 
viable cells can be quantified by measuring the absorbance at 490-500nm. The assay can be used 
for the measurement of cell proliferation in response to growth factors, cytokines, mitogens and 
nutrients [247].  
 
MIN6 cells were cultured in 96-well plates. After treatment, cells were washed and 100ul fresh 
SFM was added to each well. To detect cell viability, 20μl cell titre solution (Promega, Madison, WI, 
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USA) was added into 100ul SFM. After incubation at 37°C for 2 hours, the absorbance of the plate 
was read using a 96-well plate reader at wavelength of 490nm. 
2.1.2 Mitochondrial function assay 
The positively charged Rhodamine 123 selectively accumulates in the mitochondrial living cells 
after incubation. When the function of mitochondria is damaged, mitochondrial membrane potential 
declines and mitochondria fail to retain Rhodamine 123 [248]. Cells were cultured in 24-well plates, 
treated with STZ and Hex as described above. After 6-hour treatments, the cells were washed with 
PBS and Rhodamine 123 (1μg/ml) was added. After incubation for 15 minutes, the cells were 
digested with trypsin. Fluorescence intensity was measured by using a fluorescence micro plate 
reader (FLUOstar OPTIMA, BMG LABTECH, NC, USA) at λex: 500nm, λem: 530nm. Results 
were expressed as the ratio of relative fluorescence unit (RFU) to protein content. 
2.1.3 Dihydroethidium (DHE) assay 
DHE is a specific blue fluorescent and cell-permeable product. Once it enters the cell, it is oxidized 
by interacting with O2
-
 to form oxyethidium, which in turn interacts with nucleic acids to emit a 
bright red color detectable qualitatively by fluorescent microscope [249, 250]. The levels of DHE 
are determined as an indicator of superoxide production from the recorded cells. DHE levels were 
measured in all treatment groups as an indicator of the cell superoxide activity. MIN6 cells were 
cultured in 24-well plates, after serum starving, 20μM DHE was added and incubated for 30 
minutes at 37°C. After 6-hour treatments, cells were digested with trypsin. Fluorescence intensity 
was then measured by using a fluorescence micro plate reader (FLUOstar OPTIMA, BMG 
LABTECH, NC, USA) at λex: 470 nm, λem: 590 nm. Results were expressed as the ratio of RFU to 
protein content. 
2.2 Ethics 
All experiments conformed to the Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication No.85-23, revised 1996) and the protocol was 
approved by the Animal Ethics Committee of The University of Queensland (AEC # 
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SBMS/199/13/NHMRC). All surgeries were performed under sodium pentobarbital anesthesia, and 
all efforts were made to minimize suffering. 
2.3 STZ-induced diabetic rat model 
STZ is a glucosamine-nitrosourea compound and toxic to cells by DNA damage. Because of similar 
structure with glucose, STZ is only recognized and transported by GLUT2 to pancreatic islet β-cells, 
resulting in specific destruction and dysfunction of β-cell [251]. The STZ-induced animal model has 
been previously described [126]. Adult male Wistar rat (5 weeks old) between 150g and 200g were 
supplied by The University of Queensland Biological Resources. Rats were caged separately, fed 
routinely on normal diet and water ad libitum in a temperature-controlled room (22±2°C) 
maintained on a 12 hour light/dark cycle. After 1 week of environmental adaptation, animals were 
injected intraperitoneally with a single dose of freshly prepared streptozotocin (STZ, 65mg/kg, 
Sigma, MO, USA; 0.05 M citrate buffer; pH 4.5) to induce diabetes. Control group received the 
same volume of citrate buffer only. Diabetes was confirmed 5 days following injection by 
measuring blood glucose level with an Accu-Chek glucometer (Roche, Indianapolis, USA). Fasting 
blood glucose level over 16.7mmol/L was considered as diabetic rats [252]. By 4 weeks after 
injection, a group of control and diabetic rats were received hexarelin (100μg/kg, ChinaPeptides, 
Shanghai, China) daily treatment for two weeks. Others were received same volume saline. The 
experiment design is summarized in Table 2.1.  
Table 2.1 Summary of animal model 
Animal group Group description 
Control Age-matched vehicle  
STZ One single dosage 65mg/kg STZ injection & 6 weeks 
disease development  
Control+Hex Age-matched vehicle + 2 weeks daily IP injection at 
dosage 100μg/kg hexarelin treatment  
STZ+Hex One single dosage 65mg/kg STZ injection & 4 weeks 
disease development + 2 weeks daily IP injection at 
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dosage 100μg/kg hexarelin treatment  
During disease development, daily food intake, water consumption, urine production, blood glucose 
level, body and heart weight were monitored. 
2.4 Measurement of pulsatile growth hormone secretion 
2.4.1 Blood collection 
The method has been previously described [253]. Animals had free access to food and water 
through blood collection. During disease development, animals were trained to be familiar with 
procedure of sampling in order to avoid stress generated consecutive blood collection. On the day of 
experiment, 36 sequential tail-tip blood samples were collected from 0800am at 10 minutes 
intervals. 1-mm portion of distal tail was excised by surgical blade and a small volume of blood was 
pooled on the tip of tail. 4μl of whole blood was collected by 10μl Gibson pipette and transferred to 
a 500ul eppendorf tube which containing 116μl of 0.05% PBS-T. Samples then mixed by vortex and 
placed on dry ice. After collection, a gentle pressure was applied on the wound to stem blood flow. 
Due to repeat sampling, the original wound might be disrupted, gently immersed tail wound in 
physiological saline (0.9% sodium chloride; Baxter, Old Toongabbie, New South Wales, Australia) 
and if necessary, removed the remaining scab by using the edge of surgical blade. After finished 
blood collection, samples were transferred to -80°C freezer for storage until further analysis.  
2.4.2 Analysis of pulsatile growth hormone secretion by sensitive sandwich ELISA 
To determine GH concentration, a sensitive sandwich ELISA had been developed and validated (as 
shown in Figure 2.1)[253]. In general, a 96-well plate was coated by monkey anti-rat antibody 
(1:40000, NIDDK-NHPP, Torrance, CA, USA) and incubated overnight at 4°C. Plate was then 
incubated with blocking buffer (5% skim milk powder in 0.05% PBS with Tween-20) to reduce 
non-specific binding. Mouse GH was used to generate standard cure. Briefly, a 2-fold serial dilution 
of mouse GH was made in PBS-T with BSA (0.2% PBS-T/BSA). 50μl of rabbit anti-serum to rat 
GH antibody (1:40000, NIDDK-NHPP, Torrance, CA, USA) was used as detecting antibody to 
bound standards and samples. After detection antibody incubation, 50μl of anti-rabbit IgG (1:2000, 
GE Healthcare Ltd., Little Chalfont, Bucks, UK) was applied to bound complex. Enzymatic 
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colorimetric reaction was occurred by adding 100μl O-phenylenediamine (OPD, Invitrogen, 
Carlsbad, CA, USA) to each well. To stop reaction, 50μl 3M HCl was added to each well. The plate 
was read at 490nm wavelength on Rainbow 96 monochromatic microplate reader. GH concentration 
was calculated by regression of standard curve. 
 
Figure 2.1 GH sandwich ELISA 
Monkey anti-GH primary antibody was used to coat plates overnight at 4°C. After incubating with 
blocking buffer, standards and samples were loaded to each well. Rabbit anti-GH primary antibody 
was used to detect GH content in samples. Conjugated rabbit HRP antibody was used as secondary 
antibody and O-phenylenediamine (OPD) was added to initiate enzymatic colorimetric reaction and 
subsequently the reaction was stopped by adding 3M HCl. The absorbance was read at 490nm 
wavelength on Rainbow 96 monochromatic microplate reader. 
2.4.3 Deconvolution analysis 
Deconvolutional analysis was characterized as kinetics and secretary pattern of pulsatile GH 
secretion [254, 255]. Measured parameters included basal, pulsatile, total GH secretion and the 
mode of secretary bursts (time in minutes from pulse onset to the peak of the burst). Approximate 
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entropy analysis was applied to calculate the orderliness of regularity of serial GH serum 
concentration [256].     
2.5 Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
2.5.1 Glucose tolerance test (GTT) 
GTT was performed after hexarelin treatment. Animals were under fasting overnight and the 
experiment started in the morning of following day. Animals were received glucose (2g/kg body 
weight) injection intraperitoneally after 40μl of blood samples collection from tail vein at time 0. 
Subsequently, the same amount of blood samples were collected at 15, 30, 45, 60, 90, 120 minutes 
points. All blood samples were then centrifuged at 6000rpm for 3 minutes at room temperature, and 
blood plasma were collected and directly put on dry ice. Plasma samples were then stored in -80°C 
freezer for glucose and insulin assay. 
2.5.2 Insulin tolerance test (ITT) 
ITT was performed 3 days after GTT. Animals were under fasting for 6 hours from 0800 in the 
morning and experiment started 1400. Human recombinant insulin (1IU/kg, Novo Nordisk, Demark) 
was applied by intraperitoneal injection and blood glucose was measured at time 0, 15, 30, 45, 60, 
90, 120 minutes points by an Accu-Chek glucometer. 
2.6 Euthanization 
After GTT and ITT, Animals were anesthesized with sodium pentobarbital (100mg/kg body weight). 
Terminal blood samples were collected using a heparinised syringe (100IU/ml) by cardiac puncture. 
Plasma samples were immediately collected via centrifugation (6000 rpm for 3 min at room 
temperature) and stored in -80°C freezer for insulin, IGF-1 and FFAs assays. Heart and pancreas 
tissues were collected for further analysis. 
2.7 Glucose and hormone analysis 
Blood glucose level was determined by Glucose Colorimetric Assay kit (Cayman Chemical, Ann 
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Arbor, MI, USA) with plasma samples collected during GTT. Samples from control and 
control+Hex group were diluted in 1:5; samples from STZ and STZ+Hex group were diluted in 
1:20 because of higher glucose concentration in diabetic animals. Circulating level of FFAs, IGF-1, 
insulin, and fasting level of insulin were measured by using NEFA-C Assay (Wako, Osaka, Japan), 
Mouse/Rat IGF-1 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) and Mouse/Rat 
Insulin ELISA kit (EMD Millipore, St. Charles, MI, USA), respectively. Experiments were 
conducted according to the manufacture’s instructions.  
2.8 Immunofluorescence staining and imaging quantification of rat pancreatic islets 
Rat pancreas were collected after animals sacrifice and fixed in 4% paraformaldehyde at 4°C 
overnight, followed by immersion in 30% sucrose for 3 days at 4°C and then frozen. Sections were 
cut at 30um on a cryostat and incubated overnight with the following primary antibodies: mouse 
anti-insulin (1:400, Millipore Corporation, Bedford, MA, USA), and rabbit anti-glucagon (1:400, 
Thermo Scientific, Rockford, IL, USA), rabbit anti-Bax (1:400, Cell Signalling Technology, 
Danvers, MA, USA) and rabbit anti-caspase-9 (1:100, Abcam, Cambridge, UK). The appropriate 
secondary antibodies conjugated with Alexa 546 and Alexa 488 (1:2000; Invitrogen, Melbourne, 
Victoria, Australia) were used. Golden anti-fade with DAPI (Invitrogen, Melbourne, Victoria, 
Australia) was added onto the slides and coverslips were placed on the slides. The slides were dried 
for 2 hours, sealed with nail polish and stored at -20°C. Digital images were compiled using 
confocal microscopy (LSM 510 META, Zeiss).  
 
After pancreatic slide imaging, eight to twelve islets of eight sections from every investigated 
animal were quantified by Imaris software (Bitplane AG, Zurich, Switzerland). All positive stained 
cells were counted. The quantification included number of islets α-cells and β-cells, islets diameter, 
and positive staining of Bax and caspase-9.  
 
2.9 Cardiomyocytes isolation 
Rat cardiomyocytes were isolated from the intact heart after anesthesia and following a procedure 
previously described [240]. The heart was rapidly removed and the aorta was cannulated onto a 
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20-gauge stainless-steel blunt needle connected with a Langendorff perfusion system (as shown in 
Figure 2.2). To ensure cardiomyocytes was functional, the cannulated procedure was completed in 
45 seconds. The heart was perfused with 100% oxygenated Ca
2+
-free Tyrode solution (as shown in 
Table 2.2) for 5 minutes to wash out the blood left in the heart. The digestion was followed with a 
Tyrode solution (100μM Ca2+) containing 0.8mg/mL collagenase (Type I, 256 U/mg; Worthington, 
NJ, USA) and 0.15 mg/ml proteinase Type XXIV (Sigma, MO, USA) for 15–20 minutes. The actual 
digestion time was varied heart to heart among different groups. After digestion, the heart was 
perfused with 100uM Ca
2+
 Tyrode solution to remove collagenase for at most 5 minutes. Then the 
ventricle was cut and transferred into a petri dish with Tyrode solution (100μM Ca2+). The tissue 
was gently titrated after ventricle cut into small pieces by small surgical scissor. Then cells were 
released from the tissue and collected into a 50mL falcon tube for suspension. To achieve 
experiment condition, the Ca
2+
 level was gradually increased to 1.5mM. As some cardiomyocytes 
were intolerant to high Ca
2+ 
concentration during gradual increase of Ca
2+
 level, only Ca
2+
-tolerant 
and quiescent cardiomyocytes with rod shape, sharp edges and clear striation were used for 
investigation within 8 hours. 
 
Figure 2.2 Langendorff perfusion apparatus for rat cardiomyocytes isolation 
Rat heart was cannulated onto the Langendorff perfusion apparatus and isolated with Tyrode 
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solution bubbled with 100% O2. The heat circulator connected to maintain the system running at 37 
ºC. The perfusion pressure was kept at 80 mmHg (relative to the heart) so that the flow rate was 
approximately 7ml/min (Modified from [257, 258]). 
 
Table 2.2 Composition of the Tyrode solution 
 Tyrode solution (mM) 
NaCl 140 
KCl 5.4 
MgSO4 1.2 
HEPES 5 
NaH2PO4 1 
Glucose 10 
Taurine 20 
pH of the solution was adjusted to 7.4 with NaOH. 
 
2.10 Measurement of cell contractility and intracellular Ca
2+
 transients 
2.10.1 Measurement of cell contractility 
Cardiomyocyte contractility was determined by sarcomere shortening measurement using the 
IonOptix setup, as previously described (as shown in Figure 2.3) [240]. After isolation, 
cardiomyocytes in 1.5mM Ca
2+ 
Tyrode solution were transferred to the perfusion chamber (perfused 
with 1.5mM Ca
2+ 
Tyrode solution) fixed to the stage of an inverted microscope (Nikon eclipse 
TE2000-U, Nikon, Japan) connected to the IonOptix MyoCam camera (IonOptix Corporation, MA) 
for video based measurement. A pair of platinum electrodes was connected to the IonOptix 
MyoPacer field stimulator (IonOptix Corporation, MA) generated a field stimulation at 0.5 Hz with 
5ms square wave (voltages above 20% of threshold) across the bath of cell [259]. The Cell Framing 
Adapter (IonOptix Corporation, MA) was then used to adjust the position of the cardiomyocyte to 
ensure it was in the centre of the video display and the striation pattern of cell was vertically aligned 
within the view. Sarcomere length was measured by a customized region of the cell with clear 
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striation and 20-30 consecutive contractions were recorded after trace of cell contraction stabilized. 
Then the data were stored for subsequent analysis. IonWizard software (IonOptix Corporation, MA) 
was used to analyze the data by averaging traces obtained from the 20-30 cardiac cycles and 
percentage of sarcomere shortening, time-to-peak shortening, time-to-90% relaxation, rate of cell 
shortening and relaxation were analyzed. 
 
Figure 2.3 IonOptix setup for the cardiomyocyte contractility and Ca
2+
 recording system 
The isolated cardiomyocytes in 1.5mM Ca
2+ 
Tyrode solution were transferred to a perfusion 
chamber fixed to the stage of an inverted microscope connected with IonOptix MyoCam camera. A 
field stimulation at 0.5 Hz with 5ms square wave (voltages above 20% of threshold) was applied 
across the bath of cells. The Cell Framing Adapter was used to adjust the position of the 
cardiomyocyte in the view, and cell shortening was measured from the customized adjustable region 
of interest and analyzed based on the change in sarcomere length. Intracellular Ca
2+ 
transient was 
measured based on the recording of Fura-2 fluorescence signals. Cytoplasmic Fura-2 was excited by 
an IonOptix Hyperswitch dual-excitation light source at 340 and 380 nm during stimulation at 0.5 
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Hz and the emitted light was collected in a photomultiplier tube (PMT). [Ca
2+
]i concentration was 
inferred from the ratio of the intensity of the emitted fluorescence signals at these two wavelength 
(Modified from IonOptix products sheet). 
 
2.10.2 Measurement of intracellular Ca
2+ 
transient 
As shown in Figure 2.4, intracellular Ca
2+ 
concentration ([Ca
2+
]i) was determined by using 
ratio-metric fluorescent dye, Fura-2. Fura-2 is commercialized and widely applied for Ca
2+ 
imaging 
in various cell types including cardiomyocytes [195, 260, 261]. However, Fura-2 is not membrane 
permeable and cannot be directly added in extracellular solution. Therefore, its membrane 
permeable derivate Fura-2 acetoxymethyl ester (Fura-2 AM) is used for solution loading. Because 
of its membrane permeable characteristics, Fura-2 AM is able to cross cell membrane. Then the 
acetixymehyl group is cleaved by cytosolic esterase after Fura-2 AM inside the cell and transferred 
to membrane impermeable form, Fura-2. Once inside the cell, Fura-2 can capture Ca
2+ 
and be 
excited at 340nm and 380nm wavelength. The [Ca
2+
]i is calculated by the ratio of emitted 
fluorescence intensity at these two wavelength (R). Because Fura-2 can also be detected at 510nm 
of light in the absence of Ca
2+
, the reliable method of [Ca
2+
]i measurement in cardiomyocytes is the 
ratio-metric estimation way [261]. 
 
Intracellular Ca
2+ 
concentration was measured by the same set-up used for cell contractility 
measurement but loading with Fura-2 AM (Invitrogen, CA, USA). 5uM Fura-2 AM was loaded into 
50ml Falcon tube containing around 10ml cardiomyocytes suspension with 1.5mM Ca
2+
 Tyrode 
solution for 10 minutes at room temperature. Cardiomyocytes were then transferred to another 50ml 
Falcon tube containing 20ml 1.5mM Ca
2+
 Tyrode solution. Once cardiomyocytes were settled down, 
up to 1ml cell suspension was loaded into perfusion chamber (as shown in Figure 2.3) to perfuse 
with 1.5mM Ca
2+
 Tyrode solution in order to remove residual Fura-2 AM. Cardiomyocytes were 
then recorded as same procedure described above. IonOptix Hyperswitch dual-excitation light 
source (IonOptix Corporation, MA) was used to record the emitted fluorescent signals of exited 
Fura-2 at 340 and 380 nm and collected by photomultiplier tube (PMT, IonOptix Corporation, MA). 
The ratio of the emitted fluorescence intensity at these two wavelength was used to calculate 
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alteration of [Ca
2+
]i concentration in cardiomyocytes. Offline ratio-metric analysis was conducted 
with IonWizard software (IonOptix Corporation, MA). Parameters included amplitude, 
time-to-peak, time-to-90% decay, rate of rise and fell of [Ca
2+
]i transients were determined. 
 
Figure 2.4 Mechanism of the intracellular Ca
2+
concentration measurement with Fura-2. 
As membrane permeable form, Fura-2 AM cross cell membrane and transfer to membrane 
impermeable form, Fura-2 by cleaving its acetoxymethyl group with cytosolic esterase. Once 
Fura-2 trapped in the cell, it can capture Ca
2+ 
and be excited at 340nm and 380nm. The ratio of 
emitted fluorescence intensity (R) at these two wavelength (F340 and F380) is directly associated 
with the [Ca
2+
]i. This ratio-metric estimation method of [Ca
2+
]i is independent of the amount of dye 
present in the cell and the thickness of the cell. (Modified from Calcium tutorial and calcium 
signaling website) 
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2.11 Measurement of action potential and voltage-gated ion channel 
2.11.1 Measurement of action potential (AP) 
Conventional whole-cell patch clamp was applied to determine AP and current through 
voltage-gated ion channel of cardiomyocytes. Experiment procedure had been described previously 
[262, 263]. Generally, cardiomyocytes in 1.5mM Ca
2+
 Tyrode solution were loaded into the 
chamber fixed on the stage of an inverted microscope for settle down. Glass micropipettes 
purchased from borosilicate glass capillaries with inner filaments (Harvard Apparatus Ltd., 
Edenbridge, UK) were pulled by a Sutter P-87 microelectrode puller (Sutter Equipment Co., Novato, 
CA, USA). Intracellular solution was then filled into micropipettes and connected to a chloride 
silver electrode to generate conductance by ions movement through membrane channels to 
amplifier (Axopatch 200A amplifier, Axon Instruments, Foster City, CA, USA). Suction was 
applied when the micropipette was attached to the cell membrane to help form a high resistance 
(more than 1 GΩ) between the cell and the micropipette. Subsequently, the cell membrane was 
ruptured by further suction to establish the environment to exchange cytoplasmic content between 
the internal solution and the inner cell (as shown in Figure 2.5). 
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Figure 2.5 Conventional whole-cell patch clamp 
The glass with a tiny tip (0.5~1μm) was used to patch and seal the membrane surface area with 
intracellular solution. A suction was applied to the interior of the electrode to form a gigaseal (high 
resistance, 1-10GΩ) after the micropipette was attached to the cell membrane (low resistance, 
2-5MΩ). To rupture the membrane, a further suction was applied and created a low-resistance 
pathway between the electrode and inner cellular content, which allows to monitor ions movement 
across the entire cell surface (Modified from [264]). 
 
In the experiment, capacitance and series resistance compensation were optimized and 60-75% 
compensation was usually obtained. Recorded signals were low-pass filtered at 1kHz. Data 
acquisition and analysis were conducted with pClamp program (version 10.2, Axon Instruments). 
Resting membrane potential (RMP) and AP were recorded by using zero current clamping. 
Cardiomyocytes were depolarized by given a positive stimulation to induce changes of membrane 
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potential. For AP recording, 1.5-fold excitation threshold current pulses of 3ms in duration with 2s 
intervals between pulses was applied to the experiment. 10 successive traces of AP were recorded 
after recordings stabilized. Data was obtained by averaging the recorded traces and analyzed 
parameters include RMP, AP amplitude, APD at 20%, 50%, and 90% repolarization phases (APD20, 
APD50, and APD90, respectively). The composition of the patching solutions for AP recording is 
listed in Table 2.3.   
Table 2.3 Composition of the patching solution for action potential (AP) and transient outward 
potassium current (Ito). 
 Pipette solution 
Potassium asparatate (mM) 110 
KCl (mM) 20 
MgCl2 (mM) 1 
HEPES (mM) 5 
EGTA (mM) 1 
MgATP (mM) 5 
pH of the solution was adjusted to 7.3 with KOH. External solution was 1.5mM Ca
2+
 Tyrode 
solution (see Table 2.2). To record Ito, Tetrodotoxin (TTX, 1uM, sodium channel blocker), 
nifedipine (100nM, calcium channel blocker) and TEA-Cl (50mM, delayed rectifier potassium 
channel blocker) were applied to the external solution during the course of recording of Ito. A 
50msec pre-step of -40mV from the holding potential of -80mV was applied to inactivate the 
sodium channel.  
2.11.2 Measurement of transient outward potassium current (Ito) 
To record Ito, Tetrodotoxin (TTX, 1μM, sodium channel blocker), nifedipine (100nM, calcium 
channel blocker) and TEA-Cl (50mM, delayed rectifier potassium channel blocker) were applied to 
external solution to eliminate the noise of sodium, calcium and delayed rectifier potassium channels. 
The holding potential of -80mV was applied and a 50msec pre-step of -40mV was further applied to 
inactivate the sodium channel. Ito was then evoked by the following test pulses from -30 to +60mV 
in 10mV increments for 200msec. Steady-state inactivation of Ito was measured after a 500ms 
conditioning pre-pulses from a holding potential of -80mV to potentials between -100 mV and 0 
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mV in steps of 10mV, followed by a test pulse to +80mV (peak Ito) for 200ms. An inactivation curve 
was fitted with the Boltzmann equation. All recordings were performed at room temperature and 
data were analyzed by using Clampfit 10.2 program of pClamp software (Axon Instruments, Foster 
City, CA, USA).  
2.12 Analysis of protein expression with western blot 
The protein expression of GHS-R, Bcl-2, Bax, caspase-3 and caspase-9 was determined by western 
blot analysis. Briefly, Total protein was extracted from MIN6 cells and homogenized rat heart 
ventricle by using lysis buffer (composition shown in Table 2.4). The concentration of each protein 
sample was examined with BCA assay kit (Pierce, IL, USA). Equal amount of protein from each 
sample was denatured at 70°C (GHS-R) or 95°C (Bcl-2, Bax, caspase-3 and caspase-9) for 10 min 
in 5× sample buffer (Table 2.5) and separated by on a 10% SDS-PAGE gel. Proteins were then 
transferred to nitrocellulose membranes (Millipore Corporation, Bedford, MA, USA) and blocked 
with 5% skim milk-TBS for 1 hour. Primary antibodies for GHS-R (1:500, Abcam, Cambridge, MA, 
USA), Bcl-2 (1:500, Cell Signalling Technology, Danvers, MA, USA), Bax (1:1000, Cell Signalling 
Technology, Danvers, MA, USA), caspase-3 (1:1000, Cell Signalling Technology, Danvers, MA, 
USA) and caspase-9 (1:1000, Cell Signalling Technology, Danvers, MA, USA) were incubated with 
1% skim milk-TBS overnight at 4°C. Subsequently, horseradish peroxidise (HRP)-conjugated 
secondary antibody (1:10000, GE Healthcare, Freiburg, Germany) and Pierce ECL western blotting 
substrate (Thermo scientific, Rockford, IL, USA) were used to detect protein bands. α-tubulin and 
β-tubulin were used as a loading control and quantification was performed by ImageJ software with 
scanned films [265]. 
Table 2.4 Composition of lysis buffer 
 Lysis buffer (mM) 
HEPES (ph 7.4) 50 
NaCl 150 
Triton- X 1% 
Na3VO4 1 
NaF 30 
Na4P2O7 10 
EDTA 10 
Protease inhibitor 1 Tablet in 1ml 
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Milli-Q 
 
Table 2.5 Composition of 5× sample buffer 
 5× sample buffer (mM) 
TEA-Cl (mM) 250 
Sodium dodecyl sulfate (%) 2 
Glycerol (%) 10 
Dithiothreitol (mM) 20 
Bromophenol blue (%) 0.01 
Na3VO4 (mM) 165 
The Tris-HCl used for 5× sample buffer needs to be adjusted at pH 6.8 with HCl. 
2.13 Statistical analysis 
All data were analyzed by using GraphPad Prism software (GraphPad Software, San Diego, CA, 
USA) and expressed as mean ± standard error of the mean (SEM). Two-sample comparisons were 
performed using Student’s t-test and multiple comparisons were carried out by one-way ANOVA 
with Tukey-post hoc test as appropriate. In all comparisons, the differences were considered to be 
statistically significant at a value of P<0.05. 
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CHAPTER THREE – EFFECT OF HEX ON METBOLISM OF ANIMALS 
WITH/WITHOUT STZ TREATMENT 
As stated in 2.3, the diabetic rat model was induced by a single dose of STZ (65mg/kg) IP injection. 
Because the study was initially designed for investigating diabetic cardiomyopathy, a 4-week 
disease development was given after STZ injection to promote cardiovascular complications, as 
previously suggested [121]. The dosage and duration of Hex treatment (100μg/kg) was applied 
according to a previous study [266]. Therefore, administration of Hex commenced at week 4 after 
STZ induction for a subsequent two weeks.  
3.1 Effect of Hex on body weight gain and blood glucose 
Body weight gain was measured twice a week and blood glucose levels were determined once a 
week. Results showed characteristics of hyperglycemia, polyphagia, polydipsia and polyuria in 
STZ-treated diabetic rats, which was consistent with previously published studies [267-269]. As 
shown in Figure 3.1, the body weight gain of the STZ group was quite slow in comparison of 
control animals, whereas blood glucose level of STZ rats was dramatically increased and 
maintained at high levels through their life span, indicating apparent hyperglycemia presented in 
STZ-treated rats. Hex significantly elevated body weight gain in both control and STZ animals. 
Meanwhile, STZ+Hex co-treated rats showed declined levels of blood glucose after 1-week Hex 
injection and achieved significant difference following the 2-week treatment, suggesting Hex was 
able to reduce blood glucose levels in diabetes. No effect was observed on blood glucose level of 
Hex-treated control group.  
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Figure 3.1 Effect of Hex on body weight gains and blood glucose levels from control, 
control+Hex, STZ and STZ+Hex rats. 
(A) Body weight gain and (B) blood glucose levels were monitored weekly after STZ injection. 
Animals were received daily Hex treatment from week 4 for two weeks. Hex increased body weight 
gain in both control and STZ rat, and also slightly recovered blood glucose level of STZ animals. 
No changes were observed on blood glucose level of Hex-treated control rats. n=36 from each 
group, data are shown as means ± SEM *P<0.05, ** P<0.01 was compared to STZ group and ## 
P< 0.01 is compared to control group. 
3.2 Effect of Hex on weight of heart and adipose tissue 
Weight of heart and adipose tissue were measured after animals were sacrificed. Along with 
decreased body weight gain, weight of heart and adipose tissue in STZ-treated rats also declined (as 
shown in Figure 3.2). Compared to the control group, approximately 30% percent of heart weight 
was lost in STZ rats (1.25 ± 0.06g vs 0.88 ± 0.03g). In addition, the STZ group also showed a 
10-fold decline in weight of adipose tissue in comparison with control animals (6.12 ± 0.27g vs 
0.64 ± 0.07g). Hex treatment recovered this decreased heart weight in the STZ rats to 1.12 ± 0.04g; 
similar to the control level. There was also a significant increase in heart weight of Hex-treated 
control rats. Associated with elevation of heart weight, increased weight of adipose tissue was 
observed in both control and STZ animals after Hex treatment. The dramatically decreased weight 
of fat tissue in STZ rats was reversed by Hex injection. Hex-treated control animals exhibited a rise 
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of fat weight but the value did not achieve significance. There is no difference observed in the ratio 
of heart weight and body weight among groups, suggesting the increase or decrease of heart weight 
by STZ and Hex was associated with body weight. 
 
Figure 3.2 Effect of Hex on heart weight, ratio of heart weight and body weight, and adipose 
tissue from control, control+Hex, STZ and STZ+Hex rats.  
Decreased weight of (A) heart and (C) adipose tissue were observed in STZ rats compare to control 
group. Hex treatment recovered weight of both heart and adipose tissue. An increase was also 
exhibited on weight of heart and adipose tissue in Hex-treated control rats. No difference was 
observed on (B) ration of heart weight and body weight among groups. n=36 from each group, data 
are shown as means ± SEM *P<0.05, *** P<0.001.  
3.3 Effect of Hex on food intake, water consumption and urine production 
As stated above, the animal model used in the study showed apparent diabetic symptoms, such as 
polyphagia, polydipsia and polyuria. By the end of the study, daily food intake, water consumption 
and urine production were dramatically increased in STZ-induced diabetic rats compared to the 
control group (as shown in Figure 3.3). Hex treatment ameliorated urine production in STZ group, 
but had no effect on food intake or water consumption. However, increased food intake was 
observed in Hex-treated control animals with decreased urine production. Hex also exhibited no 
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effect on water consumption of the control group.  
 
Figure 3.3 Effect of Hex on daily food intake, water consumption and urine production from 
control, control+Hex, STZ and STZ+Hex rats. 
Significant increased daily (A) food intake, (B) water consumption and (C) urine production were 
observed in STZ rats. Hex treatment reduced production of urine, but had no effect on food intake 
and water consumption in STZ group. However, increased food intake was seen in Hex-treated 
control animals with slightly decreased urine production. No effect of Hex was observed on water 
consumption of the control group. n=36 from each group, data are shown as means ± SEM. 
*P<0.05, **P<0.01, ***P<0.001. 
3.4 Discussion 
STZ is a natural chemical specifically toxic to pancreatic islet β-cells and initially used for treating 
cancer in islet β-cells [270]. STZ induces DNA damage through activation of poly 
ADP-ribosylation. Due to similar structure to glucose, STZ has high affinity to bind islet β-cells via 
glucose transporter protein GLUT2 and then causes cell death, further inducing diabetes [251, 271]. 
For decades, STZ has been widely used for diabetes and diabetes-related research, because of its 
rapid effect to cause insulin deficiency. The STZ-induced animal model shows major characteristics 
of diabetes such as hyperglycemia, polyphagia, polydipsia and polyuria [267-269], and in my study, 
also presented increased blood glucose level, food intake, water consumption and urine production 
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in STZ-treated rats, consistent with diabetic patients.  
 
Ghrelin had been shown to have a protective effect on STZ-induced islets β-cells injury [210, 215] 
and Hex treatment ameliorated elevated blood glucose level in the STZ group. Published research 
on the same STZ-induced rat model demonstrated that ghrelin injection stimulated insulin secretion 
in both normal and STZ-treated rats [209]. It has been shown that the level of insulin secretion was 
increased with elevated exogenous ghrelin concentration. In addition, study on STZ-treated mice 
demonstrated that glucose metabolism was improved by ghrelin administration through islet β-cells 
proliferation [210]. Further study on ghrelin overexpressed transgenic animal model exhibited 
higher islets number, insulin levels and mRNA expression in pancreas, and protection of the 
pancreas from β-cells injury caused by STZ [215]. The similar effect of ghrelin and its synthetic 
analogue Hex indicates that Hex may acts on same pathway of ghrelin to protect pancreatic islet 
β-cells from damage caused by STZ and contribute to reduce blood glucose level in STZ animals.  
 
Increased body weight gain was observed associated with elevated weight of adipose tissue in both 
control and STZ groups after Hex treatment. As an orexigenic hormone released from stomach, 
exogenous ghrelin and Hex administration were able to increase food intake and body weight 
[272-274]. It has been shown that ghrelin acted through its receptor GHS-R in the hypothalamus to 
induce feeding behavior accompanied with increased expression of NPY mRNA, a potent 
neuropeptide located in ARC to stimulate food intake [212, 213, 275-278]. In addition, ghrelin 
regulates adipogenesis and lipid metabolism in peripheral tissue [279]. A study on adipose tissue 
revealed that preadipocyte differentiation was stimulated by ghrelin associated with antagonized 
lipolyposis [280], suggesting ghrelin administration may lead to adipocytes accumulation and 
eventually increase body weight. In present study, excess food intake occurred in STZ-treated rats, 
while STZ+Hex co-treated group showed similar amount of daily food intake but increased weight 
of body, adipose tissue, and heart tissue. This may be a result of Hex working through the same 
pathway on adipogenesis with ghrelin. Another ameliorated sign of diabetic symptoms was the 
decreased amount of urine produced in Hex-treated STZ group, it might be directly result from 
attenuated blood glucose level. Increased heart weight was also observed in both control and STZ 
groups after Hex treatment. Initially, elevated heart weight in Hex-treated control group may lead to 
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cardiac hypertrophy. However, after analyzing the ratio between heart and body weight, there was 
no difference observed among groups, indicating increased heart weight was associated with body 
weight.  
 
Put these findings together, Hex treatment improved STZ-induced diabetic symptoms, such as 
blood glucose level, urine production, body, heart and adipose tissue weight, possibly through 
promoting insulin secretion and stimulating pancreatic islet β-cells proliferation. Although there 
was no improvement of water consumption, Hex is still a potential and valuable candidate for 
diabetes therapy. Therefore, to further elucidate the mechanism of protective effect by Hex on 
STZ-induced diabetes, insulin secretion and pancreatic islet β-cells function were investigated next. 
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CHAPTER FOUR – PROTECTIE EFFECT OF HEX ON PANCREATIC ISLET β-CELLS 
FUNCTION AND PULSATILE GH SECRETION IN STZ-INDUCED DIABETES 
4.1 Effect of STZ and Hex on viability of MIN6 cells in vitro 
To clarify the protective effect of Hex on pancreatic islet β-cells, the mouse β-cell line (MIN6) was 
employed. The effect of STZ on the viability of MIN6 cells was first tested to identify a suitable 
dosage for the following experiments. Cell viability was significantly decreased by STZ treatment 
in a dose- and time-dependent manner (as shown in Figure 4.1A). After 1 hour of STZ treatment, 
cell viability was significantly decreased in the 2.0mM STZ groups compared with the control 
group. Further increases in incubation time resulted in a pronounced reduction of MIN6 viability, 
reaching the lowest viability at 6 hours with 2.0mM STZ. STZ-induced morphological changes of 
MIN6 cells were also observed by hematoxylin-eosin (HE) staining. As expected, HE staining 
showed that STZ produced a dose- and time-dependent cytotoxic effect in MIN6 cells (as shown in 
Figure 4.1B). The number of viable MIN6 cells was greatly decreased after 6 hours of 2.0mM STZ 
treatment. In 40×10 visual fields, STZ treatment significantly increased chromatin condensation and 
nuclear fragmentation; specifically, the apoptotic body formation was increased after 2.0mM 
STZ-treatment. The cytotoxic effects of Hex were also pronounced in a dose- and time-dependent 
manner in MIN6 cells (as shown in Figure 4.1C). High concentration of Hex (2.0μM) inhibited cell 
viability after 2 hours of treatment, whereas low concentration of Hex (0.5 and 1.0μM) did not 
show significant inhibition of cell viability throughout the experiment. Based on this observed 
growth inhibition of the individual compounds, 1.0mM STZ was selected to treat the MIN6 cells for 
4 hours (under such condition, MIN6 survival ability was decreased to 66% of control), and 1.0μM 
Hex for 2 hours in the subsequent experiments. 
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Figure 4.1 STZ induced time- and dose-dependent apoptosis and necrosis in MIN6 cells. 
(A) The viability of MIN6 cells treated with STZ (0.5, 1.0 and 2.0mM) for various time periods. (B) 
The representative images of STZ-treated MIN6 cells at a magnification of 100× and 400×, 
respectively. MIN6 cells were stained with Hematoxylin-erosin (HE). (C) The viability of MIN6 
cells treated with Hex (0.5, 1.0 and 2.0M) for various time periods. n=6 from each group, data are 
shown as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, compared with the corresponding 
control group at each time point. 
4.1.1 Protective effect of Hex on STZ-treated MIN6 cells 
To investigate the effect of Hex on STZ-treated pancreatic cells, cultured MIN6 were exposed to 
SFM, 1.0μM Hex, 1.0mM STZ alone or followed by Hex for 6 hours. The viability of MIN6 was 
significantly affected by different treatments (as shown in Fig 4.2A). As expected, 1.0mM STZ 
alone induced significant growth inhibition in MIN6 cells (69.3% of control), as compared with 
controls. Hex alone did not affect the viability of MIN6. Hex treatment produced a significant 
increase in cell viability (105.3% of control) compared with those treated with STZ alone. The 
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effect of STZ and Hex was also investigated on α-TC6 cells, a mouse pancreatic α-cell line (as 
shown in Figure 4.2B). STZ and/or Hex treatment did not significantly affect the α-TC6 viability 
(as shown in Figure 4.2B). 
 
Figure 4.2 Effect of Hex on STZ-treated pancreatic cells. 
(A) The MIN6 and (B) α-TC6 cells were treated with 1.0mM STZ and 1.0M Hex alone or in 
combination. Cell viability was measured by MTS assay. Hex significantly attenuated STZ-induced 
cytotoxic effect on MIN6, but not α-TC6 cells. n=6 from each group, data are shown as the mean ± 
SEM. *P<0.05, **P<0.01. 
4.1.2 Protective effect of Hex on mitochondrial function and superoxide activity of STZ-treated 
MIN6 cells 
It is known that STZ can damage β-cells via its harmful effect on mitochondrial function [281, 282]. 
In order to examine the protective effect of Hex on STZ-induced mitochondrial damage, 
mitochondrial function was determined by the Rhodamine 123 assay (Figure 4.3A). The ratio of 
RFU to protein content (mg) for STZ-treated cells was significantly lower compared to controls, 
indicating an impairment in mitochondrial function. Cells treated with both STZ and Hex produced 
a significant increase in the Rhodamine 123 accumulation in MIN6 cells than those treated with 
STZ alone, indicating that low concentrations of Hex reduced STZ-induced damage in 
mitochondria. The protective effects of Hex on mitochondria were further verified by superoxide 
DHE production assay (Figure 4.3B). The DHE levels in the STZ-treated cells were significantly 
higher than in the controls. Cells treated with STZ followed by Hex significantly decreased the ratio 
of RFU to protein content compared to STZ treatment alone. These results demonstrated that Hex 
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protected β-cells against STZ-induced mitochondrial damage and superoxide activity. 
 
Figure 4.3 Hex reduced STZ-induced mitochondrial damage and in MIN6 cells. 
The MIN6 cells were treated with 1.0mM STZ and 1.0M Hex alone or in combination. (A) The 
changes in the mitochondrial potential were determined by Rhodamine 123 assay. (B) Cell 
superoxide activity was detected by superoxide DHE production. n=8 from each group, data are 
shown as the mean ± SEM. *P<0.05. 
4.1.3 Influence of Hex on protein level of Bax/Bcl2 and cleaved caspase-3 and caspase-9 in 
MIN6 Cells 
In addition to oxidation and ATP production, mitochondria play a key role in cell apoptosis. 
Therefore, the effect of STZ and Hex on mitochondrial apoptotic pathways was examined. Western 
blot analysis was performed to determine the expression of Bax/Bcl2, cleaved caspase-3 and 
caspase-9. As shown in Figure 4.4, STZ-treated MIN6 cells showed a significant increase in the 
ratio of Bax/Bcl2, cleaved caspase-3 and cleaved caspase-9 expression as compared with the control 
group. Cells treated with STZ followed by Hex significantly decreased the ratio of Bax/Bcl2 and 
cleaved caspase-3 protein levels, and there was a trend to decrease cleaved caspase-9, as compared 
with the STZ treatment alone. These results indicate that Hex may reduce the level of STZ-induced 
apoptosis of MIN6 cells. 
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Figure 4.4 Expression of Bax/Bcl-2 and activated caspase-3 and caspase-9 caused by STZ and 
Hex in MIN6 cells. 
The MIN6 cells were treated with 1.0mM STZ and/or 1.0M Hex, the alterations of Bax/Bcl-2, 
cleaved caspase-3 and cleaved-caspase 9 were detected by western blotting. The upper panels show 
the representative immunoblots for each protein. (A) Hex significantly decreased the elevated ratio 
of Bax to Bcl-2 by STZ treatment. (B and C) Hex significantly decreased the STZ-induced 
expression of cleaved Caspase-3 and 9. n=4 from each group, data are shown as the mean ± SEM. 
*P<0.05, **P<0.01, ***P<0.001. 
4.2 Effect of STZ and Hex on pancreatic islet β-cells function in STZ- and Hex-treated rats 
Since the in vitro experiments showed that Hex exerted protective effects against STZ-induced 
MIN6 damage, further experiments were conducted to examine the in vivo effect of Hex in 
STZ-induced diabetic rat model. 
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4.2.1 Insulin secretion in STZ- and Hex-treated rats 
Plasma insulin levels were first investigated using a commercial insulin ELISA kit (Mouse/Rat 
Insulin ELISA kit, EMD Millipore, St. Charles, MI, USA) in rats under fasting or fed conditions. 
Different treatments exerted significant effects on fasting insulin levels (Figure 4.5A). The Hex 
alone increased the plasma insulin, whereas STZ dramatically decreased it. There was a significant 
difference of fasting plasma insulin levels between the STZ group and the STZ+Hex-treated rats. 
Similar to fasting insulin levels, fed insulin levels were significantly higher in Hex-treated rats and 
lower in STZ-treated rats than in control rats (Figure 4.5B). Furthermore, the Hex also ameliorated 
the STZ-induced decreases in fed plasma insulin levels. 
 
Figure 4.5 Fasting and fed plasma insulin levels from control, control+Hex, STZ and 
STZ+Hex rats.  
After the STZ or Hex treatment, terminal blood samples were collected. Plasma insulin levels from 
(A) fasting or (B) fed rats were determined by insulin ELISA kits. n=4 from each group, data are 
shown as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. 
4.2.2 Immunostaining of islet and image quantification in STZ- and Hex-treated rats 
PFA fixed sections from rat pancreas were stained with mouse anti-insulin, rabbit anti-glucagon, 
rabbit anti-Bax and rabbit anti-caspase-9 antibodies. Figure 4.6 showed the representative 
observation of insulin and glucagon immunostaining, using the same amplification scale, in rats 
after 6 weeks of different treatments. In the control animals, the islets were round, with a clear 
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boundary, normal structure and cell numbers. The insulin-positive cells (yellow) were located in the 
central portions whereas glucagon-positive cells (green) were located in the periphery of the islets 
as expected. In the STZ-treated group, the numbers of insulin-positive cells were sharply declined; 
the proportion of glucagon-positive cells was increased. The structure of the islets was disrupted, as 
glucagon-positive cells were observed within the central portion of the islets. In the group 
co-treated with STZ and Hex, the numbers of insulin-positive cells increased significantly and 
showed close-to-normal structure of the islets. 
 
Figure 4.6 Morphological alteration of islet in control, control+Hex, STZ and STZ+Hex rats. 
Representative histological image of pancreas sections from rats after STZ and/or Hex treatment are 
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showen. The sections were double immunofluorescent stained with glucagon antibody (α-cells, 
green) and insulin antibody (β-cells, yellow) and observed under confocal microscopy, n=4 from 
each group. 
 
Quantitative analysis of these images (as shown in Figure 4.7), revealed that the number of β-cells 
in STZ rats was significantly reduced in comparison to that in the control group. Animals co-treated 
with STZ and Hex exhibited a remarkable recovery of β-cell number. There was no difference on 
number of α-cells among groups. Due to destructive morphology of pancreatic islets in STZ rats, 
islet diameters were significantly reduced in comparison to that in control group. Hex treatment 
partially rescued islet diameters reduced by STZ treatment.  
 
Figure 4.7 Quantification of glucagon and insulin immunostaining of islet in control, 
control+Hex, STZ and STZ+Hex rats. 
After image quantification, (A) number of β-cell and (B) α-cell, (C) diameter of pancreatic islets 
were calculated from rats after STZ and/or Hex treatment. n=4 from each group, data are shown as 
the mean ± SEM. *P<0.05, ***P<0.001. 
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Figure 4.8A and B shows pancreatic islet staining with Bax and caspase-9. Bax staining in STZ 
treated animals was slightly higher compared to control animals, but no difference was obtained in 
Hex and STZ+Hex treated animals. However, there was a large portion of caspase-9 positive cells 
in STZ-treated pancreatic islet compared to the control group. The amount of caspase-9 staining 
was significantly decreased in STZ+Hex co-treated rats. Quantification of Bax and caspase-9 
staining was performed by counting positive immunofluorescenced cells relative to total cell 
number and data was expressed as a percentage relative to the control group. As shown in Figure 
4.8C and D, Bax staining in STZ-treated rats was approximately 70% higher than that in control 
group. STZ+Hex treatment reduced approximately 50% of the Bax staining compared to the 
STZ-treated group. Accompanying the Bax staining, there was a dramatic increase in caspase-9 
expression in STZ-treated islet. After STZ+Hex treatment, the expression level of caspase-9 was 
partially attenuated, indicating the effect of Hex was via the mitochondrial pathway. These data 
suggest that Hex protects β-cells in vivo from STZ-induced damage in islets. 
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Figure 4.8 Islet immunostaining and quantification of Bax and caspase-9 in control, 
control+Hex, STZ and STZ+Hex rats. 
Representative histological image of pancreas sections from rats after STZ and/or Hex treatment. 
The sections were immunofluorescently stained with (A) Bax and (B) caspase-9 antibodies and 
observed by confocal microscopy. After image quantification, the percentage of (C) Bax and (D) 
caspase-9 staining of islets were calculated from rats after STZ and/or Hex treatment. n=4, data are 
shown as the mean ± SEM. **P<0.01, ***P<0.001.  
4.2.3 GTT and ITT in STZ- and Hex-treated rats 
To further investigate glucose tolerance in STZ and Hex-treated rats, GTT was performed after 
overnight fasting. Animals received glucose (2g/kg body weight) injection intraperitoneally 
followed by collection of blood samples (40μl) from the tail vein at time 0, and same amount of 
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blood samples were collected at 15, 30, 45, 60, 90, 120 minutes points. All blood samples were then 
centrifuged and blood plasma were collected for glucose and insulin assay.  
 
As shown in Figure 4.9A, Hex-treated control rats showed lower levels of blood glucose at 15 and 
30 minutes after glucose injection compared to controls, while STZ animals shared the same pattern 
of GTT as the STZ+Hex co-treated group. Area under curve analysis exhibited a dramatic increase 
in STZ-treated rats compared to controls, indicating a declined ability responding to glucose in the 
STZ group. However, the impaired glucose response was recovered by Hex treatment as shown in 
Figure 4.9B. Consistent with GTT, the level of insulin secretion in STZ animals were suppressed 
compared to controls, whereas both Hex-treated control and STZ groups showed improved 
glucose-stimulated insulin secretion.  
 
Insulin sensitivity was subsequently examined by ITT after 3 days of GTT. The experiment was 
conducted after 6-hours of fasting from 0800 in the morning. Following measurement of the blood 
glucose level at the 0 point, human recombinant insulin (1IU/kg, Novo Nordisk, Demark) was 
applied by intraperitoneal injection and blood glucose was determined at the times 15, 30, 45, 60, 
90, and 120 minutes points. Although blood glucose levels were still maintained at a high level, the 
STZ group showed similar patterns to control animals. However, STZ-Hex co-treated rats exhibited 
decreased blood glucose levels at 90 minutes after insulin injection, indicating increased insulin 
sensitivity in Hex-treated rats under STZ state, but not under normal conditions. 
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Figure 4.9 GTT and ITT in control, control+Hex, STZ and STZ+Hex rats. 
Glucose tolerance tests and insulin tolerance tests were performed in rats with STZ and/or Hex 
treatment. Results of (A) GTT, (C) GTT insulin and (D) ITT are shown at different time points. 
Corresponding analysis of area under curve of (B) GTT and (E) ITT exhibited glucose intolerance 
and insulin insensitivity of STZ group, which recovered by Hex treatment. n=8, data are shown as 
the mean ± SEM. **P<0.01, ***P<0.001.  
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4.2.4 Circulating levels of IGF-1 and FFAs in STZ- and Hex-treated rats 
Diabetes is associated with decreased levels of plasma IGF-1 and increased levels of FFAs [283, 
284]. To clarify whether IGF-1 and FFAs were altered in the STZ-induced rat model, I examined 
circulating levels of IGF-1 and FFAs using commercial assay kits (Mouse/Rat IGF-1 Quantikine 
ELISA kit, R&D Systems, Minneapolis, MN and NEFA-C Assay, Wako, Osaka, Japan). Results 
were consistent with previous investigations. As shown in Figure 4.10, circulating levels of plasma 
IGF-1 showed a 2-fold decrease and the level of FFAs relative to fat tissue was dramatically 
increased in STZ-treated rats compared to control group. Hex treatment normalized the increased 
FFAs level, but there was no effect on plasma IGF-1, indicating normalized levels of FFAs might 
contribute to the increased weight of fat tissue stimulated by Hex.   
 
Figure 4.10 Circulating levels of IGF-1 and FFAs from control, control+Hex, STZ and 
STZ+Hex rats.  
After the STZ or Hex treatment, terminal blood samples were collected. Circulating levels of (A) 
IGF-1 and (B) FFAs relative to fat tissue were determined by IGF-1 and FFAs ELISA kits. n=6 
from each group, data are shown as the mean ± SEM. ***P<0.001. 
4.3 Pulsatile GH secretion in STZ- and Hex-treated rats 
Previous studies showed that suppressed levels of GH occurs in STZ-induced diabetic rat [72, 73, 
87]. To further elucidate the effect of Hex in STZ-induced diabetic rats, pulsatile GH secretion was 
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evaluated in STZ- and Hex-treated rats. As shown in Figure 4.11, the level of pulsatile GH secretion 
in the STZ group was dramatically decreased compared to controls and the number of pulses was 
also declined. After Hex treatment, both control and STZ-treated animals showed elevated level of 
pulsatile GH secretion with unchanged pulse number. Subsequent deconvolutional analysis 
exhibited that pulsatile GH secretion in diabetic animals was characterized by a significant decline 
in basal (19.2±9.67 vs 213±41.9ng/ml per 6h, p<0.001) pulsatile (192±24.6 vs 1053±136ng/ml per 
6h, p<0.001), total (356±75.3 vs 1243±141ng/ml per 6h, p<0.001) and the mass of GH secreted per 
burst (118±23.0 vs 355±39.9ng/ml, p<0.001) compared to controls. After Hex treatment, pulsatile 
GH secretion in the STZ group was characterized by a significant increase in total (826±197 vs 
356±75.3ng/ml per 6h, p<0.05), pulsatile (524±44.6 vs 192±24.6ng/ml per 6h, p<0.001), basal 
(159±36.6 vs 19.2±9.67ng/ml per 6h, p<0.01) but not the mass of GH secreted per burst (178±28.9 
vs 118±23.0ng/ml, p=0.14) compared to pre-treatment. Although an elevation of GH secretion was 
observed in the Hex-treated control group, the value did not reach significance. 
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Figure 4.11 Pulsatile GH secretion from control, control+Hex, STZ and STZ+Hex rats. 
Representative profiles of pulsatile GH secretion from (A) control, (B) STZ, (C) control+Hex and 
(D) STZ+Hex rats. (E) Basal, (F) pulsatile, (G) total and (H) the mass of secreted per burst were 
determined by deconvolutional analysis. n=16, data are shown as the mean ± SEM. *P<0.05, 
**P<0.01, ***P<0.001. 
4.4 Discussion 
My study showed that Hex has a protective effect on STZ-induced β-cell damage through its action 
to improve mitochondrial functions. Hex is a synthetic peptide that has some similar properties to 
ghrelin. Previous studies showed that Hex protects cardiomyocytes from ischemic damage [259, 
263]. In the present study, the protective effect of Hex was extended to STZ-caused β-cell damage. 
A high dose of STZ was used to cause β-cell apoptosis in vitro, and the damage by STZ has been 
reconfirmed in vivo in STZ-induced T1D rats. Hex showed beneficial effects on pancreatic islets in 
rats injected with high doses of STZ. In vitro, STZ decreased β-cell survival and Hex diminished 
the effects of STZ.  
 
The STZ model is a commonly used experimental system to test the effect of treatment on 
pancreatic β-cells both in vivo and in vitro. Many agents have been tested in this model, such as 
phytochemicals and cytokines [282, 285]. Studies have also shown that up-regulation of signaling 
pathways or overexpression of selective proteins in the STZ model may have a protective effect on 
β-cells. The SDF-1/CXCL12/Akt system protects β-cells in both in vivo and in vitro experiments 
[286]. Reg-2 overexpression in MIN6 has also been shown to increase survived STZ-treated β-cells 
[287]. Although these chemicals have been shown to protect β-cells from STZ-induced β-cell 
damages, the molecular mechanisms underlying the protective effect of these compounds have not 
been fully investigated. 
 
Previous studies have shown that insulin secretion could be inhibited by ghrelin, and 
pharmacological blockade of ghrelin signaling maybe a promising therapeutic strategy for T2D 
[288]. However, there was also evidence that overexpression of ghrelin promotes proliferation and 
inhibits apoptosis of β-cells after STZ-induced injury [289, 290]. A synthetic analogue of ghrelin, 
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Hex may have similar protective effects on β-cells. In this experiment, high doses of Hex (2.0μM) 
produced cytotoxic effects on MIN6 cells; whereas the appropriate dose of Hex (1.0μM, without 
significant toxic effect on MIN6 cells) protected MIN6 cells from STZ-induced damage. 
 
Apoptosis is a programmed cell death, which is closely associated with β-cell numbers in diabetes. 
It is known that mitochondrial signaling systems directs cells to apoptosis via the Bcl2 family [291], 
through increases in cleaved caspase-3 and capase-9. Several agents have been shown to protect 
STZ-caused β-cell damage via an influence on mitochondrial survival pathways. For example, Jian 
et al. showed that overexpression of adiponectin in mice reduces STZ-induced apoptosis through 
caspase-3, caspase-8 and caspase-9 [292]. My study shows that STZ increases the ratio of Bax to 
Bcl-2, whereas Hex restored the STZ-increased ratio, indicating that Hex protected β-cells via a 
mitochondrial survival pathway. This was further demonstrated by the finding that Hex decreased 
STZ-caused activation of caspase-3 and caspase-9.  
 
The in vivo protective effects of Hex against STZ-induced β-cell damage were further supported in 
the STZ-induced diabetic rat model. A similar study showed increased insulin secretion in both 
normal and STZ-induced diabetic rats by ghrelin [209]. In the present study, Hex treatment also 
significantly increased the plasma insulin levels in normal and STZ-treated rats under fasting and 
feeding conditions. Ameliorated plasma insulin levels in STZ+Hex co-treated rats were most likely 
a result of improved β-cell function. Results of islets immunostaining exhibited recovered islet 
structure and declined apoptotic markers in the STZ-treated group by Hex. Quantification analysis 
further clarified the protective effect of Hex on STZ-induced β-cell damage through increased β-cell 
number and a decreased apoptotic population, indicating an appropriate concentration of Hex 
protected β-cells in vivo from STZ-induced β-cell death. 
 
Pancreatic α-cell mass remained unchanged, consistent with previous investigation on STZ-induced 
diabetic mice [293]. However, multiple low dose STZ investigations have reported that α-cell 
expansion is associated with elevated level of glucagons [294]. It was revealed that islet α-cell 
proliferated with β-cell death before the significantly increased blood glucose levels in STZ-treated 
mice, suggesting depressed insulin action may lead to increased α-cell mass in STZ-treated 
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pancreatic islets [295]. But due to different results obtained among studies, whether STZ affects 
pancreatic α-cell function still remained unclear. Ghrelin and its receptor GHS-R are present in 
pancreatic islet α-cells of human and rats and are able to stimulate insulin secretion [296]. A recent 
study on mouse islet α-cell illustrated that ghrelin administration increased plasma glucagon release 
with elevated blood glucose [297], indicating ghrelin injection may cause glycemia in mouse. 
However, in vitro and in vivo results also showed that Hex had no effect on α-cell with/without STZ 
treatment, suggesting Hex may exert different effects on islet α-cell compared to ghrelin. 
 
Because of STZ-induced islet β-cell death, glucose tolerance was impaired in STZ-treated rats. A 
study on STZ-induced diabetic mice showed that blood glucose level remained at a high level 
during GTT, suggesting inhibited glucose-induced insulin secretion [298], an observation also 
observed in the present study. As there was an elevated number of β-cells, glucose intolerance was 
ameliorated in STZ-Hex co-treated rats through a recovered function of glucose-stimulated insulin 
secretion. Further, ITT showed that insulin sensitivity was not changed by STZ as the same insulin 
response pattern was observed in both control and STZ-treated rats. However, a Hex-treated STZ 
group exhibited increased insulin sensitivity and this effect was not observed in Hex-treated control 
animals. Because there are no studies reporting how Hex increases insulin sensitivity, the possible 
mechanism is working through peroxisome proliferator-activated receptors isoform γ (PPARγ), a 
metabolic regulator of insulin resistance. The thiazolidinediones (TZDs), a high-affinity ligand for 
PPARγ, is able to enhance insulin sensitivity through PPARγ activation [299-301]. As Hex has been 
shown to promote PPARγ activation [302], increased insulin sensitivity in STZ group by Hex may 
be mediated by elevated TZDs. 
 
Lower levels of plasma IGF-1 were associated with STZ-induced diabetes, consistent with previous 
pulications on rat and human with T1D [303, 304]. Decreased IGF-1 levels may correlate with 
decreased insulin levels and increased blood glucose levels. Chronic treatment of GHSs in human 
subjects indicated increased levels of IGF-1 while animal model of left ventricular dysfunction 
suggested that ghrelin administration attenuated development of cardiac cachexia possibly mediated 
by increased levels of GH and IGF-1 [238, 305, 306]. However, there was no effect of Hex on 
plasma IGF-1 in present study, suggesting Hex may not exert an effect on circulating IGF-1 or 
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treatment time was not enough to alter plasma IGF-1 levels as previous studies showed 
longer-lasting treatment. Besides the unchanged IGF-1, the level of FFAs relative to adipose tissue 
weight was dramatically increased. Because glucose metabolism is impaired in diabetes, increased 
levels of FFAs were reported in blood plasma and various tissues [307-309]. A study on T2D 
showed that an elevated FFA concentration was associated with decreased glucose uptake and 
utilization, predominantly in muscle tissue [67]. It was implicated that increased FFA oxidation 
suppressed glucose oxidation by inhibiting glycolytic enzymes, resulting in inhibition of glycogen 
synthesis. A further study demonstrated that body glucose uptake decreased by 30-40% in diabetic 
patients compared to non-diabetic subjects [310]. Moreover, a study using an anti-lipolytic drug 
exhibited declined level of FFAs through ameliorated blood glucose level in diabetic rat [311]. After 
Hex treatment, normalized plasma FFAs levels were observed in my study. As stated above, Hex 
showed an effect of lowering blood glucose levels via stimulating insulin secretion and recovering 
islet β-cell function, resulting in attenuated symptoms of STZ-induced diabetes. Hence, normalized 
plasma FFAs levels were probably a consequence of improved glucose metabolism.    
 
To further understand the effect of STZ and Hex on metabolism of STZ-induced diabetes, pulsatile 
GH secretion was investigated. There are controversial results on GH secretion in diabetes. 
Elevated GH levels were found in studies on Type 1 diabetic patients and Biobred (BB) rats 
[312-314]. The results, however, showed suppressed pulsatile GH secretion in STZ-induced diabetic 
rats, consistent with previous reports on STZ-treated rats [74, 88, 90]. It has been demonstrated that 
both basal and pulsatile GH levels were reduced in STZ-treated animals, associated with decreased 
hypothalamic GH-releasing hormone (GHRH), pituitary GH mRNA expression and circulating 
IGF-1 [63, 315]. Increased levels of hypothalamic somatostatin (SS) has been considered as a 
possible explanation for reduced GH responses in STZ-induced rats. Both in vivo and in vitro 
studies showed that elevation of hypothalamic SS tone was accompanied with remarkably declined 
GHRH secretion and somatotrophic axis activity in a high single dosage of STZ-treated rats [62, 63, 
316, 317]. However, a study conducted by the Park group stated that a different STZ regime could 
cause differential responses of the GH axis [317]. They showed that circulating levels of GH in one 
single high dosage of STZ-treated rats was associated with depressed plasma IGF-1, gene 
expression of pituitary GH and hypothalamic GHRH whereas multiple low dosages of STZ 
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treatment rats exhibited normal GH axis activity except decreased IGF-1 level, suggesting 
hyperglycemia may not be the primary modulator of GH secretion in STZ-treated diabetes. The 
reason why two different STZ regimes caused differential responses of GH axis remains unknown. 
As a single dose of STZ was applied in the present study, it was believed that suppressed pulsatile 
GH release in the STZ-treated group was caused by depressed hypothalamic GHRH activity with 
increased somatostatin tone. GHSs stimulate GH secretion in both STZ-induced mice and rats. A 
study using GHRH and GHRP-6 showed a dose-dependent GH response in both control and STZ 
rats [318]. This indicated that independent GHRH injection and low dose GHRP-6 (3μg/kg) had no 
effect on GH release, whereas high dosage of GHRP-6 (30ug/kg) induced an increase in GH 
response. When animals received a combined injection of GHRH and GHRP-6, a potent GH 
secretion was observed in both control and STZ groups. The effect of GHRP-6 on GH responses 
was abolished by anti-GHRH serum in passive immunization, suggesting GHRP-6 or GHS may 
stimulate GH secretion through provoking GHRH release in the hypothalamus [223, 319]. Other 
GHSs studies such as ghrelin and ipamorelin, also showed similar effects on GH secretion with or 
without simultaneous administration of GHRH on both control and STZ-induced diabetic rodents 
[320, 321]. Therefore, as a member of the GHS family, Hex may exert the same effect on pulsatile 
GH secretion in both control and STZ-treated rats. 
 
In conclusion, the present study demonstrated that Hex was able to restore STZ-caused β-cell 
damage via its action on mitochondrial pathways both in vivo and in vitro. Besides pancreatic islet 
β-cell protection, Hex was able to recover diminished pulsatile GH secretion via elevating 
hypothalamic GHRH activity in STZ-induced diabetes, indicating a possible mechanism against the 
impaired growth system in diabetes. As few side effects of Hex were reported in clinic trials, and it 
is economic to make this 6 amino acid peptide; Hex represents a superior performance as a potential 
protective agent in the management of diabetes. 
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CHAPTER FIVE – PROTECTIVE EFFECT OF HEX ON DIABETIC 
CARDIOMYOPATHY 
Cardiovascular complications are responsible for over 70% of the mortality among diabetic patients. 
Diabetic cardiomyopathy is defined as ventricular dysfunction without hypertension and CAD; it is 
essential and important to investigate the function of ventricular myocardium. Hence, the present 
study used single cardiomyocytes to measure contractility, intracellular Ca
2+
 concentrations, ion 
channel activity and apoptosis pathway. 
5.1 Effect of Hex on cardiomyocyte contractility and intracellular Ca
2+
 transients in STZ 
and/or Hex-treated rats 
Cardiomyocyte contractility and intracellular Ca
2+
 transients were measured using the Ionoptix 
setup as described above. 20-30 stabilized contractions were recorded during stimulation at 0.5 Hz 
with voltages steps to 20% over the threshold. As shown in Figure 5.1, STZ-treated rats exhibited a 
decreased amplitude of contraction, prolonged time courses (time to peak and time to 90% 
relaxation), and declined frequency (rate of contraction and relaxation) compared to controls, 
indicating depressed systolic and diastolic function in STZ-induced diabetic rats. Increased 
contraction amplitudes and time to peak were observed in Hex-treated control and STZ animals. 
Hex prolonged the time to peak and rate of contraction in STZ-treated cardiomyocytes, which 
showed abnormality of systolic function. However, considering normalized contractility and 
diastolic parameters (time to 90% relaxation and rate of relaxation) after Hex treatment, it might 
take a longer time to recover normal contraction in Hex-treated STZ cardiomyocytes. Therefore, 
Hex is able to improve contractility in both control and STZ-induced diabetic rats.  
 
Associated with contractility measurements, intracellular Ca
2+
 transients were determined by using 
the fluorescent dye Fura-2 and calculated by alterations in cytoplasmic fluorescent Fura-2 ratios, 
excited at 340nm and 380nm. As shown in Figure 5.2, impaired [Ca
2+
]i homeostasis was observed 
in the STZ group. STZ significantly increased the time course (elevated time to peak and time to 90% 
decay of fluorescence), decreased the amplitude of intracellular Ca
2+
 transient and frequency (rate 
of [Ca
2+
]i rise and decay), are shown defective [Ca
2+
]i activity in cardiomyocytes of STZ-treated rats. 
After Hex treatment, there was a dramatic increase in the amplitude of intracellular Ca
2+
 transients 
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of the control and STZ groups. Hex also recovered the depressed time course in STZ-treated rats 
and further increased the rate of intracellular Ca
2+
 transients, indicating Hex is not only able to 
normalize impaired [Ca
2+
]i homeostasis but also improved intracellular Ca
2+
 transient performance 
in STZ-induced diabetic cardiomyocytes.  
 
Figure 5.1 Effect of Hex on cardiomyocyte contractility from control, control+Hex, STZ and 
STZ+Hex rats.  
(A) The representative superimposed traces of sarcomere shortening from different groups. 
Increased (B) amplitude of contraction was observed in both control and STZ-treated group after 
Hex treatment. Prolonged (D) time to 90% relaxation and (F) rate of relaxation in STZ-treated rats 
were normalized by Hex treatment, whereas Hex further increased (C) time to peak and decreased 
(E) rate of contraction in STZ group. n=81, 84, 90 and 87 cells/6 rats from control, control+Hex, 
STZ and STZ+Hex group, respectively. Data are shown as means ± SEM, *P< 0.05, ** P< 0.01, 
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*** P< 0.001.  
 
 
Figure 5.2 Effect of Hex on cardiomyocyte [Ca
2+
]i transients from control, control+Hex, STZ 
and STZ+Hex rats.  
The emission fluorescence ratio of Fura-2 from excitation of 340 and 380nm was short for R in the 
figure and Ru represented ratio unit. (A) The representative superimposed traces of cardiomyocyte 
[Ca
2+
]i transients from different groups. Significantly increased (B) amplitude of contraction was 
observed in both control and STZ-treated groups after Hex treatment. Prolonged (C) time to peak 
and (D) time to 90% decay of fluorescence in STZ-treated rats were normalized by Hex treatment. 
Hex also recovered and further increased the rate of [Ca
2+
]i transient (E) rise (+dR/dt) and (F) decay 
(-dR/dt). n=63, 64, 68 and 65 cells/6 rats from control, control+Hex, STZ and STZ+Hex group, 
respectively. Data are shown as means ± SEM, *P< 0.05, ** P< 0.01, *** P< 0.001. 
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5.2 Effect of Hex on membrane potential and ion channel activity of cardiomyocytes in STZ 
and/or Hex-treated rats  
To further clarify the effect of Hex on cardiomyocyte function in STZ-induced diabetes, membrane 
potential and ion channel activity were investigated. Whole-cell current patch configuration was 
employed in the study and the spontaneous AP was elicited by a small stimulus (3ms of 
depolarizing current pulse) applied on the recorded cardiomyocyte. 10 successive AP were recorded 
and averaged for analysis. 
 
As shown in Figure 5.3, no difference of resting membrane potential (RMP) and action potential 
(AP) was observed among groups with STZ and/or Hex treatment. However, there was prolonged 
action potential duration (APD) at 20, 50 and 90% of repolarization phase (APD20, APD50 and 
APD90) in diabetic cardiomyocytes compared to the control group, consistent with previous studies 
on membrane potential of diabetic cardiomyopahty [190, 192]. After Hex treatment, increased APD 
was recovered in STZ-treated cardiomyocytes, indicating Hex was able to rescue prolonged APD in 
STZ-induced diabetic cardiomyocytes. There were no changes found in membrane potential of 
Hex-treated controls.  
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Figure 5.3 Effect of Hex on membrane potential of cardiomyocyte from control, control+Hex, 
STZ and STZ+Hex rats.  
(A) Representative traces of AP from different groups. No changes were found in (B) AP and (C) 
RMP. Prolonged APD was observed at (D) APD20, (E) APD50 and (F) APD90 in STZ-induced 
diabetic cardiomyocytes. Hex-treated STZ group showed normalized level of APD at (D) APD20, (E) 
APD50 and (F) APD90. n=14, 18, 16, 13 cells/6 rats from control, control+Hex, STZ and STZ+Hex 
group, respectively. Data are shown as means ± SEM, *P< 0.05, ** P< 0.01, *** P< 0.001. 
 
Prolonged APD with unchanged RP and AP amplitude indicated depressed repolrization in the STZ 
group. The time course of repolarization relies on the function of different ion channels, such as the 
inward Ca
2+
 and K
+
 currents [322, 323]. Previous investigations in the STZ-induced diabetic rat 
model with the same treatment condition showed unchanged activity of the Ca
2+
 current and K
+
 
currents but calcium-independent transient outward potassium current (Ito) [121, 324]. Therefore, Ito 
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which is mainly responsible for APD in cardiomyocytes was further studied [325, 326]. Ito was 
measured by applying a whole-cell voltage clamp for current recording. All the other currents were 
eliminated from the whole-cell recording through application of blockers and voltage pre-steps to 
-40 mV. 
 
Representative traces shown in Figure 5.4 demonstrated that, with increased testing potential, 
declined Ito amplitudes were observed in the STZ group in comparison to that of control 
cardiomyocytes. Current-voltage (I-V) relationship analysis of Ito further proved that decreased 
current density in STZ-treated cardiomyocytes was associated with increased testing potential, 
indicating that prolonged APD may result from decreased Ito. In addition, the steady-state 
inactivation cure of Ito in STZ group was left shifted compared to control groups, indicating 
decreased availability of Ito. After Hex treatment, relatively normalized current density and right 
shifted inactivation curves were displayed in the STZ group, suggesting Hex can restore decreased 
Ito and further recover prolonged APD in STZ-induced diabetic cardiomyocytes. 
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Figure 5.4 Effect of Hex on calcium-independent transient outward potassium current (Ito) of 
cardiomyocyte from control, control+Hex, STZ and STZ+Hex rats.  
(A) Representative traces of Ito from different groups. (B) The current-voltage (I-V) relation and (C) 
the steady-state inactivation of Ito. For I-V relation, n=11, 10, 12 and 13 cells/6 rats from control, 
control+Hex, STZ and STZ+Hex group, respectively. For steady-state inactivation of Ito, n=10, 9, 
12, 10 cells/6 rats from control, control+Hex, STZ and STZ+Hex group, respectively. Data are 
shown as means ± SEM. 
5.3 Effect of Hex on GHS-R expression of ventricular myocardium in STZ and/or Hex-treated 
rats 
The expression of GHS-R in heart ventricles was examined by western blot measurement. As 
shown in Figure 5.5, the level of GHS-R expression was decreased 50% in the STZ group compared 
to controls. As a GHS-R ligand, Hex treatment restored approximately 20% of GHS-R expression 
in the STZ-treated ventricular myocardium and also significantly increased that of controls. 
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Therefore, Hex was capable of rescuing decreased expression of GHS-R in STZ-induced diabetic 
rat heart and increased that of normal rat heart, indicating Hex increased expression of GHS-R may 
contribute to the beneficial effects of Hex on cardiomyocytes.   
 
Figure 5.5 Protein expression of GHS-R in heart ventricles from control, control+Hex, STZ 
and STZ+Hex rats. 
The level of GHS-R protein expression was determined by western blot analysis. Rat β-Tubulin was 
chosen as an internal control. Densitometric quantification of GHS-R was expressed as percentage 
relative to control. n=6 from each group. Data are shown as means ± SEM, *** P< 0.001.  
5.4 Effect of Hex on mitochondrial apoptotic signaling of ventricular myocardium in STZ 
and/or Hex-treated rats 
Cell loss was considered as a major cause of ventricular dysfunction in diabetic cardiomyopathy 
through a mitochondrial-signaled apoptotic pathway and an anti-apoptotic effect of GHS has been 
documented in a variety of cardiomyopathies [236, 241, 266, 327]. Therefore, my experiments 
aimed to clarify the effect of Hex on STZ-induced cardiac apoptosis via a mitochondrial signaling 
pathway. As shown in Figure 5.6, the ratio of pro-apoptotic protein, Bax and anti-apoptotic protein, 
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Bcl-2 was significantly increased and associated with up-regulated apoptosis-activated cascades, 
caspase-3 and caspase-9 in STZ-treated heart ventricles compared to those in control group. No 
significant effect of Hex administration was observed on the expression of these proteins in the 
control group. However, the corrected ratio of Bax and Bcl-2 was found after Hex treatment to 
correlate with reduced level of caspase-3 and caspase-9 expression, indicating Hex was able to 
normalize mitochondrial-signaled apoptosis.  
 
Figure 5.6 Protein expression of mitochondrial-mediated apoptotic marker in heart ventricles 
from control, control+Hex, STZ and STZ+Hex rats. 
The ration of (A) Bax/Bcl-2, (B) caspase-3 and (C) caspase-9 protein expression was determined by 
western blot analysis. Rat β-Tubulin was chosen as an internal control. Densitometric quantification 
of caspase-3 and caspase-9 was expressed as percentage relative to control. n=6 from each group. 
Data are shown as means ± SEM, ** P< 0.01, *** P< 0.001.  
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5.5 Discussion 
In this study, defects of intracellular Ca
2+
 handling were associated with depressed contractility, 
prolonged APD and mitochondrial signaling triggered apoptosis in STZ-induced diabetic 
cardiomyocytes, indicating these alterations contributed to the development of diabetic 
cardiomyopathy. Evidence from previous studies has shown that diastolic dysfunction first emerges 
in diabetic cardiomyopathy, followed by depressed systolic performance [328, 329]. Similar studies 
on STZ-induced diabetic cardiomyocytes reported down-regulated expression of SR Ca
2+
-ATPase at 
both the mRNA and protein level with reduced SR content and its ability to restore Ca
2+
 [121, 330]. 
As SR Ca
2+
-ATPase is mainly responsible for taking up Ca
2+
 into the SR during contractile 
relaxation [331], diminished SR Ca
2+
-ATPase expression possibly contributed to a prolonged time 
to relaxation and decay in cell shortening and [Ca
2+
]i transients, respectively in diabetic 
cardiomyocytes. Although NCX is another protein responsible for Ca
2+
 extrusion (approximately 15% 
of total) during diastole [331, 332], the level of expression is controversy in diabetic 
cardiomyopathy [121, 330, 333]. Further investigation revealed that RyR expression was also 
reduced with normal L-type Ca
2+
 current density and kinetics in diabetic cardiomyocytes. Because 
RyR is a SR Ca
2+
 channel mediated Ca
2+
 release into the cytosol during systole [331], combined 
discovery of decreased SR content, and depressed RyR expression with unchanged L-type Ca
2+
 
channel activity in STZ-induced diabetes may explain slow time to peak of contraction and [Ca
2+
]i 
transient. Therefore, parallel depression on contractility and [Ca
2+
]i transient clearly indicated that 
the contractile dysfunction was a result of defective Ca
2+
 signaling in diabetic cardiomyopathy 
[121]. Ca
2+
 overload was originally considered as the reason for abnormal cardiac function in 
diabetes [334, 335], however, due to unchanged basic Ca
2+
 leveld, it was hypothesised that 
depressed [Ca
2+
]i transients were mainly responsible for cardiac dysfunction rather than altered 
basic [Ca
2+
]i transient [336-338]. Another indicator contributing to diabetic cardiomyopathy was 
possibly impaired glucose metabolism. Abnormal cardiac function in the STZ-induced diabetic 
model was consistent with clinical evidence of existing cardiomyopathy found in T1D patients 
without apparent atherosclerosis, vascular, or valvular diseases [339-341]. It was deduced that 
insulin deficiency and impaired glucose metabolism may partly contribute to depressed cardiac 
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contractility in diabetic cardiomyopathy [121]. In addition, studies on insulin treated STZ diabetic 
rats showed that insulin injection recovered declined expression of SR Ca
2+
-ATPase and RyR [330], 
suggesting normalized glucose metabolism may be potentially of benefit to defective Ca
2+
 signaling 
in diabetic cardiomyopathy.   
 
In the present study, administration of Hex recovered impaired Ca
2+
 homeostasis and depressed 
contractility. As a GHS, the cardio-protective effects of Hex and its natural analog ghrelin has been 
well characterized in both clinical and experimental studies [233, 240, 259, 342]. Clinical evidence 
showed that both Hex and ghrelin administration improve cardiac output in healthy volunteers with 
normal blood pressure and heart rate [233]. Further investigations on patients with CAD and GH 
deficiency revealed that Hex and ghrelin treatment increased LVEF and cardiac output without 
alteration of systemic vascular resistance index and heart rate [232, 342], indicating GHS was able 
to improve cardiac contractility in both healthy individuals and patients with onset diseases. Single 
mice ventricular myocyte studies exhibited that pre- and post-treatment of Hex and ghrelin 
normalized depressed contractility and [Ca
2+
]i transient after I/R injury through maintaining Ca
2+
 
homeostasis by recovering SR content, SR Ca
2+
-ATPase and RyR activity [259]. Another study on 
isolated adult rat cardiomyocytes also showed that Hex and ghrelin exerted a dose-dependent 
cardio-protective effect via GHS-R as these beneficial effects was abolished after applying an 
inhibitor of GHS-R [240]. Up-regulation of GHS-R protein expression was observed with increased 
cell shortening and [Ca
2+
]i transient of both control and STZ-induced diabetic rat hearts in current 
study, indicating Hex acted as a positive inotrope on rat cardiomyocytes through GHS-R signaling. 
Moreover, recovered contractility was found in an experimental study on STZ-induced diabetic rat 
treated by obestatin (another member of GHS) with restored oxidative balance [343]. Insulin 
treatment reverses depressed contractility in diabetic rats and rabbits [344, 345]. Combined with 
results about stimulated insulin secretion, it is believed that improved glucose metabolism was 
partly contributed to normalized contractility and Ca
2+
 homeostasis in STZ-induced diabetic hearts.  
 
The present study also showed prolonged APD with unchanged RMP and AP in STZ-induced 
diabetic cardiomyocytes. APD prolongation in diabetic cardiomyocytes led to suppressed Ca
2+
 
extrusion, resulting in increased net Ca
2+
 influx [192]. Studies on AP of diabetic heart revealed that 
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decreased Ito was responsible for the prolonged APD [191, 197]. Depressed Ito associated with 
lengthened APD by abolishing the influence from other currents [192]. Further studies on 
STZ-induced diabetic hearts revealed that, after 14 days of STZ injection, potassium channel gene 
expression was significantly down-regulated with decreased Ito current density [191]. Impaired 
glucose metabolism is another contributor to suppressed function of Ito [197, 346-348]. 
Voltage-clamp studies demonstrated corrected Ito current density in insulin or metabolic activator, 
dichloroacetate-treated diabetic cardiomyocytes [349]. Specifically, STZ-induced diabetic hearts 
displayed decreased thioredoxin reductase with increased thioredoxin activity. An inhibitor of 
thioredoxin reductase reduced activity of thioredoxin and abolished the effect of up-regulated Ito 
caused by insulin and dichloroacetate. Moreover, normalized Ito by insulin and dichloroacetate 
could also be blocked by an antagonist of glucose-6-phosphate dyhydrogenase, which produces 
NADPH required by thioredoxin system. These data indicated that Ito was regulated in a 
redox-sensitive manner by the thioredoxin system and decreased thioredoxin reductase activity may 
lead to suppression of Ito [349]. Similar studies on STZ-induced diabetic rats also elucidated that 
increased oxidative stress was associated with diminished Ito density, resulting in a shift of redox 
state. Treatment with an anti-oxidant drug restored Ito density and recovered homeostasis of redox 
system [350], further indicating oxidative stress was major contributor to depressed Ito.  
 
Growing of evidence shows that ghrelin decreases oxidative stress by enhancing anti-oxidant 
defense [351, 352]. Endogenous ghrelin levels were increased during early stage of heart failure 
development to maintain myocardial energy balance and improve cardiac function as a 
compensatory effect, indicating ghrelin exerted anti-oxidative and anti-apoptotic effect through 
myocardial mitochondrial function [351]. An in vitro study on hypoxic injury demonstrated that 
ghrelin administration reduced ROS content with increased Mn-SOD gene expression and activity 
via an AMPK-dependent pathway [352]. A previous study also revealed that both ghrelin and Hex 
was able to rescue impaired Ito activity of cardiomyocyte by decreasing MARK-signaled ROS 
activity after I/R injury[263]. As restored Ito density by Hex was observed in my study, I conclude 
that Hex recovered abnormal Ito through improving anti-oxidant function in STZ-induced diabetic 
cardiomyocytes, further normalizing prolonged APD.     
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Cardiomyoytes are also susceptible to diabetic-induced cell death. Clinical evidence showed that 
apoptotic myocytes were 85-fold higher in diabetic patients than those from the control population 
[353]. Studies on STZ-treated mice displayed slightly increased myocardial cell death with absence 
of hyperglycemia. Further insulin treatment ameliorated myocardial apoptosis with reduced blood 
glucose level in these mice, suggesting hyperglycemia had a predominant role in diabetes-induced 
myocardial apoptosis [354]. Mitochondria have been considered as a key regulator of apoptosis 
with the Bcl-2 family in a variety of the pro-apoptotic conditions [45, 355]. It has been exhibited 
that the apoptogenic factor cytochrome C release is induced by pro-apoptotic protein Bax with 
direct activation of caspases and occurrence of mitochondrial dysfunction such as loss of membrane 
potential and transition of membrane permeability [47, 49-53]. Bcl-2, as anti-apoptotic candidate, 
prevents release of cytochrome C by inactivation of caspases [46-48, 356]. Mitochondrial mediated 
apoptosis has been well documented in both diabetic animal models and patients [327, 353, 354, 
357]. An in vitro study on high glucose-treated H9c2 cells demonstrated that increased 
cardiomyocytes apoptosis was associated with increased intracellular ROS level, leading to an 
elevated activity of caspase-3 and caspase-9 with depolarization of mitochondrial transmembrane 
potential. Further in vivo investigations on STZ-induced diabetic mice revealed that up-regulated 
Bax and down-regulated Bcl-2 was accompanied by increased release of cytoplasmic cytochrome C 
[327]. Similar results were also observed in a STZ-treated rat model [357]. In my study, 
STZ-treated rat hearts displayed an increased ratio of Bax/Bcl-2 with increased expression of 
caspase-3 and caspase-9, indicating developed apoptosis via mitochondrial signaling pathway in 
diabetic cardiomyopathy. 
 
Mitochondrial mediated apoptosis, as stated above, was recovered by Hex treatment. In vitro, 
administration of Hex declined angiotensin-II induced apoptosis in H9c2 cell line through 
up-regulation of Bcl-2, down-regulation of Bax and inhibition of caspase-3 activity [236], 
indicating GHS exerted anti-apoptotic effects on cell survival signaling pathways. The results were 
further supported by in vivo studies on a rat model with chronic heart failure [266]. It was 
demonstrated that Hex treatment dramatically decreased apoptotic cell number via recovering an 
imbalanced Bcl-2/Bax ratio and elevated caspase-3 expression with increased GHS-R gene 
expression. Besides, investigation on H9c2 cardiomyocytes illustrated that high glucose and 
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palmitate-induced apoptosis could be rescued by ghrelin exposure through increasing anti-apoptotic 
expression which further inhibited caspase-3 and caspased-9 activity to retain mitochondrial 
membrane potential and reduce cytoplasmic cytochrome C release. This ghrelin-induced 
anti-apoptotic effect was associated with activation of the PI3K/Akt signaling pathway, indicating 
GHS may enhance cell proliferative effects to prevent apoptosis [358].     
 
In conclusion, my study illustrated that Hex treatment was able to restore STZ-induced cardiac 
dysfunction in single myocytes through normalization of depressed contractility, maintenance of 
impaired Ca
2+
 homeostasis, recovery of prolonged APD and diminished Ito, and inhibition of 
mitochondrial-signaled apoptosis with up-regulated GHS-R expression. These results suggest that 
Hex is a potential therapeutic candidate for treatment of diabetic cardiomyopathy.    
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CHAPTER SIX – GENERAL CONCLUSION AND FUTURE DIRECTION 
My study showed the beneficial effect of Hex on STZ-induced diabetes through its action on 
pancreatic islet β-cells and cardiomyocytes. Islet β-cell dysfunction is the predominant cause of 
diabetic pathogenesis, further leading to hyperglycemia, polyphagia, polydipsia and polyuria in 
diabetic patients. I employed STZ-induced diabetic rats, a well characterized model of T1D without 
long term influence of metabolic imbalances on cardiomyocytes, as an experimental model. After 6 
weeks of STZ injection, diabetic rats exhibited a significant increase in blood glucose level, food 
intake, water consumption and urine production associated with slow body weight gain caused by 
dramatically decreased weight of adipose tissue. Hex treatment ameliorated diabetic symptoms, 
such as decreased urine production and increased body weight gain, possibly through increased 
insulin secretion and reduced blood glucose level in diabetic animals. Meanwhile, increased food 
intake was observed with elevated adipose tissue weight in Hex-treated control rats. Abnormal 
metabolic control in STZ-treated rats was associated with depressed circulating hormones, such as 
GH, IGF-1 and increased FFAs. Administration of Hex attenuated STZ-induced suppression on GH 
pulsatile parameters, decreased FFAs levels related to adipose tissue weight, but did not affect 
circulating IGF-1. Abnormal mitochondrial activity is the major contributor of β-cell dysfunction. 
Declined cell viability and increased apoptosis of islet β-cells were observed both in vitro and in 
vivo investigations. Results revealed that increased Bax, caspase-3 and capase-9 expression was 
associated with down-regulated Bcl-2 in MIN6 β-cell after STZ incubation. Further 
immunostaining on rat pancreatic sections supported the in vitro observation and exhibited 
destructive islet and decreased β-cell number with increased Bax and caspase-9 staining after STZ 
treatment. Hex recovered STZ-induced abnormal apoptotic activity through normalizing islet β-cell 
function and apoptosis-signaling protein expression, which may explain decreased blood glucose in 
Hex treated STZ rats. Diabetic cardiomyopathy is one of the major complications of diabetes and 
responsible for over 70% of mortality among diabetic patients. My study assessed cardiomyocyte 
contractility of the single cell level with intracellular Ca
2+
 activity and electrophysiology properties. 
Depressed contractility was characterized as decreased amplitude of cell contraction, prolonged 
time course and decreased rate of contraction in the STZ group in compared to controls. Along with 
cell shortening measurement, [Ca
2+
]i was determined and also exhibited a lower amplitude, slower 
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time course and frequency after STZ injection, suggesting impaired Ca
2+ 
homeostasis in 
accompanied with depressed contractility. Electrophysiology investigations showed prolonged APD 
with unchanged RMP and AP amplitude in STZ-induced diabetic cardiomyocytes, indicating slower 
occurrence of repolarization. The time course of repolarization relies on the function of inward Ca
2+
 
currents and K
+
 currents [322, 323] and the STZ-induced diabetic rat model showed unchanged 
activity of Ca
2+
 current and K
+
 currents, but Ito [121, 324]. Ito which is mainly responsible for APD 
in cardiomyocyte was further examined [325, 326]. The data demonstrated that STZ suppressed Ito 
density across different testing potential and the inactivation curve revealed decreased Ito activity in 
STZ-treated cardiomyocytes, indicating the abnormal activity of Ito may result in prolonged APD. 
Apoptosis is considered as major contributor to myocardial dysfunction and mitochondria-mediated 
apoptotic pathway plays a central role in diabetes [355, 359-362]. Therefore, I measured the 
pro-anti-apoptotic protein expression in ventricular myocardia. Increased ratio of Bax/Bcl-2 
expression was observed with up-regulated apoptosis activation cascades, caspase-3 and caspase-9 
in heart of STZ-treated group. As a synthetic analogue of ghrelin, the cardio-protective effect of 
Hex has been reported in other studies by binding with its ligand GHS-R [259, 263, 274]. My study 
expanded our knowledge about the cardio-protective effects of Hex in diabetic cardiomyopathy. 
Hex treatment recovered depressed contractility and [Ca
2+
]i of diabetic cardiomyocyte to control 
level correlated with prompted cell contraction and [Ca
2+
]i in Hex-treated control group, inferring 
Hex is not only curing the abnormal contractile activity in STZ-induced diabetic rat heart cells but 
also improving cardiomyocyte performance in normal rat cardiomyocytes. In addition, the 
decreased Ito current density was restored by Hex, which may further contribute to normalized APD 
in STZ group. Hex also exhibited anti-apoptosis actions. With increased GHS-R expression, Hex 
administration decreased the expression of caspase-3 and caspase-9 with recovered ratios of 
Bax/Bcl-2. Together, the data of my study indicated that Hex protected islet β-cell function through 
improving mitochondrial function and stimulating insulin secretion while recovered abnormal 
cardiomyocyte activity via normalizing depressed contractility, maintaining Ca
2+
 homeostasis and 
prompting anti-apoptosis associated with up-regulation of GHS-R in STZ-induced diabetes. 
 
Ghrelin has been well documented since it was discovered in 1999, its action was verified in 
various tissues in both experimental and clinical investigations. As its synthetic analogue, Hex 
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showed similar effects to ghrelin through the GH secretary and cardiac protection. Finnaly, a 
cardiovascular study demonstrated that Hex had more potent beneficial effect than ghrelin; while 
Hex displayed greater improvement of heart function on ghrelin-null mice after myocardial 
infarction compared to equimolar administration of ghrelin [363]. Previous investigation also 
showed that ghrelin (10nmol/L) or Hex (1nmol/L) exerted the same positive inotropic effect on 
cardiomyocytes after ischemia/reperfusion injury [259]. Given the higher half-life and lower price, 
Hex could be a better candidate for treating cardiovascular-related diseases.   
 
My study also has some limitations. The animal model employed in the study is typical T1D, which 
mainly reflected diabetic syndromes under insulin-dependent condition, whereas most of diabetic 
patients are diagnosed with insulin resistance. The effect of Hex should be investigated in a T2D 
animal model. Moreover, the severity of diabetes in present study was very severe where the 
protective action of Hex on islet β-cell was relatively restricted. In addition, the investigation of 
diabetic cardiomyopathy focused on single myocyte level which was lack of intact heart 
examination. In the future, to better elucidate the mechanism of Hex on islet β-cell and heart 
function, the study should involve T2D animal model which reflects the syndrome of most diabetic 
population. Hex administration may be started at an early stage of diabetes and last longer time to 
reach ideal recovery. Echocardiography or MRI may be employed in the study to investigate intact 
heart function, which can precisely examine the effect of Hex on diabetic cardiomyopathy.   
 
 
 
 
 
 
 
83 
 
REFERENCES 
1. Danaei, G., et al., National, regional, and global trends in fasting plasma glucose and 
diabetes prevalence since 1980: systematic analysis of health examination surveys and 
epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 2011. 
378(9785): p. 31-40. 
2. Eisenbarth, G.S., Type 1 diabetes: molecular, cellular and clinical immunology. Adv Exp 
Med Biol, 2004. 552: p. 306-10. 
3. Alberti, K.G. and P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus 
and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional 
report of a WHO consultation. Diabet Med, 1998. 15(7): p. 539-53. 
4. Iburi, T., H. Izumiyama, and Y. Hirata, [Endocrine glands of pancreas]. Nihon Rinsho, 2011. 
69 Suppl 2: p. 95-9. 
5. Slack, J.M., Developmental biology of the pancreas. Development, 1995. 121(6): p. 
1569-80. 
6. Youos, J.G., The role of alpha-, delta- and F cells in insulin secretion and action. Diabetes 
Res Clin Pract, 2011. 93 Suppl 1: p. S25-6. 
7. Wilkin, T.J., The accelerator hypothesis: a review of the evidence for insulin resistance as 
the basis for type I as well as type II diabetes. Int J Obes (Lond), 2009. 33(7): p. 716-26. 
8. Islam, M.S., The islets of Langerhans. Preface. Adv Exp Med Biol, 2010. 654: p. vii-viii. 
9. Meier, J.J., et al., Pancreatic diabetes manifests when beta cell area declines by 
approximately 65% in humans. Diabetologia, 2012. 55(5): p. 1346-54. 
10. Iynedjian, P.B., Molecular physiology of mammalian glucokinase. Cell Mol Life Sci, 2009. 
66(1): p. 27-42. 
11. Leibiger, B., et al., Selective insulin signaling through A and B insulin receptors regulates 
transcription of insulin and glucokinase genes in pancreatic beta cells. Mol Cell, 2001. 7(3): 
p. 559-70. 
12. Matschinsky, F.M., B. Glaser, and M.A. Magnuson, Pancreatic beta-cell glucokinase: 
closing the gap between theoretical concepts and experimental realities. Diabetes, 1998. 
47(3): p. 307-15. 
84 
 
13. Detimary, P., et al., The changes in adenine nucleotides measured in glucose-stimulated 
rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. 
J Biol Chem, 1998. 273(51): p. 33905-8. 
14. Heimberg, H., et al., Heterogeneity in glucose sensitivity among pancreatic beta-cells is 
correlated to differences in glucose phosphorylation rather than glucose transport. EMBO J, 
1993. 12(7): p. 2873-9. 
15. Velho, G., et al., Primary pancreatic beta-cell secretory defect caused by mutations in 
glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet, 1992. 
340(8817): p. 444-8. 
16. Postic, C., et al., Dual roles for glucokinase in glucose homeostasis as determined by liver 
and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem, 
1999. 274(1): p. 305-15. 
17. Grupe, A., et al., Transgenic knockouts reveal a critical requirement for pancreatic beta cell 
glucokinase in maintaining glucose homeostasis. Cell, 1995. 83(1): p. 69-78. 
18. Sekine, N., et al., Low lactate dehydrogenase and high mitochondrial glycerol phosphate 
dehydrogenase in pancreatic beta-cells. Potential role in nutrient sensing. J Biol Chem, 
1994. 269(7): p. 4895-902. 
19. Sener, A. and W.J. Malaisse, Hexose metabolism in pancreatic islets. Ca(2+)-dependent 
activation of the glycerol phosphate shuttle by nutrient secretagogues. J Biol Chem, 1992. 
267(19): p. 13251-6. 
20. Giroix, M.H., et al., Study of hexose transport, glycerol phosphate shuttle and Krebs cycle in 
islets of adult rats injected with streptozotocin during the neonatal period. Mol Cell 
Endocrinol, 1992. 83(2-3): p. 95-104. 
21. Fransson, U., et al., Anaplerosis via pyruvate carboxylase is required for the fuel-induced 
rise in the ATP:ADP ratio in rat pancreatic islets. Diabetologia, 2006. 49(7): p. 1578-86. 
22. Owen, O.E., S.C. Kalhan, and R.W. Hanson, The key role of anaplerosis and cataplerosis 
for citric acid cycle function. J Biol Chem, 2002. 277(34): p. 30409-12. 
23. Maechler, P., S. Carobbio, and B. Rubi, In beta-cells, mitochondria integrate and generate 
metabolic signals controlling insulin secretion. Int J Biochem Cell Biol, 2006. 38(5-6): p. 
696-709. 
85 
 
24. Eliasson, L., et al., Novel aspects of the molecular mechanisms controlling insulin secretion. 
J Physiol, 2008. 586(14): p. 3313-24. 
25. Ashcroft, F.M., K(ATP) channels and insulin secretion: a key role in health and disease. 
Biochem Soc Trans, 2006. 34(Pt 2): p. 243-6. 
26. Yu, B.P., Cellular defenses against damage from reactive oxygen species. Physiol Rev, 1994. 
74(1): p. 139-62. 
27. Nishikawa, T., et al., Normalizing mitochondrial superoxide production blocks three 
pathways of hyperglycaemic damage. Nature, 2000. 404(6779): p. 787-90. 
28. Chance, B., H. Sies, and A. Boveris, Hydroperoxide metabolism in mammalian organs. 
Physiol Rev, 1979. 59(3): p. 527-605. 
29. Turrens, J.F. and A. Boveris, Generation of superoxide anion by the NADH dehydrogenase 
of bovine heart mitochondria. Biochem J, 1980. 191(2): p. 421-7. 
30. Ambrosio, G., et al., Evidence that mitochondrial respiration is a source of potentially toxic 
oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem, 
1993. 268(25): p. 18532-41. 
31. Syed, I., et al., Increased phagocyte-like NADPH oxidase and ROS generation in type 2 
diabetic ZDF rat and human islets: role of Rac1-JNK1/2 signaling pathway in 
mitochondrial dysregulation in the diabetic islet. Diabetes, 2011. 60(11): p. 2843-52. 
32. Li, N., et al., NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen 
species and cAMP/PKA in the regulation of insulin secretion. Diabetes, 2012. 61(11): p. 
2842-50. 
33. Maechler, P., L. Jornot, and C.B. Wollheim, Hydrogen peroxide alters mitochondrial 
activation and insulin secretion in pancreatic beta cells. J Biol Chem, 1999. 274(39): p. 
27905-13. 
34. Robertson, R.P., et al., Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in 
type 2 diabetes. Diabetes, 2004. 53 Suppl 1: p. S119-24. 
35. Li, N., et al., Transient oxidative stress damages mitochondrial machinery inducing 
persistent beta-cell dysfunction. J Biol Chem, 2009. 284(35): p. 23602-12. 
36. Tang, C., et al., Evidence for a role of superoxide generation in glucose-induced beta-cell 
dysfunction in vivo. Diabetes, 2007. 56(11): p. 2722-31. 
86 
 
37. Oprescu, A.I., et al., Free fatty acid-induced reduction in glucose-stimulated insulin 
secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes, 2007. 56(12): 
p. 2927-37. 
38. Supale, S., et al., Mitochondrial dysfunction in pancreatic beta cells. Trends Endocrinol 
Metab, 2012. 23(9): p. 477-87. 
39. Chan, C.B., et al., Increased uncoupling protein-2 levels in beta-cells are associated with 
impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes, 2001. 50(6): 
p. 1302-10. 
40. Zhang, C.Y., et al., Uncoupling protein-2 negatively regulates insulin secretion and is a 
major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell, 2001. 105(6): p. 
745-55. 
41. Joseph, J.W., et al., Uncoupling protein 2 knockout mice have enhanced insulin secretory 
capacity after a high-fat diet. Diabetes, 2002. 51(11): p. 3211-9. 
42. Lameloise, N., et al., Uncoupling protein 2: a possible link between fatty acid excess and 
impaired glucose-induced insulin secretion? Diabetes, 2001. 50(4): p. 803-9. 
43. Lowell, B.B. and G.I. Shulman, Mitochondrial dysfunction and type 2 diabetes. Science, 
2005. 307(5708): p. 384-7. 
44. Newmeyer, D.D. and S. Ferguson-Miller, Mitochondria: releasing power for life and 
unleashing the machineries of death. Cell, 2003. 112(4): p. 481-90. 
45. Tsujimoto, Y., Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? 
Genes Cells, 1998. 3(11): p. 697-707. 
46. Yang, J., et al., Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria 
blocked. Science, 1997. 275(5303): p. 1129-32. 
47. Liu, X., et al., Induction of apoptotic program in cell-free extracts: requirement for dATP 
and cytochrome c. Cell, 1996. 86(1): p. 147-57. 
48. Kluck, R.M., et al., The release of cytochrome c from mitochondria: a primary site for Bcl-2 
regulation of apoptosis. Science, 1997. 275(5303): p. 1132-6. 
49. Susin, S.A., et al., The central executioner of apoptosis: multiple connections between 
protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced 
apoptosis. J Exp Med, 1997. 186(1): p. 25-37. 
87 
 
50. Zoratti, M. and I. Szabo, The mitochondrial permeability transition. Biochim Biophys Acta, 
1995. 1241(2): p. 139-76. 
51. Jurgensmeier, J.M., et al., Bax directly induces release of cytochrome c from isolated 
mitochondria. Proc Natl Acad Sci U S A, 1998. 95(9): p. 4997-5002. 
52. Shimizu, S., et al., Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton 
flux. Proc Natl Acad Sci U S A, 1998. 95(4): p. 1455-9. 
53. Narita, M., et al., Bax interacts with the permeability transition pore to induce permeability 
transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci U S A, 
1998. 95(25): p. 14681-6. 
54. Ryter, S.W., et al., Mechanisms of cell death in oxidative stress. Antioxid Redox Signal, 
2007. 9(1): p. 49-89. 
55. Federici, M., et al., High glucose causes apoptosis in cultured human pancreatic islets of 
Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic 
cell death program. Diabetes, 2001. 50(6): p. 1290-301. 
56. Piro, S., et al., Chronic exposure to free fatty acids or high glucose induces apoptosis in rat 
pancreatic islets: possible role of oxidative stress. Metabolism, 2002. 51(10): p. 1340-7. 
57. Thomas, H.E., J.A. Trapani, and T.W. Kay, The role of perforin and granzymes in diabetes. 
Cell Death Differ, 2010. 17(4): p. 577-85. 
58. Sutton, V.R., et al., Initiation of apoptosis by granzyme B requires direct cleavage of bid, but 
not direct granzyme B-mediated caspase activation. J Exp Med, 2000. 192(10): p. 1403-14. 
59. Estella, E., et al., Granzyme B-mediated death of pancreatic beta-cells requires the 
proapoptotic BH3-only molecule bid. Diabetes, 2006. 55(8): p. 2212-9. 
60. Cnop, M., et al., Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: 
many differences, few similarities. Diabetes, 2005. 54 Suppl 2: p. S97-107. 
61. Allagnat, F., et al., Mcl-1 downregulation by pro-inflammatory cytokines and palmitate is an 
early event contributing to beta-cell apoptosis. Cell Death Differ, 2011. 18(2): p. 328-37. 
62. Giustina, A. and J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone 
secretion in experimental animals and the human. Endocr Rev, 1998. 19(6): p. 717-97. 
63. Olchovsky, D., et al., Altered pituitary growth hormone (GH) regulation in 
streptozotocin-diabetic rats: a combined defect of hypothalamic somatostatin and 
88 
 
GH-releasing factor. Endocrinology, 1990. 126(1): p. 53-61. 
64. Underwood, L.E., et al., Paracrine functions of somatomedins. Clin Endocrinol Metab, 1986. 
15(1): p. 59-77. 
65. Roelfsema, V. and R.G. Clark, The growth hormone and insulin-like growth factor axis: its 
manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol, 2001. 
12(6): p. 1297-306. 
66. Davidson, M.B., Effect of growth hormone on carbohydrate and lipid metabolism. Endocr 
Rev, 1987. 8(2): p. 115-31. 
67. Randle, P.J., et al., The glucose fatty-acid cycle. Its role in insulin sensitivity and the 
metabolic disturbances of diabetes mellitus. Lancet, 1963. 1(7285): p. 785-9. 
68. Yde, H., Abnormal growth hormone response to ingestion of glucose in juvenile diabetics. 
Acta Med Scand, 1969. 186(6): p. 499-504. 
69. Hansen, A.P., Abnormal serum growth hormone response to exercise in juvenile diabetics. J 
Clin Invest, 1970. 49(8): p. 1467-78. 
70. Hansen, A.P. and K. Johansen, Diurnal patterns of blood glucose, serum free fatty acids, 
insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia, 
1970. 6(1): p. 27-33. 
71. Schaper, N.C., Growth hormone in type I diabetic and healthy man. Acta Endocrinol 
(Copenh), 1990. 122 Suppl 2: p. 1-47. 
72. Ndon, J.A., A. Giustina, and W.B. Wehrenberg, Hypothalamic regulation of impaired growth 
hormone secretion in diabetic rats. 1. Studies in streptozotocin-induced diabetic rats. 
Neuroendocrinology, 1992. 55(5): p. 500-5. 
73. Ortiz-Caro, J., C. Gonzalez, and T. Jolin, Diurnal variations of plasma growth hormone, 
thyrotropin, thyroxine, and triiodothyronine in streptozotocin-diabetic and food-restricted 
rats. Endocrinology, 1984. 115(6): p. 2227-32. 
74. Tannenbaum, G.S., Growth hormone secretory dynamics in streptozotocin diabetes: 
evidence of a role for endogenous circulating somatostatin. Endocrinology, 1981. 108(1): p. 
76-82. 
75. Amiel, S.A., et al., Effect of diabetes and its control on insulin-like growth factors in the 
young subject with type I diabetes. Diabetes, 1984. 33(12): p. 1175-9. 
89 
 
76. Horner, J.M., S.F. Kemp, and R.L. Hintz, Growth hormone and somatomedin in 
insulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1981. 53(6): p. 1148-53. 
77. Yde, H., THE GROWTH-HORMONE-DEPENDENT SULPHATION FACTOR IN SERUM 
OF UNTREATED DIABETICS. Lancet, 1964. 2(7360): p. 625-6. 
78. Lanes, R., et al., Impaired somatomedin generation test in children with insulin-dependent 
diabetes mellitus. Diabetes, 1985. 34(2): p. 156-60. 
79. Tamborlane, W.V., et al., Insulin-infusion-pump treatment of diabetes: influence of improved 
metabolic control on plasma somatomedin levels. N Engl J Med, 1981. 305(6): p. 303-7. 
80. Berelowitz, M., et al., Somatomedin-C mediates growth hormone negative feedback by 
effects on both the hypothalamus and the pituitary. Science, 1981. 212(4500): p. 1279-81. 
81. Brazeau, P., et al., [Somatomedin inhibition of the growth hormone secretion stimulated by 
the hypothalamic factor somatocrinin or the synthetic peptide hpGRF]. C R Seances Acad 
Sci III, 1982. 295(11): p. 651-4. 
82. Ceda, G.P., et al., Regulation of growth hormone release from cultured human pituitary 
adenomas by somatomedins and insulin. J Clin Endocrinol Metab, 1985. 60(6): p. 1204-9. 
83. Yamashita, S. and S. Melmed, Insulinlike growth factor I regulation of growth hormone 
gene transcription in primary rat pituitary cells. J Clin Invest, 1987. 79(2): p. 449-52. 
84. Ceda, G.P., et al., The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin 
axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth 
factors I and II. Endocrinology, 1987. 120(4): p. 1658-62. 
85. Asplin, C.M., et al., Alterations in the pulsatile mode of growth hormone release in men and 
women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1989. 69(2): p. 
239-45. 
86. Franek, E., et al., Abnormal pulsatile secretion of growth hormone in non-insulin-dependent 
diabetes mellitus. Clin Endocrinol (Oxf), 1997. 47(4): p. 471-8. 
87. Bluet-Pajot, M.T., D. Durand, and C. Kordon, Influence of streptozotocin-induced diabetes 
on growth hormone secretion in the rat. Neuroendocrinology, 1983. 36(4): p. 307-9. 
88. Locatelli, V., et al., Effect of growth hormone-releasing stimuli in streptozotocin diabetic 
rats. Brain Res, 1985. 341(1): p. 35-40. 
89. Murao, K., et al., Acute effects of hypoglycemia and hyperglycemia on hypothalamic growth 
90 
 
hormone-releasing hormone and somatostatin gene expression in the rat. Endocrinology, 
1994. 134(1): p. 418-23. 
90. Nieves-Rivera, F., et al., Altered growth hormone (GH) secretion in vivo and in vitro in the 
diabetes-prone BB/Worcester rat. Growth Regul, 1993. 3(4): p. 235-44. 
91. Baes, M. and W.W. Vale, Characterization of the glucose-dependent release of growth 
hormone-releasing factor and somatostatin from superfused rat hypothalami. 
Neuroendocrinology, 1990. 51(2): p. 202-7. 
92. Welsh, J.B. and M. Szabo, Impaired suppression of growth hormone release by somatostatin 
in cultured adenohypophyseal cells of spontaneously diabetic BB/W rats. Endocrinology, 
1988. 123(5): p. 2230-4. 
93. Baxter, R.C., A.S. Brown, and J.R. Turtle, Association between serum insulin, serum 
somatomedin and liver receptors for human growth hormone in streptozotocin diabetes. 
Horm Metab Res, 1980. 12(8): p. 377-81. 
94. Bhathena, S.J., et al., Decreased glucagon receptors in diabetic rat hepatocytes. Evidence 
for regulation of glucagon receptors by hyperglucagonemia. J Clin Invest, 1978. 61(6): p. 
1488-97. 
95. Rubler, S., et al., NEW TYPE OF CARDIOMYOPATHY ASSOCIATED WITH DIABETIC 
GLOMERULOSCLEROSIS. American Journal of Cardiology, 1972. 30(6): p. 595-&. 
96. Regan, T.J., et al., EVIDENCE FOR CARDIOMYOPATHY IN FAMILIAL 
DIABETES-MELLITUS. Journal of Clinical Investigation, 1977. 60(4): p. 885-899. 
97. Astorri, E., et al., Isolated and preclinical impairment of left ventricular filling in 
insulin-dependent and non-insulin-dependent diabetic patients. Clinical Cardiology, 1997. 
20(6): p. 536-540. 
98. Zabalgoitia, M., et al., Prevalence of diastolic dysfunction in normotensive, asymptomatic 
patients with well-controlled type 2 diabetes mellitus. American Journal of Cardiology, 2001. 
87(3): p. 320-323. 
99. Boyer, J.K., et al., Prevalence of ventricular diastolic dysfunction in asymptomatic, 
normotensive patients with diabetes mellitus. American Journal of Cardiology, 2004. 93(7): 
p. 870-875. 
100. Hsueh, W., et al., Recipes for creating animal models of diabetic cardiovascular disease. 
91 
 
Circulation Research, 2007. 100(10): p. 1415-1427. 
101. Russell, J.C. and S.D. Proctor, Small animal models of cardiovascular disease: tools for the 
study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovascular 
Pathology, 2006. 15(6): p. 318-330. 
102. Christoffersen, C., et al., Cardiac lipid accumulation associated with diastolic dysfunction in 
obese mice. Endocrinology, 2003. 144(8): p. 3483-3490. 
103. Dong, F., et al., Impaired cardiac contractile function in ventricular myocytes from 
leptin-deficient ob/ob obese mice. Journal of Endocrinology, 2006. 188(1): p. 25-36. 
104. Stolen, T.O., et al., Interval Training Normalizes Cardiomyocyte Function, Diastolic Ca(2+) 
Control, and SR Ca(2+) Release Synchronicity in a Mouse Model of Diabetic 
Cardiomyopathy. Circulation Research, 2009. 105(6): p. 527-U47. 
105. Fang, Z.Y., J.B. Prins, and T.H. Marwick, Diabetic cardiomyopathy: Evidence, mechanisms, 
and therapeutic implications. Endocrine Reviews, 2004. 25(4): p. 543-567. 
106. Fang, Z.Y., et al., Screening for heart disease in diabetic subjects. American Heart Journal, 
2005. 149(2): p. 349-354. 
107. Fang, Z.Y., et al., Echocardiographic detection of early diabetic myocardial disease. Journal 
of the American College of Cardiology, 2003. 41(4): p. 611-617. 
108. Yu, C.M., et al., Progression of systolic abnormalities in patients with "isolated" diastolic 
heart failure and diastolic dysfunction. Circulation, 2002. 105(10): p. 1195-1201. 
109. Yue, P., et al., Magnetic resonance imaging of progressive cardiomyopathic changes in the 
db/db mouse. American Journal of Physiology-Heart and Circulatory Physiology, 2007. 
292(5): p. H2106-H2118. 
110. Radovits, T., et al., Comparative investigation of the left ventricular pressure-volume 
relationship in rat models of type 1 and type 2 diabetes mellitus. American Journal of 
Physiology-Heart and Circulatory Physiology, 2009. 297(1): p. H125-H133. 
111. Van den Bergh, A., W. Flameng, and P. Herijgers, Type II diabetic mice exhibit contractile 
dysfunction but maintain cardiac output by favourable loading conditions. European Journal 
of Heart Failure, 2006. 8(8): p. 777-783. 
112. Zarich, S.W. and R.W. Nesto, DIABETIC CARDIOMYOPATHY. American Heart Journal, 
1989. 118(5): p. 1000-1012. 
92 
 
113. Coleman, R., et al., A mouse model for human atherosclerosis: Long-term histopathological 
study of lesion development in the aortic arch of apolipoprotein E-deficient (E-0) mice. Acta 
Histochemica, 2006. 108(6): p. 415-424. 
114. James, J.F., T.E. Hewett, and J. Robbins, Cardiac physiology in transgenic mice. Circulation 
Research, 1998. 82(4): p. 407-415. 
115. An, D. and B. Rodrigues, Role of changes in cardiac metabolism in development of diabetic 
cardiomyopathy. American Journal of Physiology-Heart and Circulatory Physiology, 2006. 
291(4): p. H1489-H1506. 
116. Boudina, S. and E.D. Abel, Diabetic cardiomyopathy revisited. Circulation, 2007. 115(25): p. 
3213-3223. 
117. Fleischer, S. and M. Inui, BIOCHEMISTRY AND BIOPHYSICS OF 
EXCITATION-CONTRACTION COUPLING. Annual Review of Biophysics and Biophysical 
Chemistry, 1989. 18: p. 333-364. 
118. Cesario, D.A., R. Brar, and K. Shivkumar, Alterations in ion channel physiology in diabetic 
cardiomyopathy. Endocrinology and Metabolism Clinics of North America, 2006. 35(3): p. 
601-+. 
119. Lopaschuk, G.D., et al., CARDIAC SARCOPLASMIC-RETICULUM FUNCTION IN 
INSULIN-TREATED OR CARNITINE-TREATED DIABETIC RATS. American Journal of 
Physiology, 1983. 245(6): p. H969-H976. 
120. Pierce, G.N. and N.S. Dhalla, CARDIAC MYOFIBRILLAR ATPASE ACTIVITY IN 
DIABETIC RATS. Journal of Molecular and Cellular Cardiology, 1981. 13(12): p. 
1063-1069. 
121. Choi, K.M., et al., Defective intracellular Ca(2+) signaling contributes to cardiomyopathy 
in Type 1 diabetic rats. American Journal of Physiology-Heart and Circulatory Physiology, 
2002. 283(4): p. H1398-H1408. 
122. Pereira, L., et al., Mechanisms of Ca2+ (i) transient decrease in cardiomyopathy of db/db 
type 2 diabetic mice. Diabetes, 2006. 55(3): p. 608-615. 
123. Belke, D.D., E.A. Swanson, and W.H. Dillmann, Decreased sarcoplasmic reticulum activity 
and contractility in diabetic db/db mouse heart. Diabetes, 2004. 53(12): p. 3201-3208. 
124. Kashihara, H., et al., Effects of diabetes and hypertension on myocardial Na+-Ca2+ 
93 
 
exchange. Canadian Journal of Physiology and Pharmacology, 2000. 78(1): p. 12-19. 
125. Noda, N., et al., Cytosolic Ca2+ concentration and pH of diabetic rat myocytes during 
metabolic inhibition. Journal of Molecular and Cellular Cardiology, 1992. 24(4): p. 435-446. 
126. Flarsheim, C.E., I.L. Grupp, and M.A. Matlib, Mitochondrial dysfunction accompanies 
diastolic dysfunction in diabetic rat heart. American Journal of Physiology-Heart and 
Circulatory Physiology, 1996. 271(1): p. H192-H202. 
127. Oliveira, P.J., et al., Enhanced permeability transition explains the reduced calcium uptake 
in cardiac mitochondria from streptozotocin-induced diabetic rats. Febs Letters, 2003. 
554(3): p. 511-514. 
128. Raha, S. and B.H. Robinson, Mitochondria, oxygen free radicals, disease and ageing. 
Trends in Biochemical Sciences, 2000. 25(10): p. 502-508. 
129. Wallace, D.C., A mitochondrial paradigm for degenerative diseases and ageing. Novartis 
Foundation symposium, 2001. 235: p. 247-63; discussion 263-6. 
130. Frustaci, A., et al., Myocardial cell death in human diabetes. Circulation Research, 2000. 
87(12): p. 1123-1132. 
131. Cai, L., et al., Inhibition of superoxide generation and associated nitrosative damage is 
involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes, 2005. 54(6): p. 
1829-1837. 
132. Turko, I.V., et al., Protein tyrosine nitration in the mitochondria from diabetic mouse heart - 
Implications to dysfunctional mitochondria in diabetes. Journal of Biological Chemistry, 
2003. 278(36): p. 33972-33977. 
133. Ye, G., et al., Metallothionein prevents diabetes-induced deficits in cardiomyocytes by 
inhibiting reactive oxygen species production. Diabetes, 2003. 52(3): p. 777-783. 
134. Andreyev, A.I., Y.E. Kushnareva, and A.A. Starkov, Mitochondrial metabolism of reactive 
oxygen species. Biochemistry-Moscow, 2005. 70(2): p. 200-214. 
135. Boudina, S., et al., Mitochondrial energetics in the heart in obesity-related diabetes - Direct 
evidence for increased uncoupled respiration and activation of uncoupling proteins. 
Diabetes, 2007. 56(10): p. 2457-2466. 
136. Shen, X., et al., Protection of cardiac mitochondria by overexpression of MnSOD reduces 
diabetic cardiomyopathy. Diabetes, 2006. 55(3): p. 798-805. 
94 
 
137. Johnson, D.T., et al., Proteomic changes associated with diabetes in the BB-DP rat. 
American Journal of Physiology-Endocrinology and Metabolism, 2009. 296(3): p. 
E422-E432. 
138. Coughlan, M.T., et al., RAGE-induced Cytosolic ROS Promote Mitochondrial Superoxide 
Generation in Diabetes. Journal of the American Society of Nephrology, 2009. 20(4): p. 
742-752. 
139. Li, L.N. and G. Renier, Activation of nicotinamide adenine dinucleotide phosphate (reduced 
form) oxidase by advanced glycation end products links oxidative stress to altered retinal 
vascular endothelial growth factor expression. Metabolism-Clinical and Experimental, 2006. 
55(11): p. 1516-1523. 
140. Kim, J.S., Y.G. Jin, and J.J. Lemasters, Reactive oxygen species, but not Ca2+ overloading, 
trigger pH- and mitochondrial permeability transition-dependent death of adult rat 
myocytes after ischemia-reperfusion. American Journal of Physiology-Heart and Circulatory 
Physiology, 2006. 290(5): p. H2024-H2034. 
141. Bhamra, G.S., et al., Metformin protects the ischemic heart by the Akt-mediated inhibition of 
mitochondrial permeability transition pore opening. Basic Research in Cardiology, 2008. 
103(3): p. 274-284. 
142. Abel, E.D., S.E. Litwin, and G. Sweeney, Cardiac remodeling in obesity. Physiological 
Reviews, 2008. 88(2): p. 389-419. 
143. Bugger, H. and E.D. Abel, Molecular mechanisms for myocardial mitochondrial dysfunction 
in the metabolic syndrome. Clinical Science, 2008. 114(3-4): p. 195-210. 
144. Akbal, E., et al., Serum heart type fatty acid binding protein levels in metabolic syndrome. 
Endocrine, 2009. 36(3): p. 433-437. 
145. Herrero, P., et al., Increased myocardial fatty acid metabolism in patients with type 1 
diabetes mellitus. Journal of the American College of Cardiology, 2006. 47(3): p. 598-604. 
146. Finck, B.N. and D.P. Kelly, Peroxisome proliferator-activated receptor alpha (PPAR alpha) 
signaling in the gene regulatory control of energy metabolism in the normal and diseased 
heart. Journal of Molecular and Cellular Cardiology, 2002. 34(10): p. 1249-1257. 
147. Aoyama, T., et al., Altered constitutive expression of fatty acid-metabolizing enzymes in mice 
lacking the peroxisome proliferator-activated receptor alpha (PPAR alpha). Journal of 
95 
 
Biological Chemistry, 1998. 273(10): p. 5678-5684. 
148. Duncan, J.G., et al., Insulin-resistant heart exhibits a mitochondrial biogenic response 
driven by the peroxisome proliferator-activated receptor-alpha/PGC-1 alpha gene 
regulatory pathway. Circulation, 2007. 115(7): p. 909-917. 
149. Eckel, J. and H. Reinauer, INSULIN ACTION ON GLUCOSE-TRANSPORT IN ISOLATED 
CARDIAC MYOCYTES - SIGNALING PATHWAYS AND DIABETES-INDUCED 
ALTERATIONS. Biochemical Society Transactions, 1990. 18(6): p. 1125-1127. 
150. Young, M.E., P. McNulty, and H. Taegtmeyer, Adaptation and maladaptation of the heart in 
diabetes: Part II - Potential mechanisms. Circulation, 2002. 105(15): p. 1861-1870. 
151. Mjos, O.D., EFFECT OF FREE FATTY ACIDS ON MYOCARDIAL FUNCTION AND 
OXYGEN CONSUMPTION IN INTACT DOGS. Journal of Clinical Investigation, 1971. 
50(7): p. 1386-&. 
152. Martin, C., et al., Effect of NO synthase inhibition on myocardial metabolism during 
moderate ischemia. American Journal of Physiology-Heart and Circulatory Physiology, 
2003. 284(6): p. H2320-H2324. 
153. Buchanan, J., et al., Reduced cardiac efficiency and altered substrate metabolism precedes 
the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin 
resistance and obesity. Endocrinology, 2005. 146(12): p. 5341-5349. 
154. Peterson, L.R., et al., Effect of obesity and insulin resistance on myocardial substrate 
metabolism and efficiency in young women. Circulation, 2004. 109(18): p. 2191-2196. 
155. Boudina, S. and E.D. Abel, Mitochondrial uncoupling: A key contributor to reduced cardiac 
efficiency in diabetes. Physiology, 2006. 21: p. 250-258. 
156. Russell, L.K., et al., Cardiac-specific induction of the transcriptional coactivator 
peroxisome proliferator-activated receptor gamma coactivator-1 alpha promotes 
mitochondrial biogenesis and reversible cardiomyopathy in a developmental 
stage-dependent manner. Circulation Research, 2004. 94(4): p. 525-533. 
157. Kuo, T.H., et al., DEFECTIVE OXIDATIVE-METABOLISM OF HEART-MITOCHONDRIA 
FROM GENETICALLY DIABETIC MICE. Diabetes, 1983. 32(9): p. 781-787. 
158. Boudina, S., et al., Reduced mitochondrial oxidative capacity and increased mitochondrial 
uncoupling impair myocardial energetics in obesity. Circulation, 2005. 112(17): p. 
96 
 
2686-2695. 
159. Bugger, H., et al., Tissue-Specific Remodeling of the Mitochondrial Proteome in Type 1 
Diabetic Akita Mice. Diabetes, 2009. 58(9): p. 1986-1997. 
160. Tanaka, Y., N. Konno, and K.J. Kako, MITOCHONDRIAL DYSFUNCTION OBSERVED 
INSITU IN CARDIOMYOCYTES OF RATS IN EXPERIMENTAL DIABETES. 
Cardiovascular Research, 1992. 26(4): p. 409-414. 
161. Kanazawa, A., et al., Reduced activity of mtTFA decreases the transcription in mitochondria 
isolated from diabetic rat heart. American Journal of Physiology-Endocrinology and 
Metabolism, 2002. 282(4): p. E778-E785. 
162. Turko, I.V. and F. Murad, Quantitative protein profiling in heart mitochondria from diabetic 
rats. Journal of Biological Chemistry, 2003. 278(37): p. 35844-35849. 
163. Di Carli, M., et al., Effects of autonomic neuropathy on coronary blood flow in patients with 
diabetes mellitus. Circulation, 1999. 100(8): p. 813-819. 
164. Kahn, J.K., et al., RADIONUCLIDE ASSESSMENT OF LEFT-VENTRICULAR DIASTOLIC 
FILLING IN DIABETES-MELLITUS WITH AND WITHOUT CARDIAC AUTONOMIC 
NEUROPATHY. Journal of the American College of Cardiology, 1986. 7(6): p. 1303-1309. 
165. Movahed, M.R., M. Hashemzadeh, and M. Jamal, Increased prevalence of ventricular 
fibrillation in patients with type 2 diabetes mellitus. Heart and Vessels, 2007. 22(4): p. 
251-253. 
166. Airaksinen, K.E.J., et al., AUGMENTATION OF ATRIAL CONTRIBUTION TO 
LEFT-VENTRICULAR FILLING IN IDDM SUBJECTS AS ASSESSED BY DOPPLER 
ECHOCARDIOGRAPHY. Diabetes Care, 1989. 12(2): p. 159-161. 
167. Monteagudo, P.T., et al., Influence of autonomic neuropathy upon left ventricular 
dysfunction in insulin-dependent diabetic patients. Clinical Cardiology, 2000. 23(5): p. 
371-375. 
168. Uusitupa, M., et al., IMPAIRMENT OF DIASTOLIC FUNCTION IN MIDDLE-AGED 
TYPE-1 (INSULIN-DEPENDENT) AND TYPE-2 (NON-INSULIN-DEPENDENT) 
DIABETIC-PATIENTS FREE OF CARDIOVASCULAR-DISEASE. Diabetologia, 1988. 
31(11): p. 783-791. 
169. Park, J.Y., et al., Induction of endothelin-1 expression by glucose - An effect of protein 
97 
 
kinase C activation. Diabetes, 2000. 49(7): p. 1239-1248. 
170. Chou, E., et al., Decreased cardiac expression of vascular endothelial growth factor and its 
receptors in insulin-resistant and diabetic states - A possible explanation for impaired 
collateral formation in cardiac tissue. Circulation, 2002. 105(3): p. 373-379. 
171. Shinohara, K., et al., Expression of vascular endothelial growth factor in human myocardial 
infarction. Heart and Vessels, 1996. 11(3): p. 113-122. 
172. Yoon, Y.S., et al., Progressive attenuation of myocardial vascular endothelial growth factor 
expression is a seminal event in diabetic cardiomyopathy - Restoration of microvascular 
homeostasis and recovery of cardiac function in diabetic cardiomyopathy after 
replenishment of local vascular endothelial growth factor. Circulation, 2005. 111(16): p. 
2073-2085. 
173. Jesmin, S., et al., Endothelin antagonism normalizes VEGF signaling and cardiac function 
in STZ-induced diabetic rat hearts. American Journal of Physiology-Endocrinology and 
Metabolism, 2007. 292(4): p. E1030-E1040. 
174. Hattori, Y., et al., SUPEROXIDE-DISMUTASE RECOVERS ALTERED 
ENDOTHELIUM-DEPENDENT RELAXATION IN DIABETIC RAT AORTA. American 
Journal of Physiology, 1991. 261(4): p. H1086-H1094. 
175. Bucala, R., K.J. Tracey, and A. Cerami, ADVANCED GLYCOSYLATION PRODUCTS 
QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT 
VASODILATATION IN EXPERIMENTAL DIABETES. Journal of Clinical Investigation, 
1991. 87(2): p. 432-438. 
176. Andersson, C., et al., Diabetes is associated with impaired myocardial performance in 
patients without significant coronary artery disease. Cardiovascular Diabetology, 2010. 9. 
177. Privratsky, J.R., et al., AT(1) blockade prevents glucose-induced cardiac dysfunction in 
ventricular myocytes - Role of the AT(1) receptor and NADPH oxidase. Hypertension, 2003. 
42(2): p. 206-212. 
178. Fein, F.S. and E.H. Sonnenblick, DIABETIC CARDIOMYOPATHY. Progress in 
Cardiovascular Diseases, 1985. 27(4): p. 255-270. 
179. Fiordaliso, F., et al., Myocyte death in streptozotocin-induced diabetes in rats is angiotensin 
II-dependent. Laboratory Investigation, 2000. 80(4): p. 513-527. 
98 
 
180. Ballard, C. and S. Schaffer, Stimulation of the Na+/Ca2+ exchanger by phenylephrine, 
angiotensin II and endothelin I. Journal of Molecular and Cellular Cardiology, 1996. 28(1): 
p. 11-17. 
181. Ferron, L., et al., Angiotensin II signaling pathways mediate expression of cardiac T-type 
calcium channels. Circulation Research, 2003. 93(12): p. 1241-1248. 
182. Gunasegaram, S., et al., Regulation of sarcolemmal Na+/H+ exchanger activity by 
angiotensin II in adult rat ventricular myocytes opposing actions via AT(1) versus AT(2) 
receptors. Circulation Research, 1999. 85(10): p. 919-930. 
183. Yaras, N., et al., Restoration of diabetes-induced abnormal local Ca2+ release in 
cardiomyocytes by angiotensin II receptor blockade. American Journal of Physiology-Heart 
and Circulatory Physiology, 2007. 292(2): p. H912-H920. 
184. Liu, X.L., et al., Blockade of the renin-angiotensin system attenuates sarcolemma and 
sarcoplasmic reticulum remodeling in chronic diabetes, in Diabetes Mellitus and Its 
Complications: Molecular Mechanisms, Epidemiology, and Clinical Medicine, E. Adeghate, 
et al., Editors. 2006, Blackwell Publishing: Oxford. p. 141-154. 
185. Kajstura, J., et al., IGF-1 overexpression inhibits the development of diabetic 
cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes, 2001. 50(6): p. 
1414-1424. 
186. Leri, A., et al., Overexpression of insulin-like growth factor-1 attenuates the myocyte 
renin-angiotensin system in transgenic mice. Circulation Research, 1999. 84(7): p. 752-762. 
187. Yu, Z., G.F. Tibbits, and J.H. McNeill, CELLULAR FUNCTIONS OF DIABETIC 
CARDIOMYOCYTES - CONTRACTILITY, RAPID-COOLING CONTRACTURE, AND 
RYANODINE BINDING. American Journal of Physiology, 1994. 266(5): p. H2082-H2089. 
188. Yu, J.Z., G.A. Quamme, and J.H. McNeill, Altered Ca2+ (i) mobilization in diabetic 
cardiomyocytes: Responses to caffeine, KCl, ouabain, and ATP. Diabetes Research and 
Clinical Practice, 1995. 30(1): p. 9-20. 
189. Bouchard, R.A. and D. Bose, INFLUENCE OF EXPERIMENTAL DIABETES ON 
SARCOPLASMIC-RETICULUM FUNCTION IN RAT VENTRICULAR MUSCLE. American 
Journal of Physiology, 1991. 260(2): p. H341-H354. 
190. Nobe, S., et al., CHRONIC DIABETES-MELLITUS PROLONGS ACTION-POTENTIAL 
99 
 
DURATION OF RAT VENTRICULAR MUSCLES - CIRCUMSTANTIAL EVIDENCE FOR 
IMPAIRED CA-2+ CHANNEL. Cardiovascular Research, 1990. 24(5): p. 381-389. 
191. Qin, D.Y., et al., Downregulation of K+ channel genes expression in type I diabetic 
cardiomyopathy. Biochemical and Biophysical Research Communications, 2001. 283(3): p. 
549-553. 
192. Shigematsu, S., et al., RATE-DEPENDENT PROLONGATION OF ACTION-POTENTIAL 
DURATION IN SINGLE VENTRICULAR MYOCYTES OBTAINED FROM HEARTS OF 
RATS WITH STREPTOZOTOCIN-INDUCED CHRONIC DIABETES SUSTAINED FOR 
30-32 WEEKS. Heart and Vessels, 1994. 9(6): p. 300-306. 
193. Shimoni, Y., et al., Gender-dependent attenuation of cardiac potassium currents in type 2 
diabetic db/db mice. Journal of Physiology-London, 2004. 555(2): p. 345-354. 
194. Ding, Y.F., et al., Effects of gender difference on cardiac myocyte dysfunction in 
streptozotocin-induced diabetic rats. Endocrine, 2006. 29(1): p. 135-141. 
195. Yu, J.Z., B. Rodrigues, and J.H. McNeill, Intracellular calcium levels are unchanged in the 
diabetic heart. Cardiovascular Research, 1997. 34(1): p. 91-98. 
196. Ren, J. and A.F. Ceylan-Isik, Diabetic cardiomyopathy - Do women differ from men? 
Endocrine, 2004. 25(2): p. 73-83. 
197. Shimoni, Y., H.S. Ewart, and D. Severson, Insulin stimulation of rat ventricular K(+) 
currents depends on the integrity of the cytoskeleton. Journal of Physiology-London, 1999. 
514(3): p. 735-745. 
198. Li, X., et al., Redox regulation of I-to remodeling in diabetic rat heart. American Journal of 
Physiology-Heart and Circulatory Physiology, 2005. 288(3): p. H1417-H1424. 
199. Zhang, X.L. and C. Chen, A new insight of mechanisms, diagnosis and treatment of diabetic 
cardiomyopathy. Endocrine, 2012. 41(3): p. 398-409. 
200. Van der Lely, A.F., et al., Biological, physiological, pathophysiological, and 
pharmacological aspects of ghrelin (vol 25, pg 426, 2004). Endocrine Reviews, 2004. 25(5): 
p. 866-866. 
201. Howard, A.D., et al., A receptor in pituitary and hypothalamus that functions in growth 
hormone release. Science, 1996. 273(5277): p. 974-977. 
202. Kojima, M., et al., Ghrelin is a growth-hormone-releasing acylated peptide from stomach. 
100 
 
Nature, 1999. 402(6762): p. 656-660. 
203. Broglio, F., et al., Ghrelin, a natural GH secretagogue produced by the stomach, induces 
hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab, 2001. 
86(10): p. 5083-6. 
204. Egido, E.M., et al., Inhibitory effect of ghrelin on insulin and pancreatic somatostatin 
secretion. Eur J Endocrinol, 2002. 146(2): p. 241-4. 
205. Reimer, M.K., G. Pacini, and B. Ahren, Dose-dependent inhibition by ghrelin of insulin 
secretion in the mouse. Endocrinology, 2003. 144(3): p. 916-21. 
206. Dezaki, K., et al., Endogenous ghrelin in pancreatic islets restricts insulin release by 
attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. 
Diabetes, 2004. 53(12): p. 3142-51. 
207. Ikezaki, A., et al., Fasting plasma ghrelin levels are negatively correlated with insulin 
resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes, 2002. 
51(12): p. 3408-11. 
208. Poykko, S.M., et al., Low plasma ghrelin is associated with insulin resistance, hypertension, 
and the prevalence of type 2 diabetes. Diabetes, 2003. 52(10): p. 2546-53. 
209. Adeghate, E. and A.S. Ponery, Ghrelin stimulates insulin secretion from the pancreas of 
normal and diabetic rats. J Neuroendocrinol, 2002. 14(7): p. 555-60. 
210. Irako, T., et al., Ghrelin prevents development of diabetes at adult age in 
streptozotocin-treated newborn rats. Diabetologia, 2006. 49(6): p. 1264-73. 
211. Cassoni, P., et al., Identification, characterization, and biological activity of specific 
receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in 
human breast carcinomas and cell lines. J Clin Endocrinol Metab, 2001. 86(4): p. 1738-45. 
212. Nakazato, M., et al., A role for ghrelin in the central regulation of feeding. Nature, 2001. 
409(6817): p. 194-8. 
213. Shintani, M., et al., Ghrelin, an endogenous growth hormone secretagogue, is a novel 
orexigenic peptide that antagonizes leptin action through the activation of hypothalamic 
neuropeptide Y/Y1 receptor pathway. Diabetes, 2001. 50(2): p. 227-32. 
214. Takaya, K., et al., Ghrelin strongly stimulates growth hormone release in humans. J Clin 
Endocrinol Metab, 2000. 85(12): p. 4908-11. 
101 
 
215. Bando, M., et al., Overexpression of intraislet ghrelin enhances beta-cell proliferation after 
streptozotocin-induced beta-cell injury in mice. Am J Physiol Endocrinol Metab, 2013. 
305(1): p. E140-8. 
216. Granata, R., et al., Acylated and unacylated ghrelin promote proliferation and inhibit 
apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine 
monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and 
phosphatidyl inositol 3-Kinase/Akt signaling. Endocrinology, 2007. 148(2): p. 512-29. 
217. Rahim, A., P.A. O'Neill, and S.M. Shalet, Growth hormone status during long-term 
hexarelin therapy. J Clin Endocrinol Metab, 1998. 83(5): p. 1644-9. 
218. Hataya, Y., et al., A low dose of ghrelin stimulates growth hormone (GH) release 
synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab, 2001. 
86(9): p. 4552. 
219. Clark, R.G., et al., The effects of a growth hormone-releasing Peptide and growth 
hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol, 1989. 
1(4): p. 249-55. 
220. Pandya, N., et al., Growth hormone (GH)-releasing peptide-6 requires endogenous 
hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab, 
1998. 83(4): p. 1186-9. 
221. Maheshwari, H.G., et al., Selective lack of growth hormone (GH) response to the 
GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. 
J Clin Endocrinol Metab, 1999. 84(3): p. 956-9. 
222. Gondo, R.G., et al., Growth hormone-releasing peptide-2 stimulates GH secretion in 
GH-deficient patients with mutated GH-releasing hormone receptor. J Clin Endocrinol 
Metab, 2001. 86(7): p. 3279-83. 
223. Guillaume, V., et al., Growth hormone (GH)-releasing hormone secretion is stimulated by a 
new GH-releasing hexapeptide in sheep. Endocrinology, 1994. 135(3): p. 1073-6. 
224. Tannenbaum, G.S., et al., Expression of growth hormone secretagogue-receptors by growth 
hormone-releasing hormone neurons in the mediobasal hypothalamus. Endocrinology, 1998. 
139(10): p. 4420-3. 
225. Dickson, S.L. and S.M. Luckman, Induction of c-fos messenger ribonucleic acid in 
102 
 
neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate 
nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. 
Endocrinology, 1997. 138(2): p. 771-7. 
226. Hewson, A.K. and S.L. Dickson, Systemic administration of ghrelin induces Fos and Egr-1 
proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol, 2000. 
12(11): p. 1047-9. 
227. Drisko, J.E., et al., Administration of a nonpeptidyl growth hormone secretagogue, L-163, 
255, changes somatostatin pattern, but has no effect on patterns of growth 
hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig. Proc 
Soc Exp Biol Med, 1999. 222(1): p. 70-7. 
228. Korbonits, M., et al., Ghrelin--a hormone with multiple functions. Front Neuroendocrinol, 
2004. 25(1): p. 27-68. 
229. Cheng, K., et al., The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth 
hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 
3',5'-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology, 
1989. 124(6): p. 2791-8. 
230. Cunha, S.R. and K.E. Mayo, Ghrelin and growth hormone (GH) secretagogues potentiate 
GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production 
in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, 2002. 
143(12): p. 4570-82. 
231. Malagon, M.M., et al., Intracellular signaling mechanisms mediating ghrelin-stimulated 
growth hormone release in somatotropes. Endocrinology, 2003. 144(12): p. 5372-80. 
232. Bisi, G., et al., Cardiac effects of hexarelin in hypopituitary adults. European Journal of 
Pharmacology, 1999. 381(1): p. 31-38. 
233. Bisi, G., et al., Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic 
GH-releasing peptide, in humans. Journal of Endocrinological Investigation, 1999. 22(4): p. 
266-272. 
234. Bodart, V., et al., CD36 mediates the cardiovascular action of growth hormone-releasing 
peptides in the heart. Circulation Research, 2002. 90(8): p. 844-849. 
235. Nagaya, N., et al., Effects of ghrelin administration on left ventricular function, exercise 
103 
 
capacity, and muscle wasting in patients with chronic heart failure. Circulation, 2004. 
110(24): p. 3674-3679. 
236. Pang, J.J., et al., Hexarelin protects rat cardiomyocytes from angiotensin II-induced 
apoptosis in vitro. American Journal of Physiology-Heart and Circulatory Physiology, 2004. 
286(3): p. H1063-H1069. 
237. Xu, X.B., et al., Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis 
in rat. American Journal of Physiology-Heart and Circulatory Physiology, 2007. 293(5): p. 
H2952-H2958. 
238. Nagaya, N., et al., Chronic administration of ghrelin improves left ventricular dysfunction 
and attenuates development of cardiac cachexia in rats with heart failure. Circulation, 2001. 
104(12): p. 1430-5. 
239. Li, W.G., et al., Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B 
activation in human endothelial cells. Circulation, 2004. 109(18): p. 2221-2226. 
240. Sun, Q., et al., Effects of GH Secretagogues on Contractility and Ca(2+) Homeostasis of 
Isolated Adult Rat Ventricular Myocytes. Endocrinology, 2010. 151(9): p. 4446-4454. 
241. Xu, Z.W., et al., Ghrelin prevents doxorubicin-induced cardiotoxicity through 
TNF-alpha/NF-kappa B pathways and mitochondrial protective mechanisms. Toxicology, 
2008. 247(2-3): p. 133-138. 
242. Chang, L., et al., Protective effects of ghrelin on ischemia/reperfusion injury in the isolated 
rat heart. Journal of Cardiovascular Pharmacology, 2004. 43(2): p. 165-170. 
243. Pemberton, C.J., et al., Ghrelin induces vasoconstriction in the rat coronary vasculature 
without altering cardiac peptide secretion. American Journal of Physiology-Heart and 
Circulatory Physiology, 2004. 287(4): p. H1522-H1529. 
244. Baldanzi, G., et al., Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and 
endothelial cells through ERK1/2 and PI 3-kinase/AKT. Journal of Cell Biology, 2002. 
159(6): p. 1029-1037. 
245. Cao, J.M., H. Ong, and C. Chen, Effects of ghrelin and synthetic GH secretagogues on the 
cardiovascular system. Trends in Endocrinology and Metabolism, 2006. 17(1): p. 13-18. 
246. Fischer, A.H., et al., Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc, 
2008. 2008: p. pdb prot4986. 
104 
 
247. Malich, G., B. Markovic, and C. Winder, The sensitivity and specificity of the MTS 
tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell 
lines. Toxicology, 1997. 124(3): p. 179-92. 
248. Zhao, Y.-F., et al., Cholesterol induces mitochondrial dysfunction and apoptosis in mouse 
pancreatic beta-cell line MIN6 cells. Endocrine, 2010. 37(1): p. 76-82. 
249. Tarpey, M.M., D.A. Wink, and M.B. Grisham, Methods for detection of reactive metabolites 
of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr 
Comp Physiol, 2004. 286(3): p. R431-44. 
250. Zhao, H., et al., Superoxide reacts with hydroethidine but forms a fluorescent product that is 
distinctly different from ethidium: potential implications in intracellular fluorescence 
detection of superoxide. Free Radic Biol Med, 2003. 34(11): p. 1359-68. 
251. Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat 
pancreas. Physiol Res, 2001. 50(6): p. 537-46. 
252. Wu, T., et al., Valsartan protects against ER stress-induced myocardial apoptosis via 
CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur J Pharm Sci, 
2011. 42(5): p. 496-502. 
253. Steyn, F.J., et al., Development of a method for the determination of pulsatile growth 
hormone secretion in mice. Endocrinology, 2011. 152(8): p. 3165-71. 
254. Keenan, D.M., S. Chattopadhyay, and J.D. Veldhuis, Composite model of time-varying 
appearance and disappearance of neurohormone pulse signals in blood. J Theor Biol, 2005. 
236(3): p. 242-55. 
255. Keenan, D.M., A. Iranmanesh, and J.D. Veldhuis, Analytical construct of reversible 
desensitization of pituitary-testicular signaling: illustrative application in aging. Am J 
Physiol Regul Integr Comp Physiol, 2011. 300(2): p. R349-60. 
256. Veldhuis, J.D., et al., Impact of pulsatility on the ensemble orderliness (approximate entropy) 
of neurohormone secretion. Am J Physiol Regul Integr Comp Physiol, 2001. 281(6): p. 
R1975-85. 
257. Davis, J., et al., Designing heart performance by gene transfer. Physiol Rev, 2008. 88(4): p. 
1567-651. 
258. Fletcher, A.J., et al., Effects of gestational age and cortisol treatment on ovine fetal heart 
105 
 
function in a novel biventricular Langendorff preparation. J Physiol, 2005. 562(Pt 2): p. 
493-505. 
259. Ma, Y., et al., Growth hormone secretagogues protect mouse cardiomyocytes from in vitro 
ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One, 2012. 
7(4): p. e35265. 
260. Grynkiewicz, G., M. Poenie, and R.Y. Tsien, A NEW GENERATION OF CA-2+ 
INDICATORS WITH GREATLY IMPROVED FLUORESCENCE PROPERTIES. Journal of 
Biological Chemistry, 1985. 260(6): p. 3440-3450. 
261. Xu, Y.J., Q. Shao, and N.S. Dhalla, Fura-2 fluorescent technique for the assessment of Ca2+ 
homeostasis in cardiomyocytes. Mol Cell Biochem, 1997. 172(1-2): p. 149-57. 
262. Sun, Q., W.J. Zang, and C. Chen, Growth Hormone Secretagogues Reduce Transient 
Outward K(+) Current via Phospholipase C/Protein Kinase C Signaling Pathway in Rat 
Ventricular Myocytes. Endocrinology, 2010. 151(3): p. 1228-1235. 
263. Ma, Y., et al., Growth hormone secretagogues preserve the electrophysiological properties 
of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart. Endocrinology, 
2012. 153(11): p. 5480-90. 
264. Malmivuo, J. and R. Plonsey, Bioelectromagnetism : principles and applications of 
bioelectric and biomagnetic fields. 1995, New York: Oxford University Press. xxii, 482 p. 
265. Fung, J.N., et al., Expression and in vitro functions of the ghrelin axis in endometrial cancer. 
Horm Cancer, 2010. 1(5): p. 245-55. 
266. Xu, X.B., et al., GH-releasing peptides improve cardiac dysfunction and cachexia and 
suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. 
American Journal of Physiology-Heart and Circulatory Physiology, 2005. 289(4): p. 
H1643-H1651. 
267. Tian, C., et al., Gain of function of cardiac ryanodine receptor in a rat model of type 1 
diabetes. Cardiovasc Res, 2011. 91(2): p. 300-9. 
268. Gajdosik, A., et al., Streptozotocin-induced experimental diabetes in male Wistar rats. Gen 
Physiol Biophys, 1999. 18 Spec No: p. 54-62. 
269. Akbarzadeh, A., et al., Induction of diabetes by Streptozotocin in rats. Indian J Clin 
Biochem, 2007. 22(2): p. 60-4. 
106 
 
270. Brentjens, R. and L. Saltz, ISLET CELL TUMORS OF THE PANCREAS: The Medical 
Oncologist's Perspective. Surgical Clinics of North America, 2001. 81(3): p. 527-542. 
271. Wang, Z. and H. Gleichmann, GLUT2 in pancreatic islets: crucial target molecule in 
diabetes induced with multiple low doses of streptozotocin in mice. Diabetes, 1998. 47(1): p. 
50-6. 
272. Bresciani, E., et al., Feeding behavior during long-term hexarelin administration in young 
and old rats. J Endocrinol Invest, 2008. 31(7): p. 647-52. 
273. Tsubone, T., et al., Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA 
expression in brown adipose tissue in mice. Regul Pept, 2005. 130(1-2): p. 97-103. 
274. Xu, X., et al., Chronic administration of hexarelin attenuates cardiac fibrosis in the 
spontaneously hypertensive rat. American Journal of Physiology - Heart and Circulatory 
Physiology, 2012. 303(6): p. H703-H711. 
275. Schwartz, M.W., et al., Central nervous system control of food intake. Nature, 2000. 
404(6778): p. 661-71. 
276. Ukkola, O. and S. Poykko, Ghrelin, growth and obesity. Ann Med, 2002. 34(2): p. 102-8. 
277. Yoshihara, F., et al., Ghrelin: a novel peptide for growth hormone release and feeding 
regulation. Curr Opin Clin Nutr Metab Care, 2002. 5(4): p. 391-5. 
278. Traebert, M., et al., Ghrelin acts on leptin-responsive neurones in the rat arcuate nucleus. J 
Neuroendocrinol, 2002. 14(7): p. 580-6. 
279. Beaumont, N.J., et al., Ghrelin can bind to a species of high density lipoprotein associated 
with paraoxonase. J Biol Chem, 2003. 278(11): p. 8877-80. 
280. Choi, K., et al., The role of ghrelin and growth hormone secretagogues receptor on rat 
adipogenesis. Endocrinology, 2003. 144(3): p. 754-9. 
281. Sellamuthu, P.S., et al., Mangiferin from Salacia chinensis Prevents Oxidative Stress and 
Protects Pancreatic β-Cells in Streptozotocin-Induced Diabetic Rats. Journal of medicinal 
food, 2013. 16(8): p. 719-727. 
282. Arunachalam, K. and T. Parimelazhagan, Antidiabetic activity of< i> Ficus amplissima</i> 
Smith. bark extract in streptozotocin induced diabetic rats. Journal of ethnopharmacology, 
2013. 
283. Hofert, J.F., S. Goldstein, and L.S. Phillips, Glucocorticoid effects on IGF-1/somatomedin-C 
107 
 
and somatomedin inhibitor in streptozotocin-diabetic rats. Metabolism, 1989. 38(6): p. 
594-600. 
284. Nawrocki, A., et al., Effect of streptozotocin diabetes on fatty acid content and composition 
of the heart lipids in the rat. Rocz Akad Med Bialymst, 1999. 44: p. 170-9. 
285. Jiménez-González, M., et al., Cardiotrophin 1 protects beta cells from apoptosis and 
prevents streptozotocin-induced diabetes in a mouse model. Diabetologia, 2013: p. 1-9. 
286. Yano, T., et al., Stromal Cell–Derived Factor-1 (SDF-1)/CXCL12 Attenuates Diabetes in 
Mice and Promotes Pancreatic β-Cell Survival by Activation of the Prosurvival Kinase Akt. 
Diabetes, 2007. 56(12): p. 2946-2957. 
287. Liu, L., J.-L. Liu, and C.B. Srikant, Reg2 protects mouse insulinoma cells from 
streptozotocin-induced mitochondrial disruption and apoptosis. Growth Factors, 2010. 28(5): 
p. 370-378. 
288. Wierup, N., F. Sundler, and S. Heller, The islet ghrelin cell. Journal of molecular 
endocrinology, 2013: p. JME-13-0122. 
289. Bando, M., et al., Overexpression of intra-islet ghrelin enhances β-cell proliferation after 
streptozotocin-induced β-cell injury in mice. American Journal of Physiology-Endocrinology 
And Metabolism, 2013. 
290. Granata, R., et al., Acylated and unacylated ghrelin promote proliferation and inhibit 
apoptosis of pancreatic β-cells and human islets: involvement of 3′, 5′-cyclic adenosine 
monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and 
phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology, 2007. 148(2): p. 512-529. 
291. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, BCL-2 family members and the 
mitochondria in apoptosis. Genes & development, 1999. 13(15): p. 1899-1911. 
292. Jian, L., Y. Su, and H. Deng, Adiponectin-induced Inhibition of Intrinsic and Extrinsic 
Apoptotic Pathways Protects Pancreatic β-Cells Against Apoptosis. Hormone and Metabolic 
Research, 2013(EFirst). 
293. Huang, Y.C., et al., In situ electrophysiological examination of pancreatic alpha cells in the 
streptozotocin-induced diabetes model, revealing the cellular basis of glucagon 
hypersecretion. Diabetes, 2013. 62(2): p. 519-30. 
294. Takeda, Y., et al., Reduction of both beta cell death and alpha cell proliferation by dipeptidyl 
108 
 
peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia, 
2012. 55(2): p. 404-12. 
295. Kawamori, D., et al., Insulin signaling in alpha cells modulates glucagon secretion in vivo. 
Cell Metab, 2009. 9(4): p. 350-61. 
296. Date, Y., et al., Ghrelin is present in pancreatic alpha-cells of humans and rats and 
stimulates insulin secretion. Diabetes, 2002. 51(1): p. 124-9. 
297. Chuang, J.C., et al., Ghrelin directly stimulates glucagon secretion from pancreatic 
alpha-cells. Mol Endocrinol, 2011. 25(9): p. 1600-11. 
298. Ardestani, A., et al., MST1 is a key regulator of beta cell apoptosis and dysfunction in 
diabetes. Nat Med, 2014. 20(4): p. 385-97. 
299. Lehmann, J.M., et al., An antidiabetic thiazolidinedione is a high affinity ligand for 
peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem, 1995. 
270(22): p. 12953-6. 
300. Lambe, K.G. and J.D. Tugwood, A human peroxisome-proliferator-activated 
receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. 
Eur J Biochem, 1996. 239(1): p. 1-7. 
301. Yki-Jarvinen, H., Thiazolidinediones. N Engl J Med, 2004. 351(11): p. 1106-18. 
302. Avallone, R., et al., A growth hormone-releasing peptide that binds scavenger receptor 
CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in 
macrophages through a peroxisome proliferator-activated receptor gamma-dependent 
pathway. Mol Endocrinol, 2006. 20(12): p. 3165-78. 
303. Masaoka, T., et al., Enhanced plasma ghrelin levels in rats with streptozotocin-induced 
diabetes. FEBS Lett, 2003. 541(1-3): p. 64-8. 
304. Teppala, S. and A. Shankar, Association between serum IGF-1 and diabetes among U.S. 
adults. Diabetes Care, 2010. 33(10): p. 2257-9. 
305. Argente, J., et al., Growth hormone-releasing peptides: clinical and basic aspects. Horm 
Res, 1996. 46(4-5): p. 155-9. 
306. Colao, A., A.L. Barkan, and R. Scarpa, Growth hormone/insulin-like growth factor-I system 
and connective tissues: basic aspects and clinical implications. Rheum Dis Clin North Am, 
2005. 31(1): p. 29-42, viii. 
109 
 
307. Dang, A.Q., et al., Decreased incorporation of long-chain fatty acids into erythrocyte 
phospholipids of STZ-D rats. Diabetes, 1991. 40(12): p. 1645-51. 
308. Muller, D., et al., Streptozotocin increases free fatty acids and decreases phospholipids in 
rat brain. J Neural Transm, 1998. 105(10-12): p. 1271-81. 
309. Scheuermann-Freestone, M., et al., Abnormal cardiac and skeletal muscle energy 
metabolism in patients with type 2 diabetes. Circulation, 2003. 107(24): p. 3040-6. 
310. DeFronzo, R.A., et al., Effects of insulin on peripheral and splanchnic glucose metabolism 
in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest, 1985. 76(1): p. 149-55. 
311. Reaven, G.M., et al., Lowering of plasma glucose in diabetic rats by antilipolytic agents. 
Am J Physiol, 1988. 254(1 Pt 1): p. E23-30. 
312. Cohen, R.M. and W.A. Abplanalp, Resistance of growth hormone secretion to somatostatin 
in men with type I diabetes mellitus. Diabetes, 1991. 40(10): p. 1251-8. 
313. Ismail, I.S., M.F. Scanlon, and J.R. Peters, Cholinergic control of growth hormone (GH) 
responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated 
hypothalamic somatostatinergic tone and decreased GH autofeedback. Clin Endocrinol 
(Oxf), 1993. 38(2): p. 149-57. 
314. Serri, O. and P. Brazeau, Growth hormone responsiveness in vivo and in vitro to growth 
hormone releasing factor in the spontaneously diabetic BB Wistar rat. Neuroendocrinology, 
1987. 46(2): p. 162-6. 
315. Busiguina, S., et al., Anatomically specific changes in the expression of somatostatin, growth 
hormone-releasing hormone and growth hormone receptor mRNA in diabetic rats. J 
Neuroendocrinol, 2000. 12(1): p. 29-39. 
316. Joanny, P., et al., Effect of diabetes on in vivo and in vitro hypothalamic somatostatin release. 
Neuroendocrinology, 1992. 55(5): p. 485-91. 
317. Kim, E., et al., Differential responses of the growth hormone axis in two rat models of 
streptozotocin-induced insulinopenic diabetes. J Endocrinol, 2006. 188(2): p. 263-70. 
318. Diz Chaves, Y., et al., GH responses to GHRH and GHRP-6 in Streptozotocin (STZ)-diabetic 
rats. Life Sci, 2003. 73(26): p. 3375-85. 
319. Tannenbaum, G.S. and C.Y. Bowers, Interactions of growth hormone secretagogues and 
growth hormone-releasing hormone/somatostatin. Endocrine, 2001. 14(1): p. 21-7. 
110 
 
320. Diz-Chaves, Y., et al., Ghrelin improves growth hormone responses to growth 
hormone-releasing hormone in a streptozotocin-diabetic model of delayed onset. J 
Endocrinol Invest, 2007. 30(4): p. 298-305. 
321. Johansen, P.B., et al., Growth hormone (GH) hypersecretion and GH receptor resistance in 
streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res, 2003. 
4(2): p. 73-81. 
322. Coraboeuf, E. and G. Vassort, Effects of some inhibitors of ionic permeabilities on 
ventricular action potential and contraction of rat and guinea-pig hearts. J Electrocardiol, 
1968. 1(1): p. 19-29. 
323. Josephson, I.R., J. Sanchez-Chapula, and A.M. Brown, A comparison of calcium currents in 
rat and guinea pig single ventricular cells. Circ Res, 1984. 54(2): p. 144-56. 
324. Magyar, J., et al., Action potentials and potassium currents in rat ventricular muscle during 
experimental diabetes. J Mol Cell Cardiol, 1992. 24(8): p. 841-53. 
325. Casis, O., et al., Differences in regional distribution of K+ current densities in rat ventricle. 
Life Sci, 1998. 63(5): p. 391-400. 
326. Greenstein, J.L., et al., Role of the calcium-independent transient outward current I(to1) in 
shaping action potential morphology and duration. Circ Res, 2000. 87(11): p. 1026-33. 
327. Sun, X., et al., Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition 
of oxidative stress and cell apoptosis. Food Chem Toxicol, 2014. 63: p. 221-32. 
328. Bouchard, R.A. and D. Bose, Influence of experimental diabetes on sarcoplasmic reticulum 
function in rat ventricular muscle. Am J Physiol, 1991. 260(2 Pt 2): p. H341-54. 
329. Fein, F.S. and E.H. Sonnenblick, Diabetic cardiomyopathy. Cardiovasc Drugs Ther, 1994. 
8(1): p. 65-73. 
330. Teshima, Y., et al., Diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase and 
ryanodine sensitive Ca(2+)Channel mRNA in streptozotocin-induced diabetic rat heart. J 
Mol Cell Cardiol, 2000. 32(4): p. 655-64. 
331. Bers, D.M., Cardiac excitation-contraction coupling. Nature, 2002. 415(6868): p. 198-205. 
332. Crespo, L.M., C.J. Grantham, and M.B. Cannell, Kinetics, stoichiometry and role of the 
Na-Ca exchange mechanism in isolated cardiac myocytes. Nature, 1990. 345(6276): p. 
618-21. 
111 
 
333. Zhang, L., et al., Altered calcium homeostasis does not explain the contractile deficit of 
diabetic cardiomyopathy. Diabetes, 2008. 57(8): p. 2158-66. 
334. Schaffer, S.W., et al., Basis for myocardial mechanical defects associated with 
non-insulin-dependent diabetes. Am J Physiol, 1989. 256(1 Pt 1): p. E25-30. 
335. Allo, S.N., et al., Non-insulin-dependent diabetes-induced defects in cardiac cellular 
calcium regulation. Am J Physiol, 1991. 260(6 Pt 1): p. C1165-71. 
336. Yu, Z., G.A. Quamme, and J.H. McNeill, Depressed [Ca2+]i responses to isoproterenol and 
cAMP in isolated cardiomyocytes from experimental diabetic rats. Am J Physiol, 1994. 
266(6 Pt 2): p. H2334-42. 
337. Yu, J.Z., G.A. Quamme, and J.H. McNeill, Altered [Ca2+]i mobilization in diabetic 
cardiomyocytes: responses to caffeine, KCl, ouabain, and ATP. Diabetes Res Clin Pract, 
1995. 30(1): p. 9-20. 
338. Cesario, D.A., R. Brar, and K. Shivkumar, Alterations in ion channel physiology in diabetic 
cardiomyopathy. Endocrinol Metab Clin North Am, 2006. 35(3): p. 601-10, ix-x. 
339. Galderisi, M., et al., Echocardiographic evidence for the existence of a distinct diabetic 
cardiomyopathy (the Framingham Heart Study). Am J Cardiol, 1991. 68(1): p. 85-9. 
340. Kannel, W.B., M. Hjortland, and W.P. Castelli, Role of diabetes in congestive heart failure: 
the Framingham study. Am J Cardiol, 1974. 34(1): p. 29-34. 
341. Rubler, S., et al., New type of cardiomyopathy associated with diabetic glomerulosclerosis. 
Am J Cardiol, 1972. 30(6): p. 595-602. 
342. Broglio, F., et al., Effects of acute hexarelin administration on cardiac performance in 
patients with coronary artery disease during by-pass surgery. Eur J Pharmacol, 2002. 
448(2-3): p. 193-200. 
343. Aragno, M., et al., Obestatin induced recovery of myocardial dysfunction in type 1 diabetic 
rats: underlying mechanisms. Cardiovasc Diabetol, 2012. 11: p. 129. 
344. Fein, F.S., et al., Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res, 
1981. 49(6): p. 1251-61. 
345. Fein, F.S., et al., Reversibility of diabetic cardiomyopathy with insulin in rabbits. Am J 
Physiol, 1986. 250(1 Pt 2): p. H108-13. 
346. Rozanski, G.J. and Z. Xu, A metabolic mechanism for cardiac K+ channel remodelling. Clin 
112 
 
Exp Pharmacol Physiol, 2002. 29(1-2): p. 132-7. 
347. Xu, Z., K.P. Patel, and G.J. Rozanski, Intracellular protons inhibit transient outward K+ 
current in ventricular myocytes from diabetic rats. Am J Physiol, 1996. 271(5 Pt 2): p. 
H2154-61. 
348. Xu, Z., K.P. Patel, and G.J. Rozanski, Metabolic basis of decreased transient outward K+ 
current in ventricular myocytes from diabetic rats. Am J Physiol, 1996. 271(5 Pt 2): p. 
H2190-6. 
349. Li, X., et al., Redox regulation of Ito remodeling in diabetic rat heart. Am J Physiol Heart 
Circ Physiol, 2005. 288(3): p. H1417-24. 
350. Xu, Z., et al., Up-regulation of K(+) channels in diabetic rat ventricular myocytes by insulin 
and glutathione. Cardiovasc Res, 2002. 53(1): p. 80-8. 
351. Xu, Z., et al., Endogenous ghrelin increases in adriamycin-induced heart failure rats. J 
Endocrinol Invest, 2007. 30(2): p. 117-25. 
352. Tong, X.X., et al., Ghrelin protects against cobalt chloride-induced hypoxic injury in 
cardiac H9c2 cells by inhibiting oxidative stress and inducing autophagy. Peptides, 2012. 
38(2): p. 217-27. 
353. Frustaci, A., et al., Myocardial cell death in human diabetes. Circ Res, 2000. 87(12): p. 
1123-32. 
354. Cai, L., et al., Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial 
cytochrome C-mediated caspase-3 activation pathway. Diabetes, 2002. 51(6): p. 1938-48. 
355. Green, D.R. and J.C. Reed, Mitochondria and apoptosis. Science, 1998. 281(5381): p. 
1309-12. 
356. Chinnaiyan, A.M., et al., Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL 
function upstream of the CED-3-like apoptotic proteases. J Biol Chem, 1996. 271(9): p. 
4573-6. 
357. Li, C.J., et al., Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression 
of mitochondrial oxidative stress to reduce diabetic cardiomyopathy. Chin Med J (Engl), 
2009. 122(21): p. 2580-6. 
358. Kui, L., et al., Ghrelin inhibits apoptosis induced by high glucose and sodium palmitate in 
adult rat cardiomyocytes through the PI3K-Akt signaling pathway. Regul Pept, 2009. 
113 
 
155(1-3): p. 62-9. 
359. Kang, Y.J., Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect, 
2001. 109 Suppl 1: p. 27-34. 
360. Teiger, E., et al., Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin 
Invest, 1996. 97(12): p. 2891-7. 
361. Feuerstein, G.Z. and P.R. Young, Apoptosis in cardiac diseases: stress- and 
mitogen-activated signaling pathways. Cardiovasc Res, 2000. 45(3): p. 560-9. 
362. Swynghedauw, B., Molecular mechanisms of myocardial remodeling. Physiol Rev, 1999. 
79(1): p. 215-62. 
363. Mao, Y., et al., Hexarelin treatment in male ghrelin knockout mice after myocardial 
infarction. Endocrinology, 2013. 154(10): p. 3847-54. 
 
 
